🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
The Pill That Promised a Revolution: Why Eli Lilly's Foundayo Is Launching Slower Than Wall Street Expected ◆ Speed Over Scrutiny? The High-Stakes Gamble Behind the NHS's New Fast-Track Drug Pilots ◆ A Global Milestone for Wellness: Chanelle McCoy Health Secures Historic Dual SFDA and European Novel Food Regulatory Approvals ◆ The Digital and Regulatory Frontier: Top 10 Technical and GMP Trends Shaping Pharma in 2026 ◆ Funding the Future: Inside the €75k Women TechEU and £10M Createch Grants for Startups and SMEs ◆ FDA Fires Warning Shot at Sanofi's Irish Plant Over Data Cover-Up and Altuviiio Quality Failings ◆ Top Universities in Ireland: Discover the Country's Leading Higher Education Institutions ◆ The Irish Startup Ecosystem: A Comprehensive Funding and Development Guide for Entrepreneurs ◆ The Pill That Promised a Revolution: Why Eli Lilly's Foundayo Is Launching Slower Than Wall Street Expected ◆ Speed Over Scrutiny? The High-Stakes Gamble Behind the NHS's New Fast-Track Drug Pilots ◆ A Global Milestone for Wellness: Chanelle McCoy Health Secures Historic Dual SFDA and European Novel Food Regulatory Approvals ◆ The Digital and Regulatory Frontier: Top 10 Technical and GMP Trends Shaping Pharma in 2026 ◆ Funding the Future: Inside the €75k Women TechEU and £10M Createch Grants for Startups and SMEs ◆ FDA Fires Warning Shot at Sanofi's Irish Plant Over Data Cover-Up and Altuviiio Quality Failings ◆ Top Universities in Ireland: Discover the Country's Leading Higher Education Institutions ◆ The Irish Startup Ecosystem: A Comprehensive Funding and Development Guide for Entrepreneurs ◆
Markets · 15 min delay
NBI4,187.6▲ +1.14%
PFE28.42▼ -0.38%
AZN74.18▲ +0.81%
NVO103.55▲ +2.07%
ROG261.40▼ -0.55%
ABBV174.92▲ +0.29%
EUR/USD1.0842▼ -0.12%
ISEQ9,241.3▲ +0.62%
NBI4,187.6▲ +1.14%
PFE28.42▼ -0.38%
AZN74.18▲ +0.81%
NVO103.55▲ +2.07%
ROG261.40▼ -0.55%
ABBV174.92▲ +0.29%
EUR/USD1.0842▼ -0.12%
Updated 06 Jul 2026 · EMA CTIS official data

EU Clinical Trials Tracker

The most recently authorised clinical trials across the European Union - drawn live from the European Medicines Agency's Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation. Searchable by country, phase, sponsor and condition.

600
Recent authorisations
186
Phase III trials
26
Member states
Phase I/II Neoplasms Authorised 03/07/2026
A Phase 1b-2, Open-Label, Dose-Escalation, Expansion and Optimization Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of LRK-4189 Alone and in Combination with mFOLFOX6 or FOLFIRI in Patients with Solid Tumors
Solid tumors
Larkspur Biosciences Inc. · 80 participants
📍 France
2026-525629-20-00 on CTIS ↗
Phase I Hemic and Lymphatic Diseases Authorised 03/07/2026
Study of 3 Monoclonal Antibodies (REGN9933, REGN7508, and REGN9533) in Adult Participants with End-Stage Kidney Disease on Hemodialysis
End-Stage Kidney Disease (ESKD)
Regeneron Pharmaceuticals Inc. · 36 participants
📍 Belgium
2026-525844-14-00 on CTIS ↗
Phase II Mental Disorders Authorised 03/07/2026
The Acute and Long-term Impact of Support in Psilocybin Therapy for Depression: The Psilocybin Setting Trial (PSISET)
Depression
Kobenhavns Universitet, Koebenhavns Universitet · 180 participants
📍 Denmark
2025-522961-31-01 on CTIS ↗
Phase II Nervous System Diseases Authorised 03/07/2026
Individualized Intrathecal Chemotherapy Based on Measurement of Brain Fluid Clearance in Pediatric Patients
Acute lymphoblastic leukemia and lymphoma
Oslo University Hospital HF · 50 participants
📍 Norway
2025-522453-20-00 on CTIS ↗
Phase III Digestive System Diseases Authorised 03/07/2026
Dual-agent fluorescence-guided surgery for colorectal liver metastases
Colorectal liver metastases
Leids Universitair Medisch Centrum (LUMC) · 39 participants
📍 Netherlands
2025-524755-31-00 on CTIS ↗
Phase II Psychological Phenomena Authorised 03/07/2026
A Randomized, Delayed-Treatment Controlled, Phase 2 Pilot Study of Manualized MDMA-Assisted Therapy for Young Adults with Chronic Treatment-Resistant Major Depressive Disorder
Major Depressive Disorder
Ostfold Hospital Trust · 16 participants
📍 Norway
2024-520319-42-01 on CTIS ↗
Phase I Female Urogenital Diseases and Pregnancy Complications Authorised 03/07/2026
Calcium Electroporation for Urinary Bladder Tumors: A First-in-Human Feasibility, Safety, and Early Response Trial - The CALCIFER Trial
Bladder cancer, Bladder tumors, Urothelial cancer, Urothelial tumors
Region Sjaelland · 20 participants
📍 Denmark
2026-526388-39-00 on CTIS ↗
Phase II Neoplasms Authorised 03/07/2026
A multicenter open-label phase II study of Cemiplimab plus chemotherapy, selected on the basis of baseline cytidine deaminase activity, in advanced squamous non-small cell lung cancer - CECYDE trial - GOIRC-04-2024
Advanced squamous non-small cell lung cancer
G.O.I.R.C. Gruppo Oncologico Italiano Di Ricerca Clinica · 108 participants
📍 Italy
2024-517799-40-00 on CTIS ↗
Phase II Hemic and Lymphatic Diseases Authorised 02/07/2026
Interleukin-1 inhibition to improve the response of myeloproliferative neoplasms resistant to cytoreductive treatment
myeloproliferative neoplasms
Centre Hospitalier Regional Et Universitaire De Brest · 50 participants
📍 France
2025-523921-17-00 on CTIS ↗
Phase II Diagnosis Authorised 02/07/2026
18F-fluoro-ethyl-tyrosine (18FET) PET for difficult clinical situations in functional pituitary adenoma. A prospective, single arm, single center study. (FET-PIT)
Patients (male or female) ≥18 years old with Suspected functional pituitary adenoma (prolactinoma, Cushing's disease, acromegaly, thyrotropic adenoma), de novo or recurrence/persistence, With indeterminate pituitary MRI.
Centre Hospitalier Universitaire De Lille · 30 participants
📍 France
2025-523829-17-00 on CTIS ↗
Phase I Cardiovascular Diseases Authorised 02/07/2026
Bioequivalence Study of Dapagliflozin 10 mg
Not applicable (submitted trial is a BE study in healthy participants)
Vipharm S.A. · 40 participants
📍 Czechia
2026-526840-10-00 on CTIS ↗
Phase II Neoplasms Authorised 02/07/2026
IFCT-2501 IDEATION ctDNA-guIDEd consolidATION immunotherapy after chemoradiotherapy in patients with stage III non-small cell lung cancer
Stage III Non Small Cell Lung Cancer
Intergroupe Francophone De Cancerologie Thoracique · 177 participants
📍 France
2025-522801-39-00 on CTIS ↗
Phase I Neoplasms Authorised 02/07/2026
Network pharmacology-based personalized drug repurposing in thyroid carcinoma: a pilot feasibility trial
Advanced thyroid cancer
Stichting Radboud University Medical Center · 10 participants
📍 Netherlands
2023-507214-28-00 on CTIS ↗
Phase III Mental Disorders Authorised 01/07/2026
AugmENtation witH cAnnabidiol iN first episode psyChosis: a doublE blind randomised controlled trial (STEP-ENHANCE Trial)
First Episode Psychosis (FEP)
University Of Oxford · 124 participants
📍 Greece · Germany · Italy · Austria
2025-521929-32-01 on CTIS ↗
Phase I/II Neoplasms Authorised 01/07/2026
A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE849 in Patients with DLL3 Expressing Tumors Including Small Cell Lung Cancer
DLL3 Expressing Tumors Including Small Cell Lung Cancer
Ideaya Biosciences Inc. · 35 participants
📍 France · Spain
2025-523438-24-00 on CTIS ↗
Phase III Neoplasms Authorised 01/07/2026
"A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma after 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Antibody and Lenalidomide"
Relapsed or Refractory Multiple Myeloma
Janssen Cilag International · 181 participants
📍 Spain · Czechia · France · Italy · Germany · Greece
2025-523815-12-00 on CTIS ↗
Phase II Circulatory and Respiratory Physiological Phenomena Authorised 01/07/2026
High-dose Insulin Euglycemic Therapy in Non-Toxic Acute Cardiogenic Shock.
Non-toxic acute cardiogenic shock
Oslo Universitetssykehus HF · 20 participants
📍 Norway
2025-523858-13-01 on CTIS ↗
Phase I Skin and Connective Tissue Diseases Authorised 01/07/2026
A phase 1b trial to study the safety and effect of ZP9830 in patients with plaque psoriasis
Plaque Psoriasis
Zealand Pharma A/S · 32 participants
📍 Netherlands
2026-525220-15-00 on CTIS ↗
Phase I Immune System Diseases Authorised 01/07/2026
An open label, balanced, randomized, single dose, two-treatment, two period, two-sequence, crossover, bioequivalence study comparing Fexofenadine HCl and Pseudoephedrine HCl Extended Release Tablet 180 mg/240 mg, Manufactured by: Sun Pharmaceutical Industries Limited, India with Allegra-D® 24 HR (Fexofenadine HCl and Pseudoephedrine HCl Extended Release Tablets 180 mg + 240 mg) tablets, Distributed by: Chattem Inc., a Sanofi Company Chattanooga, TN 37409-0219, USA, in healthy, adult, human participants under fed conditions.
Seasonal allergic rhinitis
Sun Pharmaceutical Industries Limited · 48 participants
📍 Romania
2026-525421-20-00 on CTIS ↗
Phase I Immune System Diseases Authorised 01/07/2026
An open label, balanced, randomized, single dose, two-treatment, four period, two-sequence, crossover, fully replicate, bioequivalence study comparing Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended Release Tablet USP 180 mg/240 mg, Manufactured by: Sun Pharmaceutical Industries Limited, India with Allegra-D® 24 HR (Fexofenadine HCl and Pseudoephedrine HCl Extended Release Tablets 180 mg + 240 mg) tablets, Distributed by: Chattem Inc., a Sanofi Company Chattanooga, TN 37409-0219, USA, in healthy, adult, human participants under fasting conditions.
Seasonal allergic rhinitis
Sun Pharmaceutical Industries Limited · 48 participants
📍 Romania
2026-525420-22-00 on CTIS ↗
Phase I/II Nervous System Diseases Authorised 01/07/2026
The headache- and migraine-inducing effects of apremilast in women with migraine without aura
Migraine without aura
Syddansk Universitet (University of Southern Denmark) · 14 participants
📍 Denmark
2026-525987-16-00 on CTIS ↗
Phase II Respiratory Tract Diseases Authorised 01/07/2026
A Phase II, Randomized, Double-blind, 3-Period Cross-over, Dose‑ranging Study to Assess the Efficacy and Safety of Glycopyrronium (GP) versus Placebo in Participants of 4 to Less than 12 Years of Age with Asthma Receiving Background Budesonide and Formoterol Fumarate (BFF) (FAROS)
Asthma
AstraZeneca AB · 5 participants
📍 Czechia
2025-524914-26-00 on CTIS ↗
Phase I Immune System Diseases Authorised 01/07/2026
A Study to Evaluate Targeted Therapies for Patients with Rheumatoid Arthritis
Rheumatoid Arthritis
AbbVie Deutschland GmbH & Co. KG · 19 participants
📍 Belgium · Netherlands · Spain · Germany · Italy
2025-523127-21-00 on CTIS ↗
Phase I Not possible to specify Authorised 01/07/2026
A study in healthy men to find out how blocking certain transport proteins affects the amount of BI 3000202 in the blood
Healthy
Boehringer Ingelheim International GmbH · 16 participants
📍 Germany
2026-525549-60-00 on CTIS ↗
Phase III Neoplasms Authorised 01/07/2026
A Randomized, Open-Label, Phase 3 Study of Rinatabart Sesutecan (Rina-S) Plus Standard of Care Versus Standard of Care as Maintenance Treatment After 2L PlatinumBased Doublet Chemotherapy in Participants With Recurrent Platinum-Sensitive Ovarian Cancer (PSOC)
Ovarian Cancer Platinum-Sensitive Ovarian Cancer (PSOC)
Genmab A/S · 189 participants
📍 Finland · Belgium · France · Denmark · Austria · Germany · Italy · Czechia · Norway
2025-522167-15-00 on CTIS ↗
Phase I Nutritional and Metabolic Diseases Authorised 01/07/2026
C6501003 - A Phase 1, Open-Label, Randomized, Single Dose, Parallel Group Study to Assess Relative Bioavailability of PF-08653945 When Administered Across Different Injection Sites in Adults With Overweight or Obesity
chronic weight management and other weight-related co-morbidities
Pfizer Inc. · 57 participants
📍 Belgium
2026-526334-67-00 on CTIS ↗
Phase I Not possible to specify Authorised 30/06/2026
A study in healthy men to test how BI 1815368 is processed in the body
Healthy volunteers trial
Boehringer Ingelheim International GmbH · 8 participants
📍 Netherlands
2025-523949-10-00 on CTIS ↗
Phase IV Reproductive and Urinary Physiological Phenomena Authorised 30/06/2026
Progesterone Luteal Support in Unexplained Infertility Management (PLUIM study)
unexplained subfertillity, infertillity
Universitair Medisch Centrum Utrecht · 640 participants
📍 Netherlands
2026-525747-33-00 on CTIS ↗
Phase I Physiological processes Authorised 30/06/2026
Evaluation of bioequivalence of two products containing estradiol: Estradiol/INTERMED gel 0.1% w/w (Test) vs. ESTREVA 0.1% gel (Comparator). An open, randomized, single-dose, four-period, full-replicative trial in healthy postmenopausal women
No therapeutic indication in the current trial with healthy volunteers.
CCDRD Cooperative Clinical Drug Research and Development AG, Ioulia And Irene Tseti Pharmaceutical Laboratories S.A. · 140 participants
📍 Bulgaria
2025-524775-23-00 on CTIS ↗
Phase I/II Neoplasms Authorised 30/06/2026
A Phase 1/2 Study of Inhaled KB707 in Patients with Advanced Solid Tumor Malignancies Affecting the Lungs
solid tumor
Krystal Biotech Inc. · 40 participants
📍 France · Spain
2025-522723-98-00 on CTIS ↗
Phase III Immune System Diseases Authorised 30/06/2026
Phase III, Open-label Trial to Evaluate Pharmacokinetics, Pharmacodynamics, Safety, Efficacy, and Immunogenicity of Benralizumab in Children with Eosinophilic Disease (CLIPS)
Eosinophilic Disease
AstraZeneca AB · 5 participants
📍 Netherlands · France
2023-508533-14-00 on CTIS ↗
Phase II Neoplasms Authorised 30/06/2026
A phase IIa, single-arm, single-center, open label, proof-of-concept trial evaluating increased frequency dosing of VCN-01 (zabilugene almadenorepvec) in combination with nab-Paclitaxel/Gemcitabine (GnP) in Patients with Newly-Diagnosed Metastatic Pancreatic Cancer (VIRAGE2)
metastatic pancreatic adecarcinoma
Theriva Biologics S.L. · 6 participants
📍 Spain
2026-525566-21-00 on CTIS ↗
Phase III Neoplasms Authorised 30/06/2026
A Phase 3 Multicenter Double-blind Randomized Study of Taletrectinib Versus Placebo in Patients With ROS1-Fusion Positive Stage IB-IIIA Non-Small Cell Lung Cancer Who Have Undergone Complete Tumor Resection
Non Small Cell Lung Cancer (NSCLC)
Nuvation Bio Inc. · 45 participants
📍 Spain · Belgium · France · Italy · Germany
2025-521971-29-00 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 30/06/2026
A Long-term Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
Pulmonary Hypertension Associated with Interstitial Lung Disease
Insmed Inc. · 128 participants
📍 Greece · France · Italy · Belgium · Denmark · Germany · Czechia · Portugal · Austria
2025-521769-29-00 on CTIS ↗
Phase I/II Nervous System Diseases Authorised 30/06/2026
Phase 1-2, Open-Label, Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION337 in Patients with Dravet Syndrome
Dravet Syndrome
Ionis Pharmaceuticals Inc. · 10 participants
📍 France · Belgium · Portugal · Germany
2025-523835-20-00 on CTIS ↗
Phase I Skin and Connective Tissue Diseases Authorised 30/06/2026
A double-blind, prospective, randomised, placebo-controlled, single-centre, proof-of-principle trial in healthy volunteers to investigate safety, local tolerability, pharmacokinetics, and pharmacodynamics of Asacaine after topical administration on skin exposed to ultraviolet B radiation
Topical pain
Auxesis Pharma Holding AB (publ) · 12 participants
📍 Sweden
2026-526022-41-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 30/06/2026
Efficacy and safety of Dalbavancin in the treatment of infective Endocarditis caused by gram-positive cocci
Infectious endocarditis caused by Gram-positive cocci (staphylococci, enterococci, streptococci)
Friedrich-Schiller-Universitaet Jena · 166 participants
📍 Germany
2026-526149-91-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 30/06/2026
A Phase 2/3 Study to Characterize and Evaluate the Efficacy, Safety, and Tolerability of hu14.18K322A Treatment Given in Combination with Chemotherapy in Participants with High-Risk Neuroblastoma
Participants with relapsed HRNB and participants with HRNB refractory to treatment The clinical trial will recruit participants aged ≥18 months to <18 years, and therefore all participants will be minors at the time of consent.
Renaissance Pharma Limited · 56 participants
📍 France · Denmark · Ireland · Germany
2025-524397-42-00 on CTIS ↗
Phase I Not possible to specify Authorised 30/06/2026
A study to compare how the body absorbs 4 different forms of norucholic acid medicine (tablets, granules, and capsules) when taken with or without food in healthy adults
Not applicable, healthy volunteers
Dr. Falk Pharma GmbH · 32 participants
📍 Germany
2025-523778-17-00 on CTIS ↗
Phase I Not possible to specify Authorised 29/06/2026
A Phase 1 Randomized, Double-Blind, placebo-controlled, clinical study to evaluate safety and Pharmacokinetics, of Single Ascending Doses and Multiple Ascending Doses of AIK3a305 in Healthy Volunteers
Treatment of several inflammatory diseases, including inflammation-related fibrosis and autoinflammatory diseases
Allinky Biopharma S.L. · 42 participants
📍 Spain
2026-525830-49-00 on CTIS ↗
Phase III Skin and Connective Tissue Diseases Authorised 29/06/2026
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Enpatoran in Participants with Active Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease Receiving Standard of Care
Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease
Merck Healthcare KGaA · 40 participants
📍 Germany · Bulgaria · Belgium · Spain · Greece · Italy · Czechia
2025-524855-30-00 on CTIS ↗
Phase III Immune System Diseases Authorised 29/06/2026
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Enpatoran in Participants with Active Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease Receiving Standard of Care
Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease
Merck Healthcare KGaA · 46 participants
📍 Spain · Belgium · France · Germany · Slovakia · Bulgaria · Italy · Greece
2025-523871-44-00 on CTIS ↗
Phase III Neoplasms Authorised 29/06/2026
AndroMETa-CRC-560: An Open-Label, Randomized, Controlled, Global Phase 3 Study Comparing Telisotuzumab Adizutecan (ABBV-400) plus Bevacizumab to LONSURF (Trifluridine and Tipiracil) plus Bevacizumab in Subjects with Refractory Metastatic Colorectal Cancer
Colorectal Cancer
AbbVie Deutschland GmbH & Co. KG · 138 participants
📍 Greece · Portugal · Belgium
2025-521712-19-00 on CTIS ↗
Phase III Not possible to specify Authorised 29/06/2026
Methoxyflurane versus Standard Care for Non-Traumatic Pain in the Emergency Department (PAIN-THROX) : A Multicenter, Randomized, Controlled, Superiority Trial
Non-traumatic pain
Centre Hospitalier Regional Universitaire De Tours · 164 participants
📍 France
2025-525001-21-00 on CTIS ↗
Phase II Neoplasms Authorised 29/06/2026
C6461014 - A Phase 2 Interventional Study of PF-08634404 in Combination with Chemotherapy in Participants with Previously Untreated Transformed Small Cell Lung Cancer
Small Cell Lung Cancer
Pfizer Inc. · 9 participants
📍 France · Italy
2025-524686-24-00 on CTIS ↗
Phase II Mental Disorders Authorised 29/06/2026
Randomised open-label pilot Study on Thiamine supplementation to REduce braiN injury associated with chronic Alcohol use in outpatients with alcohol use disorder : STRENA
Alcoholism
Institut National De La Sante Et De La Recherche Medicale · 60 participants
📍 France
2025-524148-36-00 on CTIS ↗
Phase IV Nutritional and Metabolic Diseases Authorised 29/06/2026
ObStructive Sleep Apnoea ManageMent in Older AdUlts with Overweight or ObEsity: A Randomized ClinicaL Trial (SAMUEL study)
Obstructive sleep apnea syndrome, Obesity
Institut De Recerca Biomedica De Lleida Fundacio Dr. Pifarre · 345 participants
📍 Spain
2026-525500-10-00 on CTIS ↗
Phase II Neoplasms Authorised 29/06/2026
A Master Protocol of a Phase II, Open-label, Multicenter, Global Platform Study to Evaluate the Safety and Efficacy of Immunotherapy With or Without Other Anticancer Drugs in Participants with Unresectable Stage III Non-small Cell Lung Cancer Planning to Undergo Concurrent Chemoradiotherapy (AQUARIUS)
Non-small Cell Lung Cancer
AstraZeneca AB · 11 participants
📍 Spain · Germany
2025-523599-21-00 on CTIS ↗
Phase I/II Respiratory Tract Diseases Authorised 29/06/2026
PET imaging For eaRly predictiOn of respoNse to neoadjuvanT tReatment in lUNg caNcER
Non small cell lung cancer
Radboud universitair medisch centrum Stichting · 40 participants
📍 Netherlands · Germany
2025-524791-30-00 on CTIS ↗
Phase I/II Neoplasms Authorised 29/06/2026
A Phase 1/2 Open-Label, Multicenter Study of RAS(ON) inhibitors in Combination with Ivonescimab with or without Other Anti-Cancer Agents in Patients with Solid Tumors
Solid Tumors
Revolution Medicines Inc. · 227 participants
📍 France · Spain · Greece · Germany · Italy · Sweden · Belgium
2025-524623-50-00 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 29/06/2026
CLARITHROMYCIN TO PREVENT SECONDARY INFECTIONS IN PATIENTS WITH SEPSIS FOLLOWING LOWER RESPIRATORY TRACT INFECTIONS: THE CLASSIFY TRIAL
Community- acquired pneumonia related sepsis with evidence of Sepsis Induced Immunoparalysis SII
Elliniko Institouto Meletis Tis Sipsis · 252 participants
📍 Greece
2025-525058-20-00 on CTIS ↗
Phase I Diagnosis Authorised 29/06/2026
LAFOV-Lung PET
Investigation in healthy volunteers
Medical University Of Vienna · 41 participants
📍 Austria
2026-525834-45-00 on CTIS ↗
Phase II Immune System Diseases Authorised 29/06/2026
A Phase 2 Randomized, Double-blind, Placebo-Controlled Study to Assess the Safety and Efficacy of MTX-474 in the Treatment of Participants with Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Mediar Therapeutics Inc. · 3 participants
📍 Netherlands
2025-523288-39-00 on CTIS ↗
Phase I Neoplasms Authorised 29/06/2026
First study evaluating the safety and dosage of YG-01 in patients with a malignant brain tumor
Glioblastoma
Ygion Biomedical GmbH · 15 participants
📍 Austria
2025-524299-44-00 on CTIS ↗
Phase III Female Urogenital Diseases and Pregnancy Complications Authorised 29/06/2026
A Randomized Phase III Study to Investigate the Efficacy and Safety of Alpha1H as a Neoadjuvant Therapy in Participants with Low- to Intermediate-Risk/Low-Grade Papillary Non-Muscle Invasive Bladder Cancer
Non-Muscle Invasive Papillary Bladder Cancer
Hamlet BioPharma AB · 169 participants
📍 Czechia
2026-525531-16-00 on CTIS ↗
Phase IV Mental Disorders Authorised 29/06/2026
Unprescribing the Pill to Reassess Symptom and Cognitive Recovery in Depression (UNPRESCRIB-D)
Major Depressive Disorder
Region Hovedstaden · 106 participants
📍 Denmark
2026-526314-90-00 on CTIS ↗
Phase III Musculoskeletal Diseases Authorised 28/06/2026
Self-Assessment Method for Statin side-effects Or Nocebo 2
Cardiovascular diseases
Copenhagen University Hospital, Region Hovedstaden · 160 participants
📍 Denmark
2025-524955-30-01 on CTIS ↗
Phase III Neoplasms Authorised 26/06/2026
A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)
Pancreatic Ductal Adenocarcinoma
Incyte Corp. · 205 participants
📍 Poland · Italy · Netherlands · Sweden · Denmark · Finland · Spain · France · Belgium · Norway · Austria
2025-525009-18-00 on CTIS ↗
Phase I Neoplasms Authorised 26/06/2026
A Phase 1 Study of BMS-986460 in Metastatic Castration-resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Bristol-Myers Squibb Services Unlimited Company · 22 participants
📍 France
2024-513987-24-00 on CTIS ↗
Phase IV Cardiovascular Diseases Authorised 26/06/2026
Randomized Evaluation of fleCAinide safety vs. STandard of care in patients with coronary artery disease and Atrial Fibrillation (ReCAST AF).
Coronary artery disease, Atrial fibrillation
UZ Leuven · 988 participants
📍 Belgium
2025-525121-13-00 on CTIS ↗
Phase IV Hormonal diseases Authorised 26/06/2026
Prospective, multicenter, randomized study on combined LT4 + LT3 therapy versus LT4 in the control of TSH in patients with advanced thyroid cancer treated with tyrosine kinase inhibitors.
Advanced thyroid carcinoma. Post-thyroidectomy hypothyroidism.
Ceinge Biotecnologie Avanzate Franco Salvatore S.c.a.r.l. · 110 participants
📍 Italy
2026-526113-28-00 on CTIS ↗
Phase I Nervous System Diseases Authorised 26/06/2026
Three-part PK and PD study of AXN-027
Chronic pain, refractory epilepsy, and other neurological disorders of excitation/inhibition (E/I) imbalance within neuronal circuits.
Axonis Therapeutics Inc. · 64 participants
📍 Netherlands
2025-524019-35-00 on CTIS ↗
Phase IV Cardiovascular Diseases Authorised 26/06/2026
Short and long-term Hemodynamic and Physiological Effects of Mavacamten in Obstructive Hypertrophic Cardiomyopathy
Obstructive Hypertrophic Cardiomyopathy
Region Skane · 40 participants
📍 Sweden
2025-524722-17-00 on CTIS ↗
Phase II Disorders of Environmental Origin Authorised 26/06/2026
“In vivo” biological standardization of the allergenic extracts Dermatophagoides pteronyssinus (DPT) and Dermatophagoides farinae (DF) in patients sensitized to them.
IgE-mediated respiratory allergic disease due to the allergen whose extract is to be standardized, DPT and DF.
Probelte Pharma S.L. · 30 participants
📍 Spain
2026-525628-13-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 26/06/2026
A 2-Part, Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study to Assess Efficacy and Safety of REGN7508, a Monoclonal Antibody Against Factor XI, for the Treatment and Secondary Prevention of Venous Thromboembolism in Participants with Solid and Hematologic Cancers (ROXI-CAT-II)
Cancer Associated Thrombosis
Regeneron Pharmaceuticals Inc. · 164 participants
📍 Bulgaria · Romania
2024-519299-16-00 on CTIS ↗
Phase I Mental Disorders Authorised 26/06/2026
Skin irritation and sensitization trial
The intended indication is for the treatment of major depressive disorder.
CCDRD Cooperative Clinical Drug Research and Development AG, Corium Innovations Inc. · 230 participants
📍 Bulgaria
2026-525269-34-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 26/06/2026
Colchicine after Electrocardioversion for Atrial Fibrillation - The COLECTRO-AF Trial
Atrial Fibrillation
Universitaetsspital Basel · 1 participants
📍 Germany
2024-516033-12-00 on CTIS ↗
Phase IV Hemic and Lymphatic Diseases Authorised 26/06/2026
Phase IV study evaluating the efficacy and safety of the venetoclax + rituximab (VR) regimen in patients with relapsed chronic lymphocytic leukemia in Polish clinical practice
Adult with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL)
Uniwersytet Medyczny W Lublinie · 36 participants
📍 Poland
2025-524795-35-00 on CTIS ↗
Phase III Therapeutics Authorised 26/06/2026
Everolimus bAsed caLcineurin inhibiTor frEe immunosuppRession oNe year AfTer lIver transplantatiON (ALTERNATION) – a randomized, prospective, multicenter, open-label, controlled phase III trial
Patients after the first year following liver transplantation
Medizinische Hochschule Hannover · 150 participants
📍 Germany
2025-524312-11-00 on CTIS ↗
Phase IV Hemic and Lymphatic Diseases Authorised 25/06/2026
A multicentre, adaptive, randomised, multidomain, platform trial for dose optimization in the treatment of adult patients with haematological diseases (BLOOD-dose): core protocol
Haematological diseases; any disorder that primarily affects the blood, bone marrow, the lymphatic system and/or blood-forming organs.
Region Hovedstaden · 200 participants
📍 Denmark
2026-525658-13-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 25/06/2026
Evaluating the effect of inhaled levodopa (Inbrija®) for early morning off in Parkinson’s disease
parkinson's disease
Region Hovedstaden · 22 participants
📍 Denmark
2026-526465-18-00 on CTIS ↗
Phase I Immune system processes Authorised 25/06/2026
A Phase 1 Study of LBL-051 in Patients with Refractory Autoimmune Disease
B-cell–mediated autoimmune diseases
Oblenio Bio Inc. · 45 participants
📍 Germany
2026-525621-20-00 on CTIS ↗
Phase I Immune System Diseases Authorised 25/06/2026
Phase 1 Single Dose Study of JADE201 in Participants with Rheumatoid Arthritis
Rheumatoid Arthritis
Jade Biosciences Inc. · 24 participants
📍 Romania · Bulgaria · Germany
2025-524746-96-00 on CTIS ↗
Phase II Eye Diseases Authorised 25/06/2026
An open-label multiple dose safety, tolerability and exploratory efficacy clinical trial of PST-611 in patients with geographic atrophy secondary to age-related macular degeneration
Geographic atrophy secondary to age-related macular degeneration
PulseSight Therapeutics · 24 participants
📍 France
2025-525008-12-00 on CTIS ↗
Phase IV Diagnosis Authorised 25/06/2026
ECETEP : Pilot study evaluating PSMA positron emission tomography for monitoring clinically significant prostate cancer after focal HIFU treatment
prostate cancer
Centre Hospitalier Universitaire De Toulouse · 30 participants
📍 France
2026-525181-22-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 24/06/2026
A PHASE III, OPEN-LABEL, SINGLE-ARM, MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND USE OF AN ON-BODY DELIVERY SYSTEM FOR THE SUBCUTANEOUS HOME ADMINISTRATION OF OCRELIZUMAB IN PATIENTS WITH MULTIPLE SCLEROSIS
Multiple Sclerosis
F. Hoffmann-La Roche AG · 54 participants
📍 Spain · France · Poland · Italy
2025-523726-40-00 on CTIS ↗
Phase IV Respiratory Tract Diseases Authorised 24/06/2026
Morphine for resting breathlessness in severe illness and palliative care (MORE-B): a randomized clinical trial
Serious, chronic, life-limiting disease
Region Skane · 40 participants
📍 Sweden
2026-525838-32-00 on CTIS ↗
Phase III Mental Disorders Authorised 24/06/2026
Women victims of violences : PTSD treatment by traumatic memory reactivation under the influence of propranolol (VIOFEM)
Post-traumatic stress disorder (PTSD)
Centre Hospitalier Universitaire De Toulouse · 76 participants
📍 France
2025-523107-30-01 on CTIS ↗
Phase I Nutritional and Metabolic Diseases Authorised 24/06/2026
A single and multiple dose trial assessing safety, tolerability, pharmacokinetics and pharmacodynamics of ZP6590
Weight management
Zealand Pharma A/S · 88 participants
📍 Germany
2026-525978-19-00 on CTIS ↗
Phase I Anesthesia and Analgesia Authorised 24/06/2026
Systemic Bioavailability and Bioequivalence of Topical Diclofenac Fysioline 23.2 mg/g gel compared with Diclofenac Diethylamine - Voltaren Forte 2.32% gel
Bioequivalence, musculoskeletal pain pain
Fysioline Oy · 34 participants
📍 Finland
2026-526434-21-00 on CTIS ↗
Phase I Immune System Diseases Authorised 24/06/2026
THERIPEX - A phase I/II open label non-randomized study, monocentric, single-arm, evaluating Safety and Efficacy of induced T-CD4 Treg by LV vector transduction expressing the FoxP3 cDNA in patients with IPEX syndrom
IPEX syndrome is a primary immunodeficiency caused by hemizygous mutations in the gene FOXP3, which encodes an essential transcription factor required to maintain immunological tolerance by thymus-derived regulatory T (Treg) cells., Patients affected by IPEX syndrome, proven by molecular diagnosis, with any active autoimmune complications or controlled under immunosuppressive therapy can be enrolled in this trial.
Assistance Publique Hopitaux De Paris · 5 participants
📍 France
2025-523305-15-00 on CTIS ↗
Phase III Digestive System Diseases Authorised 23/06/2026
ALBUMINUS: Dose reduction of human albumin during large-volume paracentesis in patients with cirrhosis
liver cirrhosis
Amsterdam UMC Stichting · 634 participants
📍 Netherlands
2026-526167-38-00 on CTIS ↗
Phase IV Female Urogenital Diseases and Pregnancy Complications Authorised 23/06/2026
The impact of ovarian stimulation with hMG on embryo quality in advanced age women. A randomized controlled trial
infertility
Santiago Dexeus Font Fundacio Privada · 240 participants
📍 Spain
2025-524761-25-00 on CTIS ↗
Phase II Respiratory Tract Diseases Authorised 23/06/2026
A Randomized, Double-blinded, Placebo-controlled, Parallel Group, Phase 2a Study to Assess the Activity, Safety, and Tolerability of SAR445399 in Adult Participants with Non-Cystic Fibrosis Bronchiectasis (NCFB).
Non-cystic fibrosis bronchiectasis
Sanofi-Aventis Recherche & Developpement · 41 participants
📍 Poland · Spain · France · Netherlands · Germany
2025-523403-29-00 on CTIS ↗
Phase III Musculoskeletal Diseases Authorised 23/06/2026
Multicenter Interventional Study Somatrogon Impact on Outcomes in Naive Small for Gestational Age or Idiopathic Short Stature paediatric patients compared with daily growth hormone
Small for gestational age (SGA) and idiopathic short stature (ISS)
Schneider Children's Medical Center Of Israel · 95 participants
📍 Greece · Poland · France · Czechia
2025-523832-38-00 on CTIS ↗
Phase IV Respiratory Tract Diseases Authorised 23/06/2026
USEFULNESS OF HIGH-FLOW OXYGEN THERAPY TO IMPROVE THE SAFETY OF PATIENTS AT HIGH RISK OF HYPOXEMIA UNDERGOING DIGESTIVE ENDOSCOPY UNDER DEEP SEDATION: A RANDOMIZED MULTICENTER COMPARATIVE STUDY. THE ENDOALF-TRIAL.
Hypoxemic episodes in patients undergoing gastroscopy, colonoscopy, or oral endoscopic ultrasound under deep sedation with oxygen therapy administration.
Hospital Universitario Rio Hortega · 326 participants
📍 Spain
2026-525766-21-01 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 23/06/2026
ECSIP : Early Corticosteroids in Severe Influenza Pneumonia, a phase III randomized controlled trial
patients with influenza-induced acute hypoxemic respiratory failure
Centre Hospital Region Metz Thionville · 544 participants
📍 France
2025-524976-40-00 on CTIS ↗
Phase II Nervous System Diseases Authorised 23/06/2026
An Open-Label Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents with Relapsing-Remitting Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis (RRMS)
F. Hoffmann-La Roche AG · 9 participants
📍 Poland · Germany · France
2025-524164-37-00 on CTIS ↗
Phase II Nervous System Diseases Authorised 23/06/2026
A Phase IIb, Non-Profit, Open-label Trial for the Intrathecal Administration of AAV9/AP4M1 for Hereditary Spastic Paraplegia Type 50 (SPG50).
Heriditary spastic paraplegia (SPG50)
Rigshospitalet, Elpida Therapeutics SPC · 2 participants
📍 Denmark
2025-524481-15-00 on CTIS ↗
Phase IV Musculoskeletal Diseases Authorised 23/06/2026
Treatment strategies for juvenile idiopathic arthritis patients with sustained inactive disease: A phase 4, multicentre, randomised trial comparing maintenance versus tapered TNF alpha inhibitor monotherapy - the Treat-JIA trial
Juvenil Idiopatic Arthritis
Oslo Universitetssykehus HF · 90 participants
📍 Norway
2026-525611-13-00 on CTIS ↗
Phase III Male Urogenital Diseases Authorised 23/06/2026
SERENDIPITY: phase III multicentric randomized study assessing the reduction of chronic prostate inflammation with Permixon®
Benign prostatic hypertrophy
Azienda Ospedaliero Universitaria Careggi, University Of Florence · 410 participants
📍 Italy
2025-525123-27-00 on CTIS ↗
Phase III Neoplasms Authorised 23/06/2026
A Prospective, Randomized, Controlled, Multinational, Phase 2/3, Open-Label Trial to Evaluate the Efficacy and Safety of SIL204-SL Administered as an Integrated Therapeutic Regimen in Combination with Chemotherapy vs. Chemotherapy Treatment Alone in Participants with Locally Advanced Pancreatic Cancer
Non-Resectable Locally Advanced Pancreatic Cancer (LAPC)
Silexion Therapeutics Ltd. · 10 participants
📍 Germany
2025-525157-39-00 on CTIS ↗
Phase II Neoplasms Authorised 23/06/2026
Efficacy of asciminib in chronic phase CML patients with T315l mutations
Chronic Myeloid Leukemia
Friedrich-Schiller-Universitaet Jena · 50 participants
📍 Germany
2025-523491-23-00 on CTIS ↗
Phase III Immune System Diseases Authorised 22/06/2026
A Phase 3 Extension Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema
Hereditary Angioedema
Adarx Pharmaceuticals Inc. · 45 participants
📍 Poland · Italy · Hungary · France · Austria · Czechia · Belgium · Spain · Bulgaria · Germany · Croatia
2025-521353-16-00 on CTIS ↗
Phase I/II Neoplasms Authorised 22/06/2026
Exploratory study of the performance of dynamic PET-CT acquisition to predict 6-month morphological response in patients with hepatocellular carcinoma treated with selective internal radiotherapy
HCC – Hepatocellular Carcinoma
Centr Georges Francois Leclerc · 30 participants
📍 France
2026-526324-48-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 22/06/2026
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Non-Active Secondary Progressive Multiple Sclerosis
Non-active Secondary Progressive Multiple Sclerosis (SPMS)
Zenas Biopharma (USA) LLC · 467 participants
📍 Germany · Bulgaria · Netherlands · Sweden · Portugal · Croatia · Italy · Austria · Spain · Poland · France · Denmark · Hungary · Romania · Estonia · Slovakia · Belgium · Czechia · Norway · Lithuania · Greece
2025-524322-18-00 on CTIS ↗
Phase II Neoplasms Authorised 22/06/2026
An Open-label, Single-Arm, Phase 2 Study to Evaluate Enfortumab Vedotin plus Pembrolizumab for Bladder Preservation in Participants with Muscle-invasive Bladder Cancer (EV-209).
Muscle-invasive Bladder Cancer
Astellas Pharma Global Development Inc. · 88 participants
📍 Germany · France · Poland · Italy · Spain
2025-524488-18-00 on CTIS ↗
Phase II Digestive System Diseases Authorised 22/06/2026
A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-8690 in Adult Participants with Moderately to Severely Active Ulcerative Colitis
Colitis ulcerative
Merck Sharp & Dohme LLC · 44 participants
📍 Italy · Greece · Netherlands · Poland · Germany · France
2025-523479-49-00 on CTIS ↗
Phase II Neoplasms Authorised 22/06/2026
Open-Label Extension Study to Provide Continued Access to Avutometinib Alone or in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
Verastem Inc. · 4 participants
📍 France
2025-524713-88-00 on CTIS ↗
Phase I/II Musculoskeletal Diseases Authorised 22/06/2026
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 / 2 Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Single Ascending Doses of TRCN-1023 Administered by Intrathecal Injections to Adult People Living with Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis
Trace Neuroscience Inc. · 20 participants
📍 Germany · Netherlands
2025-523111-11-00 on CTIS ↗
Phase IV Musculoskeletal Diseases Authorised 22/06/2026
Sample Collection Study to Monitor the Risk of Malignancy Due to Insertional Oncogenesis in Early Onset Patients with Metachromatic Leukodystrophy Treated with OTL-200 in the Clinical Development Program
Metachromatic leukodystrophy
Orchard Therapeutics (Europe) Limited · 29 participants
📍 Netherlands · Germany · Italy · Sweden · France
2025-522275-28-00 on CTIS ↗
Phase I Neoplasms Authorised 22/06/2026
Safety and Tolerability of REGN17235 in Adult Participants with Clonal Cytopenia of Undetermined Significance and Low-Risk Myelodysplastic Syndrome with SF3B1 Mutation
Clonal Cytopenia of Undetermined Significance with SF3B1 mutation, Low-Risk Myelodysplastic Syndrome with SF3B1 mutation
Regeneron Pharmaceuticals Inc. · 15 participants
📍 Belgium
2026-525464-18-00 on CTIS ↗
Phase II Mental Disorders Authorised 22/06/2026
Psilocybin-Assisted Psychotherapy for Posttraumatic Stress Disorder in Military Veterans: A Pilot Feasibility Study
Posttraumatic stress disorder
ARQ National Psychotrauma Centrum · 12 participants
📍 Netherlands
2025-521488-11-00 on CTIS ↗
Phase II Bacterial Infections and Mycoses Authorised 22/06/2026
Supplementary Oxygen Therapy after Limb Debridement and Reconstruction Surgery in Infected Extremity Fractures (SOLDIER): a pilot, non-blinded, randomized controlled trial
Fracture-Related Infection
Amsterdam UMC Stichting · 50 participants
📍 Netherlands
2026-525871-24-00 on CTIS ↗
Phase II Nervous System Diseases Authorised 22/06/2026
A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 for the Treatment of Narcolepsy with Cataplexy (Narcolepsy Type 1)
Narcolepsy with Cataplexy (NT1)
Takeda Development Center Americas Inc. · 22 participants
📍 Spain
2025-522587-33-00 on CTIS ↗
Phase II Eye Diseases Authorised 22/06/2026
Pain Relief at Screening for Retinopathy of Prematurity - The PROPER study
Retinopathy of prematurity
St. Olavs Hospital HF · 33 participants
📍 Norway
2023-507975-23-01 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 22/06/2026
Effects of bempedoic acid/ezetimibe/high-intensity statin on plaque regression and stabilisation of coronary atherosclerosis among patients without cardiovascular events
Coronary atherosclerosis
Daiichi Sankyo Europe GmbH · 103 participants
📍 Italy · Spain · Germany
2025-524625-41-00 on CTIS ↗
Phase II Musculoskeletal Diseases Authorised 22/06/2026
A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety and Efficacy of AGA2115 in Adults with Type I, III, or IV Osteogenesis Imperfecta (OI)
Osteogenesis Imperfecta
Angitia Inc. Ltd. · 40 participants
📍 Netherlands · France · Denmark
2025-522951-24-00 on CTIS ↗
Phase I Neoplasms Authorised 22/06/2026
Pharmacokinetics, safety, and immunogenicity comparison of Bmab1700 and Opdivo® as adjuvant monotherapy in patients with melanoma
Stage IIB/C, Stage III, or Stage IV Melanoma
Biocon Biologics UK PLC · 43 participants
📍 Spain · Romania
2025-525158-20-00 on CTIS ↗
Phase II Musculoskeletal Diseases Authorised 22/06/2026
A Phase 2, Randomized, Double-blind, Placebo-controlled Crossover Study Evaluating the Efficacy and Safety of LTG-321 in Patients with Osteoarthritis of the Knee
Osteoarthritis of the knee
Latigo Biotherapeutics Inc. · 180 participants
📍 Denmark
2026-525966-22-00 on CTIS ↗
Phase III Immune System Diseases Authorised 19/06/2026
A Phase 3, Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of BMS-986353, CD19-targeted NEX-T CAR T Cells, Versus Standard of Care in Participants with Active Systemic Sclerosis (Breakfree-SSc)
Systemic Sclerosis
Celgene Corp. · 33 participants
📍 Spain · Germany · France · Italy
2025-524337-11-00 on CTIS ↗
Phase I Immune System Diseases Authorised 19/06/2026
A Phase 1 first-in-human study to evaluate SAR448272 in adult participants
healthy volunteers, immunological diseases
Sanofi-Aventis Recherche & Developpement · 147 participants
📍 Germany
2026-526014-87-00 on CTIS ↗
Phase IV Nutritional and Metabolic Diseases Authorised 19/06/2026
Insulin resistance in type 2 diabetes: evaluating the pathogenic mechanisms of insulin resistance in the myocardium and the effects of the treatments with GLP-1RA and SGLT2i
Type 2 diabetes
Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca · 60 participants
📍 Spain
2025-523374-17-03 on CTIS ↗
Phase II Hemic and Lymphatic Diseases Authorised 19/06/2026
Epcoritamab in Relapsed/Refractory Marginalzone Lymphoma - A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY (EPOS-1)
Marginal Zone Lymphoma
Universitaetsklinikum Ulm AöR · 53 participants
📍 Germany
2025-524879-23-00 on CTIS ↗
Phase IV Digestive System Diseases Authorised 19/06/2026
Tacrolimus as prophylaxis of post-ERCP pancreatitis: a DPSG (Dutch Pancreatitis Study Group) multicenter, double-blind, randomized, placebo-controlled study.
Post-ERCP Pancreatitis
Amsterdam UMC Stichting · 520 participants
📍 Netherlands
2025-522900-26-00 on CTIS ↗
Phase I Not possible to specify Authorised 19/06/2026
A study to see how safe a new medicine (NNC6022-0004) is in healthy people and people living with obesity
Cardiometabolic
Novo Nordisk A/S · 128 participants
📍 Netherlands
2026-525179-26-00 on CTIS ↗
Phase I/II Congenital, Hereditary, and Neonatal Diseases and Abnormalities Authorised 18/06/2026
Long-term Follow-up (LTFU) Study of Participants in any iECURE Protocol Using an Investigational Product
Ornithine Transcarbamylase Deficiency (OTC)
Iecure Inc. · 3 participants
📍 Spain · France
2024-514190-21-00 on CTIS ↗
Phase I Virus Diseases Authorised 18/06/2026
A first study in healthy volunteers to examine the safety and tolerability of convalescent plasma given through the nose,  as well as the duration of its presence in the nose
Healthy volunteers
Rode Kruis-Vlaanderen · 104 participants
📍 Belgium
2025-525085-29-00 on CTIS ↗
Phase I Skin and Connective Tissue Diseases Authorised 18/06/2026
A Study to Learn How Different Amounts of the Study Intervention Called PF-07832837 are Tolerated and Act in the Body in Healthy Adults and Patients
Atopic Dermatitis
Pfizer Inc. · 19 participants
📍 Poland
2025-524150-34-00 on CTIS ↗
Phase I Male Urogenital Diseases Authorised 18/06/2026
A study to check whether adding RUTI® to standard BCG treatment for high-risk early-stage bladder cancer is safe and how it changes the body’s defenses, with participants randomly receiving RUTI® or a look-alike treatment.
High-risk non-muscle invasive bladder cancer (NMIBC)
Laboratorio Reig Jofre S.A. · 44 participants
📍 Spain
2026-525897-20-00 on CTIS ↗
Phase III Neoplasms Authorised 18/06/2026
Paclitaxel plus ramucirumab and tislelizumab as switch maintenance versus continuation of chemotherapy and tislelizumab in patients with advanced HER2-negative and PD-L1 positive gastroesophageal adenocarcinoma: the ARMANI-2/ENGIC08 trial by GONO
Advanced HER2-negative and PD-L1 positive gastroesophageal adenocarcinoma
Fondazione GONO G.I. · 212 participants
📍 Spain · Germany · Italy
2025-524048-36-00 on CTIS ↗
Phase II Nervous System Diseases Authorised 18/06/2026
A randomized, double-blind, placebo-controlled, 104-week proof-of-concept study to evaluate the efficacy of intravenous prasinezumab in participants with Parkinson's disease carrying a severe mutation in the GBA gene (prevent cognitive decline in GBA-associated PD)
PARKINSON’S DISEASE
Universitaetsklinikum Tuebingen AöR · 110 participants
📍 Spain · Germany · Italy · Sweden · France · Luxembourg
2024-513496-40-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 17/06/2026
A multicentre, randomized, double-blind, placebo-controlled phase II/III trial investigating the efficacy of anti-FcRn targeting with efgartigimod as a first-line add-on therapy to IVMP in moderate-to-severe attacks of demyelinating diseases of the central nervous system
Demyelinating diseases
Medizinische Hochschule Hannover · 116 participants
📍 Germany · Austria
2025-523654-13-00 on CTIS ↗
Phase II Musculoskeletal Diseases Authorised 17/06/2026
Preventive effect of 5% lidocaine patch on the development of neuropathic pain following an osteoporotic vertebral fracture: A proof-of-concept, controlled, randomized trial
Osteoporotic Fracture
University Hospital Of Clermont-Ferrand · 30 participants
📍 France
2025-524889-25-00 on CTIS ↗
Phase IV Digestive System Diseases Authorised 17/06/2026
STOP - Safety and efficacy of a STOPping strategy versus classical maintenance dose of JAK inhibitors in deep remission patients with ulcerative colitis: a randomized controlled trial
ulcerative colitis
Centre Hospitalier Regional De Marseille · 224 participants
📍 France
2026-525643-32-00 on CTIS ↗
Phase I Neoplasms Authorised 17/06/2026
A Study to Learn About How Different Forms of Study Medicine Prifetrastat are Taken Up Into the Blood in Healthy Adults
Locally advanced or metastatic ER+/HER2- breast cancer
Pfizer Inc. · 32 participants
📍 Belgium
2026-526038-26-00 on CTIS ↗
Phase I Neoplasms Authorised 17/06/2026
Phase 1/1b Study of RNDO-564 in Participants with Advanced Urothelial Cancer
Other Solid Tumors Associated with Nectin-4 Expression, Relapsed/Refractory Locally Advanced or Metastatic Urothelial Cancer
Rondo Therapeutics Inc. · 34 participants
📍 Spain
2025-524687-38-00 on CTIS ↗
Phase I Nutritional and Metabolic Diseases Authorised 17/06/2026
A phase 1 first-in-human study of a phenylalanine-binding polymer (phelimin) in healthy volunteers and adult, classical PKU patients
Phenylketonuria
Mipsalus ApS · 7 participants
📍 Denmark
2024-519121-38-01 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 17/06/2026
IM0271016: An Open-label, Multi-center, Long-term Extension Study to Evaluate the Long-term Safety and Tolerability of Admilparant in Participants with Pulmonary Fibrosis
Progressive pulmonary fibrosis and Idiopathic pulmonary fibrosis
Bristol-Myers Squibb Services Unlimited Company · 318 participants
📍 Finland · Portugal · Hungary · Ireland · Poland · Greece · France · Belgium · Denmark · Italy · Spain · Netherlands · Austria · Germany
2025-522373-10-00 on CTIS ↗
Phase II Skin and Connective Tissue Diseases Authorised 17/06/2026
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Nemolizumab in Adult Patients with Systemic Sclerosis, including a 52-Week Main Treatment Period and a 156-Week Extension Treatment Period
Systemic sclerosis
Galderma S.A. · 56 participants
📍 Poland · Italy · Bulgaria · France · Greece · Spain · Croatia
2025-522294-11-00 on CTIS ↗
Phase I Skin and Connective Tissue Diseases Authorised 16/06/2026
A First‑in‑Human Phase 1 Study to Investigate the Safety, Tolerability, and PK of AB102 in Healthy Participants
Healthy volunteers
Arcus Biosciences Inc. · 130 participants
📍 Netherlands
2026-526279-52-00 on CTIS ↗
Phase II Neoplasms Authorised 16/06/2026
RADICAL-IO: thRee cycles of immunotherApy without raDical therapy In mediCALly InOperable stage I non-small cell lung cancer
Stage I non-small cell lung cancer
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting · 30 participants
📍 Netherlands
2025-524305-32-00 on CTIS ↗
Phase I Neoplasms Authorised 16/06/2026
Open-label study of BBO-11818 in adult subjects with KRAS mutant cancer
Solid Tumors
Theras Inc. · 2999997 participants
📍 Spain · Italy · France
2025-524690-16-00 on CTIS ↗
Phase II Musculoskeletal Diseases Authorised 16/06/2026
A Phase 2, Open-Label Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE)
Duchenne Muscular Dystrophy
Entrada Therapeutics Inc. · 56 participants
📍 Belgium · Italy · Netherlands · Spain
2025-525124-10-00 on CTIS ↗
Phase I Neoplasms Authorised 16/06/2026
A Phase 1, Open-Label, Multicenter Study of INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Hematological malignancies, Advanced solid tumors
Incyte Corp. · 150 participants
📍 Italy · Belgium · Denmark
2025-523130-11-00 on CTIS ↗
Phase III Neoplasms Authorised 16/06/2026
A Phase III, Multicentre, Randomised Controlled Study of Sonesitatug vedotin in Combination with Capecitabine with or without Rilvegostomig in First-line Claudin18.2-positive, HER2-negative, Advanced/Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (CLARITY-Gastric 02)
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer Expressing Claudin18.2
AstraZeneca AB · 516 participants
📍 France · Italy · Spain · Hungary · Poland · Belgium · Germany · Netherlands
2024-519787-40-00 on CTIS ↗
Phase I/II Neoplasms Authorised 16/06/2026
A Phase I/II Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD6621, a T Cell-engaging Antibody That Targets STEAP2, CD3, and CD8 in Adult Participants With Metastatic Prostate Cancer (ACTIVATED-4-PC)
Metastatic Prostate Cancer
AstraZeneca AB · 45 participants
📍 Belgium · Spain · Poland · Italy · Netherlands
2025-520626-37-00 on CTIS ↗
Phase III Neoplasms Authorised 16/06/2026
A Phase 3, Randomized, Placebo-Controlled Study of Adjuvant Intismeran Autogene Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) or Intismeran Autogene Monotherapy Versus Placebo in Participants With Completely Resected High-Risk Stage I Non-Small Cell Lung Cancer (INTerpath-014)
Stage I NSCLC
Merck Sharp & Dohme LLC · 283 participants
📍 Greece · Poland · Italy · Hungary · Germany · Netherlands · France · Spain
2025-522643-18-00 on CTIS ↗
Phase II Digestive System Diseases Authorised 16/06/2026
A Study to Evaluate the Long-term Safety and Efficacy of Long-acting Antibodies as Single Agents and in Combinations in Participants with Inflammatory Bowel Disease
Ulcerative colitis (Inflammatory Bowel Disease)
Spyre Therapeutics Inc. · 228 participants
📍 Croatia · Poland · Austria · Czechia · Italy · Slovakia · Bulgaria · Greece · Belgium · Spain · Hungary · Germany · Lithuania · France · Romania
2025-524640-35-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 15/06/2026
Achieve - ACetazolamide in patients with Heart failure, to decrease weight and relIEVE symptoms
Heart failure
Centre Hospitalier Universitaire De Montpellier · 1050 participants
📍 France
2025-524344-35-00 on CTIS ↗
Phase III Musculoskeletal Diseases Authorised 15/06/2026
A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of each of two dose levels of sarilumab in adults with early polymyalgia rheumatica
Musculoskeletal diseases
Sanofi-Aventis Recherche & Developpement · 177 participants
📍 France · Netherlands · Germany · Czechia · Belgium · Austria · Hungary · Greece · Spain
2024-511296-15-00 on CTIS ↗
Phase III Musculoskeletal Diseases Authorised 15/06/2026
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of BBP-418 (Ribitol) in Participants with Limb-Girdle Muscular Dystrophy 2I/R9 (LGMD2I/R9)
Limb Girdle Muscular Dystrophy (LGMD) Type 2I
ML Bio Solutions Inc. · 35 participants
📍 Germany · Denmark · Netherlands · Italy · Norway
2025-524371-23-00 on CTIS ↗
Phase II Hemic and Lymphatic Diseases Authorised 15/06/2026
A single arm single center exploratory observational phase II study, aimed to detect long term changes in volume of port-wine macrocheilia and color of port-wine stain in patients undergoing surgery and laser therapy during sirolimus treatment. Quality of life and efficacy and safety of sirolimus will be assessed.
Vascular malfomation
Oslo University Hospital HF · 20 participants
📍 Norway
2024-511937-37-01 on CTIS ↗
Phase II Neoplasms Authorised 15/06/2026
A Phase II, Open-label, Multicenter Study Testing Teclistamab in Combination with Pomalidomide Administered in Alternative Fashion in Participants with RRMM, who Received 1 - 3 Prior Lines of Therapy, Including Lenalidomide and Anti-CD38 Therapy
Multiple myeloma (RRMM)
Odense University Hospital · 50 participants
📍 Finland · Denmark · Estonia · Norway
2025-522114-23-00 on CTIS ↗
Phase IV Immune System Diseases Authorised 15/06/2026
Real-World Effectiveness and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy (C3G) or Primary Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN): A Multi-Country Study (PRISMC3)
Primary Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN), C3 Glomerulopathy (C3G)
Swedish Orphan Biovitrum AB (publ) · 69 participants
📍 France · Italy · Spain · Germany
2025-524487-37-00 on CTIS ↗
Phase II Diagnosis Authorised 13/06/2026
Exploratory study evaluating the relevance of [68Ga]Ga-FAPI-46 for staging and identifying progressing patients with transthyretin cardiac amyloidosis
Transthyretin cardiac amyloidosis
Centre Hospitalier Universitaire De Nantes · 40 participants
📍 France
2025-523616-36-00 on CTIS ↗
Phase III Neoplasms Authorised 12/06/2026
A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Study of MK-1084 Plus Durvalumab Versus Placebo Plus Durvalumab in Participants With Locally Advanced, Unresected KRAS G12C-Mutant Non-Small Cell Lung Cancer Without Disease Progression Following Definitive Platinum-Based Chemoradiotherapy (KANDLELIT-015)
Locally advanced, unresected (unresectable or medically inoperable or refuse surgery) Stage II-III NSCLC with KRAS G12C mutation​
Merck Sharp & Dohme LLC · 88 participants
📍 Italy · Netherlands · France · Germany · Spain · Poland · Greece
2025-522038-29-00 on CTIS ↗
Phase I Not possible to specify Authorised 12/06/2026
A Safety Study to Test a New Medicine (ANT3310) Alone and When Taken with an Antibiotic (Meropenem) in Healthy Adult Participants.
Not applicable for phase I study
Antabio · 40 participants
📍 France
2026-526411-11-00 on CTIS ↗
Phase III Neoplasms Authorised 12/06/2026
A Phase 2/3, Randomized, Open-Label, Comparison Study of MK-1045 Versus Blinatumomab in Participants With Relapsed or Refractory CD19+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)
​Relapsed/refractory B-cell Acute Lymphoblastic Leukemia​
Merck Sharp & Dohme LLC · 109 participants
📍 Greece · Netherlands · Sweden · France · Italy · Spain · Denmark
2025-522267-15-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 12/06/2026
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Tolerability of Efimosfermin Alfa in Participants With Known or Suspected F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-2)
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Glaxosmithkline Research & Development Limited · 210 participants
📍 Greece · Germany · Belgium · Netherlands · Poland · Italy · France · Spain · Bulgaria · Austria
2025-523674-16-00 on CTIS ↗
Phase IV Musculoskeletal Diseases Authorised 12/06/2026
BEAT Fatigue – Benefit of Elevated Administration of Thiamine for Fatigue in Rheumatoid Arthritis: A randomized, double-blind, placebo-controlled trial
Fatigue in rheumatoid arthritis patients
Odense University Hospital · 150 participants
📍 Denmark
2024-519268-41-00 on CTIS ↗
Phase I Reproductive and Urinary Physiological Phenomena Authorised 12/06/2026
Study to assess the relative bioavailability of Neludolat versus YAZ in healthy female subjects.
Healthy subjects
Pevisal Group Farmaceutici S.r.l. · 24 participants
📍 Czechia
2025-524871-22-00 on CTIS ↗
Phase II Neoplasms Authorised 12/06/2026
A PHASE 2 STUDY OF STRIDE (durvalumab + tremelimumab) With Lenvatinib Versus STRIDE Alone in Patients With Unresectable Hepatocellular Carcinoma (SLIDE-HCC) - HE.2
patients with unrestectable hepatocellular carcinoma (SLIDE-HCC)
IRCCS Istituto Nazionale Tumori Fondazione Pascale · 56 participants
📍 Italy
2025-521608-23-00 on CTIS ↗
Phase II Digestive System Diseases Authorised 11/06/2026
J6Z-MC-IIBD - A Master Protocol for Phase 2, Randomized, Controlled Studies of Multiple Interventions for the Treatment of Adults With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease J6Z-MC-CD01 - A Phase 2, Multicenter, Randomized, Open-Label, Active-Controlled Study to Investigate LY4395089/Mirikizumab Co-administration Compared with Mirikizumab in Adults with Moderately to Severely Active Crohn’s Disease
J6Z-MC-IIBD - Colitis, Ulcerative Crohn Disease J6Z-MC-CD01 - Crohn Disease
Eli Lilly & Co. · 37 participants
📍 Italy · Germany · Hungary · Poland · Belgium
2025-524112-11-00 on CTIS ↗
Phase I/II Immune System Diseases Authorised 11/06/2026
Phase I-IIa, national, multicenter, clinical trial to evaluate the safety and preliminary efficacy of CAR-T CD19 therapy in patients with refractory lupus nephritis.
Refractory Lupus Nephritis
Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz · 10 participants
📍 Spain
2025-522449-23-00 on CTIS ↗
Phase III Otorhinolaryngologic Diseases Authorised 11/06/2026
Evaluation of the Non-Inferiority of Topical Chloramphenicol Versus Topical Ciprofloxacin in the Resolution of Otorrhea in Adults With Chronic Suppurative Otitis Media (CSOM) – Protocol OMCOS
chronic suppurative otitis media (CSOM)
Institut De Recerca Biomedica De Lleida Fundacio Dr. Pifarre · 88 participants
📍 Spain
2026-525540-15-00 on CTIS ↗
Phase II Neoplasms Authorised 11/06/2026
A Phase 2, Open-Label, Multicenter, Randomized Study to Evaluate Denikitug as Monotherapy or in Combination With Nivolumab or Chemotherapy in Participants With HER2-Negative, Unresectable, Recurrent, and/or Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas
HER2-negative, unresectable, recurrent, and/or metastatic gastric, GEJ, and esophageal adenocarcinomas
Gilead Sciences Inc. · 45 participants
📍 Spain · France
2025-524095-27-00 on CTIS ↗
Phase IV Digestive System Diseases Authorised 11/06/2026
Efficacy of top-down therapy with mirikizumab versus standard of care with azathioprine in patients with newly diagnosed, moderate-to-severe Crohn’s disease: A 52-week, multicenter, open-label, randomized controlled trial
Crohn’s disease
Universitaetsklinikum Schleswig-Holstein AöR · 320 participants
📍 Germany
2026-525191-26-00 on CTIS ↗
Phase IV Digestive System Diseases Authorised 11/06/2026
Clinical trial to evaluate the correlation between variation in intestinal lactase activity measured with LacTEST 0.45g and alteration of intestinal barrier integrity and/or intestinal permeability in patients with celiac disease
Patients with celiac disease
Venter Pharma S.L. · 42 participants
📍 Spain
2026-525518-70-00 on CTIS ↗
Phase I/II Not possible to specify Authorised 10/06/2026
ACTIVATE - Phase 1 Clinical Trial evaluating the combination of Actinomycin D and venetoclax in patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
Assistance Publique Hopitaux De Paris · 36 participants
📍 France
2025-524728-22-01 on CTIS ↗
Phase III Neoplasms Authorised 10/06/2026
First adjuvant trial in locally resected aggressive pancreatic neuroendocrine tumors: a randomized phase III investigating the efficacy of systemic chemotherapy (ADJUPANET)
Pancreatic NeuroEndocrine Tumors (PanNET) ; Aggressive stage I-III well differentiated R0 resected
Institut Gustave Roussy · 504 participants
📍 France
2025-523593-16-00 on CTIS ↗
Phase III Bacterial Infections and Mycoses Authorised 10/06/2026
A Phase 3 prospective, randomized, multicenter, active-controlled study to evaluate the efficacy and safety of BV100 plus low-dose polymyxin B compared with colistin plus high-dose ampicillin/sulbactam in the treatment of adult patients with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex
Hospital-acquired bacterial pneumonia including ventilator-associated bacterial pneumonia caused by carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex
Bioversys S.A.S. · 58 participants
📍 Greece · Croatia
2025-524092-23-00 on CTIS ↗
Phase II Digestive System Diseases Authorised 10/06/2026
J6E-MC-KWAM: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Development Program to Evaluate the Efficacy and Safety of LY4268989 (MORF-057) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis (EMERALD-3)
Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe, Ulcerative Colitis (UC)
Eli Lilly & Co. · 104 participants
📍 Latvia · Portugal · Greece · France · Czechia · Italy · Poland · Slovakia · Hungary · Croatia · Lithuania
2025-524404-29-00 on CTIS ↗
Phase I Neoplasms Authorised 10/06/2026
A clinical trial to learn about the effects of JFI447 and how it shows up in scans compared to FFG233 in people with solid tumors
Patients with metastatic PDAC, NSCLC, HR+/HER2- ductal and lobular BC, TNBC, CRC or STS.
Novartis Pharma AG · 22 participants
📍 Denmark
2025-523665-24-00 on CTIS ↗
Phase III Neoplasms Authorised 09/06/2026
Long-term follow-up study of patients who have previously been exposed to UCART19 (allogeneic engineered T-cells expressing a lentiviral-based anti-CD19 chimeric antigen receptor)
Advanced lymphoid leukemia
Institut De Recherches Internationales Servier IRIS · 1 participants
📍 France
2026-526212-37-00 on CTIS ↗
Phase III Neoplasms Authorised 09/06/2026
A Phase 2/3 randomized, open-label study of MK-1045 in combination with rituximab in patients with 1L follicular lymphoma.
Follicular Lymphoma
Merck Sharp & Dohme LLC · 5 participants
📍 France · Spain
2025-522777-10-00 on CTIS ↗
Phase I Neoplasms Authorised 09/06/2026
A trial in healthy participants to find out how long JNJ-101556143 stays in and acts on the body when administered as different formulations and under different food conditions
Prostate Cancer
Janssen Cilag International · 48 participants
📍 Belgium
2026-526263-38-00 on CTIS ↗
Phase IV Immune System Diseases Authorised 09/06/2026
DISCO-RA:DIScontinuation of COncomitant disease modifying anti-rheumatic drugs (DMARDs) in rheumatoid arthritis patients also using TNF inhibitors - a randomized long-term non-inferiority strategy trial
Rheumatoid arthritis
Sint Maartenskliniek Stichting · 202 participants
📍 Netherlands
2026-525316-33-00 on CTIS ↗
Phase III Hemic and Lymphatic Diseases Authorised 09/06/2026
Accelerate Improvement in Multiple Myeloma for Newly Diagnosed Transplant-Eligible Patients (AugMMent)
Newly diagnosed Multiple Myeloma in patients eligible for stem cell transplantation
Universitaetsklinikum Heidelberg AöR · 399 participants
📍 Germany
2025-523990-40-00 on CTIS ↗
Phase I/II Neoplasms Authorised 09/06/2026
A Phase 1/2, Open-label Study of VS-7375, a KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and in Combination, in Patients with Advanced KRAS G12D-Mutant Solid Tumors
Advanced KRAS G12D-Mutant Solid Tumors
Verastem Inc. · 210 participants
📍 Italy · France · Germany · Belgium · Spain · Netherlands
2025-523432-39-01 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 09/06/2026
Randomized, double-blind, parallel-group clinical trial, compared with placebo to evaluate the efficacy and safety of three antibiotic treatment regimens for the eradication of primary P. aeruginosa infection in patients with bronchiectasis
Bronchiectasis
Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau · 160 participants
📍 Spain
2025-524454-34-00 on CTIS ↗
Phase III Hemic and Lymphatic Diseases Authorised 08/06/2026
Efanesoctocog alfa treatment in patients with synovitis in congenital hemophilia A: multicenter, randomized, open-label, phase 3 clinical trial
Congenital hemophilia A (HA), Synovitis
GWT-Tud GmbH · 60 participants
📍 Austria · Germany
2025-523896-44-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 08/06/2026
A Phase 2b/3, Randomized, Double-Blinded, Placebo Controlled Study ChecKing the Efficacy and Safety of ATAciguat to Slow the Progression of VaLvular DYsfunction in Participants with Moderate Calcific Aortic Valve STenosis (KATALYST-AV)
Moderate Calcific Aortic Valve Stenosis (CAVS)
Kardigan Inc. · 496 participants
📍 Norway · Czechia · Portugal · Austria · Poland · France · Spain
2025-522176-86-01 on CTIS ↗
Phase I Mental Disorders Authorised 08/06/2026
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ST‑905‑AG1 in Healthy Volunteers
Schizophrenia
Syremis Therapeutics Ltd. · 280 participants
📍 France
2026-525700-10-00 on CTIS ↗
Phase III Hemic and Lymphatic Diseases Authorised 08/06/2026
HOVON 182 CLL: Prospective randomized phase 3 study of treatment with rituximab (6 cycles) in combination with 6 or 26 cycles of venetoclax in patients with relapsed or refractory chronic lymphocytic leukemia RED RIVER CLL study: Reduced Duration Rituximab VEnetoclax in Relapsed/refractory CLL
Relapsed or refractory chronic lymphocytic leukemia, Relapsed or refractory small lymphocytic lymphoma
Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting · 456 participants
📍 Netherlands
2025-524283-38-00 on CTIS ↗
Phase IV Nutritional and Metabolic Diseases Authorised 08/06/2026
A neuropsychobiological approach to optimize patient selection for GLP-1-based pharmacotherapy for weight management across the binge eating spectrum
obesity
UZ Leuven · 96 participants
📍 Belgium
2026-526016-36-00 on CTIS ↗
Phase II Skin and Connective Tissue Diseases Authorised 08/06/2026
A multicenter, randomized, double-blind, placebo-controlled, dose-ranging Phase IIb study to assess the efficacy and safety of GIA632 in adult participants with non-segmental vitiligo followed by an extension period
Nonsegmental vitiligo
Novartis Pharma AG · 80 participants
📍 Germany · Spain · Netherlands · France · Italy
2025-522301-37-00 on CTIS ↗
Phase II Immune System Diseases Authorised 08/06/2026
J5D-MC-FPAC: A Phase 2a, Randomized, Multicenter, Double-Blind, Placebo-Controlled Proof of Concept Study to Investigate Efficacy and Safety of LY4005130 in Adult Participants With Severe Alopecia Areata
Alopecia Areata
Eli Lilly & Co. · 14 participants
📍 Poland · Netherlands
2025-524727-41-00 on CTIS ↗
Phase III Bacterial Infections and Mycoses Authorised 08/06/2026
PHASE III, OPEN-LABEL, RANDOMIZED, CONTROLLED, NON-INFERIORITY CLINICAL-TRIAL TO ASSESS THE EFFICACY AND SAFETY OF SHORT OUTPATIENT AMOXICILLIN REGIMENS IN CHILDREN WITH ACUTE STREPTOCOCCAL PHARYNGOTONSILLITIS (STOP – TRIAL)
ACUTE STREPTOCOCCAL PHARYNGOTONSILLITIS
Fundacion Para La Investigacion Biomedica Hospital Infantil Universitario Nino Jesus · 500 participants
📍 Spain
2026-525355-93-00 on CTIS ↗
Phase II Neoplasms Authorised 08/06/2026
A Phase 2, Open Label, Multicenter, Randomized Study, to Evaluate the Efficacy and Safety of Denikitug Monotherapy and Denikitug-based Combinations in Participants With Advanced Microsatellite Stable (MSS) Colorectal Cancer (CRC).
Advanced Microsatellite Stable (MSS) Colorectal Cancer (CRC)
Gilead Sciences Inc. · 94 participants
📍 Spain · Italy · France
2025-523984-39-00 on CTIS ↗
Phase III Digestive System Diseases Authorised 08/06/2026
Efficacy of sufentanil in urgent laparoscopic cholecystectomy: An alternative to the usual opioids for postoperative pain?
Laparoscopic cholecystectomy
Fundacion Biomedica Galicia Sur · 66 participants
📍 Spain
2026-525783-18-00 on CTIS ↗
Phase I/II Respiratory Tract Diseases Authorised 08/06/2026
TSRA196-AAT-201: A Phase 1/2, Open-Label, Multi-Center, Dose Escalation, Dose Expansion, and Single Repeat Dose Study of TSRA-196 in Adults With the PiZZ Genotype Who Have Lung and/or Liver Disease Associated with Severe Alpha-1 Antitrypsin Deficiency
Lung and/or Liver Disease Associated with Alpha-1 Antitrypsin Deficiency (AATD)
Tessera Therapeutics Inc. · 25 participants
📍 Ireland · Sweden · Netherlands
2025-523497-16-00 on CTIS ↗
Phase I/II Neoplasms Authorised 08/06/2026
A PHASE IB/II STUDY TO EVALUATE SAFETY AND EFFICACY OF BEXMARILIMAB IN COMBINATION WITH DOXORUBICIN IN METASTATIC SOFT-TISSUE SARCOMA (BEXAR Study)
Advanced or metastatic histologically confirmed soft tissue sarcoma (STS) in adult patients who are not candidates for curative treatment.
Medica Scientia Innovation Research S.L. · 278 participants
📍 Spain
2025-525144-18-00 on CTIS ↗
Phase III Neoplasms Authorised 08/06/2026
A Randomized, Open-Label, Phase 3 Study of ZL-1310, a DLL3 Antibody Drug Conjugate (ADC), Compared to Investigator’s Choice Therapy in Participants with Relapsed Small Cell Lung Cancer
Small Cell Lung Cancer (SCLC)
Zai Lab (US) LLC · 234 participants
📍 Belgium · Czechia · Germany · Denmark · Greece · Netherlands · Poland · Spain · Austria · Italy · France
2025-522818-23-00 on CTIS ↗
Phase II Immune System Diseases Authorised 08/06/2026
REpurposed drug evaluation for DEceleration of immunE aging & Mitigation of chronic inflammation (REDEEM)
Immune Aging, Chronic inflammation
Radboud universitair medisch centrum Stichting · 150 participants
📍 Netherlands
2026-526084-38-00 on CTIS ↗
Phase II Neoplasms Authorised 08/06/2026
Radium223 dichloride (223RaCl) in the treatment of symptomatic bone metastases from breast cancer.
Symptomatic bone metastases from breast cancer
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone · 50 participants
📍 Italy
2025-524208-31-00 on CTIS ↗
Phase II Therapeutics Authorised 08/06/2026
Evaluating cognitive effects of a three month course of methylphenidate in Parkinson's disease patients with mild cognitive impairment.
Parkinson's disease
Universidad Rey Juan Carlos · 40 participants
📍 Spain
2026-525701-12-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 08/06/2026
A prospective, open-label, non-randomized, multicentre trial to assess the safety and PD of Cangrelor as procedural platelet inhibitor in paediatric subjects from birth to <18 years of age undergoing diagnostic and/or therapeutic percutaneous vascular procedures for management of congenital heart disease
Congenital Heart Disease
Chiesi Farmaceutici S.p.A. · 48 participants
📍 Netherlands · Germany · Portugal · Austria
2025-523109-14-00 on CTIS ↗
Phase II Respiratory Tract Diseases Authorised 08/06/2026
C4531031 - AN INTERVENTIONAL PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, THIRD PARTY-UNBLINDED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF PF-07275315 IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
Pfizer Inc. · 318 participants
📍 Spain · Germany · Poland · Czechia · Greece · Italy · Bulgaria · France · Hungary
2024-518587-12-00 on CTIS ↗
Phase I Nervous System Diseases Authorised 08/06/2026
A randomized, multiple ascending doses, clinical trial to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of CV-01 after double-blind, placebo-controlled multiple oral administrations for 2 weeks in healthy volunteers, and multiple oral administrations open-label for 2 weeks in a cohort of participants with drug resistant epilepsy
Drug resistant epilepsy
Angelini Pharma Italia Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. Enunciabile Anche Angelini Pharma Italia S.p.A. Angelini Pharma S.p.A. A.C.R.A.F. S.p.A. Acraf S.p.A. Angelini S.p.A. aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. · 36 participants
📍 Sweden
2026-525478-21-00 on CTIS ↗
Phase IV Nervous System Diseases Authorised 08/06/2026
OCTAGON:A Phase 4, Single Arm Study to Investigate Oral Corticosteroid Tapering in Adult Patients with Generalized Myasthenia Gravis Treated with Ravulizumab
Generalized Myasthenia Gravis
Alexion Pharmaceuticals Inc. · 15 participants
📍 Italy · Germany
2025-522555-26-00 on CTIS ↗
Phase IV Immune System Diseases Authorised 08/06/2026
PREP-ANCA - Comparison of a strategy based on clinic-biological surveillance versus pre-emptive treatment with rituximab in the event of ANCA (anti-neutrophil cytoplasm antibodies) repositivation in patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)
granulomatosis with polyangiitis and microscopic polyangiitis
Assistance Publique Hopitaux De Paris · 70 participants
📍 France
2025-522049-23-00 on CTIS ↗
Phase II Neoplasms Authorised 08/06/2026
An open-label, non-randomized, single center, single dose, exploratory phase II trial of FG001 (an imaging agent) in combination with transoral robotic surgery for oropharyngeal squamous cell carcinoma and neck dissection surgery for oral squamous cell carcinoma with regional lymph node metastases
Oral Squamous Cell Carcinoma with neck metastases, Oropharyngeal Squamous Cell Carcinoma
Rigshospitalet · 40 participants
📍 Denmark
2025-522845-23-00 on CTIS ↗
Phase IV Virus Diseases Authorised 08/06/2026
Measles-mumps-rubella vaccine (MMR) at 6 months of age: Long-term follow-up
Prevention of measles, mumps, and rubella by vaccination
Rigshospitalet · 1000 participants
📍 Denmark
2026-526160-21-00 on CTIS ↗
Phase I Neoplasms Authorised 08/06/2026
A study to learn more about how safe BAY 3771249 is and how well it works in people with advanced or metastatic colorectal cancer that has a KRAS G12D mutation
adenocarcinoma of the colon or rectum
Bayer Consumer Care AG · 49 participants
📍 Finland · Spain · Sweden · Italy · Denmark · Netherlands · Belgium
2025-523648-11-00 on CTIS ↗
Phase I/II Neoplasms Authorised 08/06/2026
KontRASt-R: An open-label, multi-center, rollover study for participants who have been previously enrolled into a Novartis-sponsored opnurasib (JDQ443) study and are continuing to benefit from opnurasib as a single agent or in combination with other study treatments
Locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer; advanced solid tumors harboring the KRAS G12C mutation.
Novartis Pharma AG · 31 participants
📍 Spain · Italy · France · Denmark · Belgium
2025-523537-26-00 on CTIS ↗
Phase II Virus Diseases Authorised 08/06/2026
Phase II, Single-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Evaluate The Safety And Efficacy Of Dasatinib To Reduce HIV-1 Reservoir, Chronic Inflammation, And Immune Senescence In People With HIV On Long-Term Antiretroviral Treatment.
HIV-1 infection
Instituto De Salud Carlos III · 60 participants
📍 Spain
2025-524363-20-01 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 08/06/2026
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Efficacy of Efimosfermin Alfa in Participants With Biopsy-Confirmed F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-1)
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Glaxosmithkline Research & Development Limited · 173 participants
📍 Belgium · Greece · Poland · France · Spain · Bulgaria · Italy · Germany · Austria · Netherlands
2025-523675-39-00 on CTIS ↗
Phase II Behavioral Disciplines and Activities Authorised 08/06/2026
Phase II, Placebo-controlled trial of Cannabidiol for the treatment of alcohol dependence (PLACONCANALDE)
alcohol dependence
Hospital Universitario 12 De Octubre · 118 participants
📍 Spain
2023-504439-42-03 on CTIS ↗
Phase III Anesthesia and Analgesia Authorised 05/06/2026
OFA-VATS : Impact of opioid free anesthesia on postoperative quality of recovery and analgesia after video or robot assisted thoracic surgery
indication for pulmonary resection surgery (segmentectomy or lobectomy), video-assisted thoracoscopy or scheduled robot-assisted surgery.
Centre Hospitalier Universitaire De Rennes · 176 participants
📍 France
2025-524240-35-00 on CTIS ↗
Phase III Mental Disorders Authorised 05/06/2026
ERPPAD - Efficacy in Relapse Prevention: Psilocybin in Alcohol use disorder with Depressive symptoms
Alcohol use disorder, depressive symptoms
Centre Hospitalier Universitaire De Nimes · 172 participants
📍 France
2025-525069-65-00 on CTIS ↗
Phase III Neoplasms Authorised 05/06/2026
PACHA-02_Postoperative hepatic arterial chemotherapy after resection of colorectal liver metastases in patients at high risk of recurrence
Participants with R0/R1 resected liver metastases from colorectal cancer (CRLM).
Unicancer · 272 participants
📍 France
2025-523913-27-00 on CTIS ↗
Phase IV Bacterial Infections and Mycoses Authorised 05/06/2026
ANTIMIDIS - Cefazolin mediastinal distribution using microdialysis
Infection prophylaxis
Assistance Publique Hopitaux De Paris · 10 participants
📍 France
2025-521988-13-00 on CTIS ↗
Phase II Investigative Techniques Authorised 05/06/2026
Phase IIb Multicenter Randomized Controlled Trial Evaluating the Efficacy of Sivelestat in Patients with Septic Coagulopathy
Septic Coagulopathy
Les Hopitaux Universitaires De Strasbourg · 120 participants
📍 France
2025-523397-16-00 on CTIS ↗
Phase IV Respiratory Tract Diseases Authorised 05/06/2026
BIOlogical treatment GRAdual Interval Longing in severe Asthma (BIO-GRAIL)
Severe Asthma
Amsterdam UMC Stichting · 142 participants
📍 Netherlands
2025-524741-28-00 on CTIS ↗
Phase II Mental Disorders Authorised 05/06/2026
Long-term outcomes and safety of repeated rituximab treatment in psychotic disorders – RITS-LONG
Schizophrenia spectrum disorder (SSD)
Region Oerebro Laen · 122 participants
📍 Sweden
2026-525324-26-00 on CTIS ↗
Phase III Eye Diseases Authorised 05/06/2026
A randomized double-masked, multicenter, 3-arm, pivotal Phase 2/3 study to evaluate the efficacy and safety of intravitreal (IVT) EYE201/MK-8748 compared to aflibercept (2 mg) in participants with neovascular age-related macular degeneration (NVAMD)
Neovascular age-related macular degeneration (NVAMD)
Eyebiotech Limited · 250 participants
📍 Austria · Slovakia · Portugal · Czechia · Hungary · Spain · France · Denmark · Italy · Croatia
2025-524894-17-00 on CTIS ↗
Phase IV Nutritional and Metabolic Diseases Authorised 05/06/2026
A randomised, double-blind, three parallel-group, placebo controlled superiority trial assessing the effect of intravenous versus oral iron supplementation on physical performance, quality of life and cognitive function in iron deficient FRAIL elderly IndiviDuals with cardiovascular disease (FRAIL-ID trial)
Frailty with Iron Deficiency in Elderly Patients with Cardiovascular Disease
Wroclaw Medical University · 396 participants
📍 Poland
2025-521570-34-00 on CTIS ↗
Phase II Neoplasms Authorised 05/06/2026
Diagnostic Efficacy of 18F-FAPI-74 PET/CT in Patients with Gastric Cancer
Gastric cancer
Varsinais-Suomen hyvinvointialue · 80 participants
📍 Finland
2026-526494-42-00 on CTIS ↗
Phase II Nervous System Diseases Authorised 05/06/2026
A Phase 2a Study of SUN-627 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Impact on Measures of Neuroinflammation in the Central Nervous System in Participants With Non-Active Progressive Multiple Sclerosis (SPMS/PPMS)
Multiple Sclerosis; Primary Progressive Multiple Sclerosis; non-active Secondary Progressive Multiple Sclerosis
Sundance Biosciences Inc. · 30 participants
📍 Finland
2026-525817-29-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 04/06/2026
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2
Narcolepsy Type 2
Alkermes Inc. · 98 participants
📍 Spain · Netherlands · Belgium · Italy · France
2025-523912-35-00 on CTIS ↗
Phase IV Cardiovascular Diseases Authorised 04/06/2026
Pulmonary Embolism & Anticoagulation Evaluation in Cancer Patient - PEACE
Incidental Subsegmental Pulmonary Embolism in cancer patients
Region Hovedstaden · 234 participants
📍 Denmark
2025-524110-28-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 04/06/2026
TicAgreLor versus placebo to prevent cerebral ISCHemia in anEuRysmal low grade SAH A double blinded randomised controlled study TALISCHER - SAH
Aneurysmal subarachnoid hemorrhage
Centre Hospitalier Universitaire De Toulouse · 274 participants
📍 France
2023-509795-42-00 on CTIS ↗
Phase I/II Neoplasms Authorised 04/06/2026
REGENOVAR: A Phase I/II Study of Ubamatamab Plus Carboplatin, Paclitaxel, and Bevacizumab as Salvage Therapy in Ovarian Cancer with Poor Response to First-Line Chemotherapy.
Patients with poor prognostic ovarian cancers based on the tumor primary chemonsensitivity and incomplete debulking surgery.
Asso De Recherche Cancers Gynecologiques · 43 participants
📍 France
2025-524232-20-00 on CTIS ↗
Phase I Nervous System Diseases Authorised 04/06/2026
Bioequivalence of Tramadol retard 200 mg Prolonged-Release Tablets in Healthy Subjects Under Fed Conditions
Not applicable (submitted trial is a bioavailability trial in healthy participants).
Laboratorios Cinfa S.A. · 36 participants
📍 Czechia
2026-525780-41-00 on CTIS ↗
Phase I Diagnosis Authorised 04/06/2026
T cell imaging in kidney transplantation (TIK)
Renal allograft rejection
Radboud universitair medisch centrum Stichting · 9 participants
📍 Netherlands
2025-522490-11-00 on CTIS ↗
Phase I/II Respiratory Tract Diseases Authorised 04/06/2026
A study on the safety of and immune response to different doses of RSV/hMPV combination and hMPV vaccines in adults
Respiratory Syncytial Virus Infections+Metapneumovirus
GlaxoSmithKline Biologicals · 464 participants
📍 Belgium
2025-524456-58-00 on CTIS ↗
Phase II Nervous System Diseases Authorised 04/06/2026
Cosmos Trial: Cerebroprotection Of AST-004 in Mild Complicated Traumatic Brain Injuries
Traumatic brain injury
Astrocyte Pharmaceuticals Inc. · 48 participants
📍 Netherlands
2026-525554-11-00 on CTIS ↗
Phase III Diagnosis Authorised 03/06/2026
Prognostic Performance of Quantitative Myocardial Perfusion Imaging Using H2[15O] Positron Emission Tomography in Coronary Artery Disease - The AQUA COR trial
Cardiovascular disease
Vaestra Goetalandsregionen · 40000 participants
📍 Sweden
2024-518706-41-01 on CTIS ↗
Phase I/II Nervous System Diseases Authorised 03/06/2026
A Phase 1b/2 Study to Evaluate NB-4746 in Participants with Amyotrophic Lateral Sclerosis.
Amyotrofic Lateral Sclerosis (ALS)
Nura Bio Inc. · 46 participants
📍 Poland · Netherlands · Italy · Spain
2025-523939-18-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 03/06/2026
Montelukast as disease modifying treatment in mild-moderate Parkinson’s disease, an open-label, phase II extension trial (MONTPARK_OLE)
Parkinson's Disease
Karolinska University Hospital · 98 participants
📍 Sweden
2026-525906-37-00 on CTIS ↗
Phase III Eye Diseases Authorised 03/06/2026
A randomized double-masked, multicenter, 3-arm, pivotal Phase 2/3 study to evaluate the efficacy and safety of intravitreal (IVT) EYE201/MK-8748 compared to aflibercept (2 mg) in participants with neovascular age-related macular degeneration (NVAMD)
Neovascular age-related macular degeneration (NVAMD)
Eyebiotech Limited · 130 participants
📍 Spain · Poland · Estonia · Latvia · Germany
2025-524575-22-00 on CTIS ↗
Phase I/II Neoplasms Authorised 02/06/2026
A Phase 1/2, Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamic, and Antitumor Activity of CR-001 in Adult Participants with Locally Advanced or Metastatic Solid Tumors.
Locally Advanced or Metastatic Solid Tumors
Crescent Biopharma Inc. · 180 participants
📍 Spain · Ireland · Italy · France · Romania
2025-523590-42-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 02/06/2026
A Randomized Open Label Trial Exploring the Soluble and Imaging Biomarker Dynamic Responses to Tolebrutinib Compared to Rituximab Treatment in Patients with Multiple Sclerosis (MS)
Multiple Sclerosis
Region Stockholm – SLSO · 60 participants
📍 Sweden
2025-523892-50-00 on CTIS ↗
Phase II Otorhinolaryngologic Diseases Authorised 02/06/2026
Prevention of radiation-induced salivary gland damage by botulinum toxin application in patients with head and neck cancers
patients with head and neck squamous cell carcinoma (HNSCC)
Fakultni Nemocnice Kralovske Vinohrady · 40 participants
📍 Czechia
2025-524720-22-00 on CTIS ↗
Phase I Cardiovascular Diseases Authorised 02/06/2026
Randomized, open-label, multiple dose, two-period, two-treatment, cross-over pharmacodynamic study in healthy male and female participants under fasting conditions.
Pharmacodynamic study under fasting condition.
Adamed Pharma S.A. · 42 participants
📍 Czechia
2026-526556-31-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 02/06/2026
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1
Narcolepsy Type 1
Alkermes Inc. · 75 participants
📍 Italy · France · Netherlands · Spain · Belgium
2025-523911-13-00 on CTIS ↗
Phase III Immune System Diseases Authorised 02/06/2026
Multinational, Interventional, 52-week, Open-label, Single-arm Study to Evaluate the Treatment Outcomes of Anifrolumab 120 mg Subcutaneous Once Weekly in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus (SUNFLOWER)
Systemic lupus erythematosus
AstraZeneca AB · 97 participants
📍 Poland · Germany · Italy · France · Spain
2025-523670-17-00 on CTIS ↗
Phase I Musculoskeletal Diseases Authorised 02/06/2026
An open label, randomized, multiple-dose, two-treatment, two-period, cross-over bioequivalence study comparing Pyridostigmine Bromide, P.R.Tab, 180 mg/tab, VIANEX S.A., Greece versus Mestinon® retard 180 mg/prolonged-release tablet, Viatris Healthcare GmbH, Germany, in healthy male and female volunteers under fasting conditions.
treatment of myasthenia gravis
Vianex S.A. · 44 participants
📍 Czechia
2025-524219-35-00 on CTIS ↗
Phase II Nervous System Diseases Authorised 02/06/2026
A randomized, Phase 2a, double-blinded, biomarker-driven, placebo-controlled study to assess safety, CNS penetration, and target engagement of Mirivadelgat in Parkinson’s disease – SLEIPNIR-2, a sub-protocol in the SLEIPNIR platform trial
Parkinson's Disease
Helse Bergen HF · 45 participants
📍 Norway
2025-523570-17-00 on CTIS ↗
Phase I Skin and Connective Tissue Diseases Authorised 01/06/2026
IMPD-Q-only application
prick test-induced itch
Incyte Corp. · 30 participants
📍 Austria
2025-524730-26-00 on CTIS ↗
Phase III Hemic and Lymphatic Diseases Authorised 01/06/2026
A MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF NXT007 PROPHYLAXIS VERSUS FACTOR VIII PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A WITHOUT INHIBITORS
Hemophilia A Without Inhibitors
F. Hoffmann-La Roche AG · 42 participants
📍 France · Austria · Poland · Netherlands · Spain · Denmark · Italy · Germany · Hungary
2025-522434-32-00 on CTIS ↗
Phase I Neoplasms Authorised 01/06/2026
GRAIN, Prospective Pilot Study
Esophageal adenocarcinoma, Barrett's esophagus, Esophageal dysplasia
Universitair Medisch Centrum Groningen · 49 participants
📍 Netherlands
2025-524470-41-00 on CTIS ↗
Phase III Virus Diseases Authorised 01/06/2026
Post-INFECT: Investigating Neuroinflammation and its eFEcts in post-COVID syndrome: an imaging sTudy
post-COVID syndrome
Amsterdam UMC Stichting · 65 participants
📍 Netherlands
2025-522349-23-00 on CTIS ↗
Phase III Immune System Diseases Authorised 01/06/2026
Allergen extract of Lepidoglyphus destructor. Study of the sensitivity and specificity of the diagnostic preparation in prick tests
Allergy to Lepidoglyphus destructor
Inmunotek S.L. · 70 participants
📍 Spain
2025-523426-40-00 on CTIS ↗
Phase IV Skin and Connective Tissue Diseases Authorised 01/06/2026
IJAMP-Trial
prick test-induced itch
Johannes Kepler University Linz · 30 participants
📍 Austria
2025-523131-19-00 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 01/06/2026
A double-dummy, double-blind, randomized, active controlled, two-way cross-over study with 12-week treatment duration per period, to evaluate the efficacy and safety of QVM149 (indacaterol acetate / glycopyrronium bromide / mometasone furoate) compared to salmeterol xinafoate/fluticasone propionate in children from 12 years to less than 18 years of age with asthma.
Asthma
Novartis Pharma AG · 68 participants
📍 Poland · France · Slovakia · Spain · Hungary · Germany · Romania
2022-502365-26-00 on CTIS ↗
Phase III Hemic and Lymphatic Diseases Authorised 01/06/2026
A MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF NXT007 PROPHYLAXIS VERSUS EMICIZUMAB PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A
Hemophilia A
F. Hoffmann-La Roche AG · 124 participants
📍 Hungary · Spain · Ireland · Poland · Austria · Germany · Denmark · Belgium · Netherlands · Italy · France
2025-522435-33-00 on CTIS ↗
Phase II Neoplasms Authorised 01/06/2026
Safety and efficacy of treatment combination with ponatinib and asciminib in chronic myeloid leukemia patients resistant to ponatinib and/or asciminib
Chronic Myeloid Leukemia
Grupo Espanol De Leucemia Mieloide Cronica (GELMC) · 30 participants
📍 Spain
2025-521126-15-00 on CTIS ↗
Phase III Neoplasms Authorised 01/06/2026
Use of DOTATOC labeled with V-Cu64 in PET-CT imaging of neuroendocrine tumors
Neoplasms
Voxel S.A. · 80 participants
📍 Poland
2025-524050-34-01 on CTIS ↗
Phase III Neoplasms Authorised 01/06/2026
A Randomized, Double-Blind, Multicenter, Placebo-Controlled Phase 3 Study of Orelabrutinib in Combination with Rituximab and Bendamustine (BR) vs. BR in Subjects with Treatment-Naїve Mantle Cell Lymphoma
Treatment-naїve mantle cell lymphoma (MCL)
Innocare Pharma Inc. · 102 participants
📍 Poland · France · Czechia · Spain · Romania
2025-524241-27-00 on CTIS ↗
Phase I/II Musculoskeletal Diseases Authorised 01/06/2026
A Phase 1b/2a, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL952 in Adult Participants with Late-Onset Pompe Disease
Late-Onset Pompe Disease
Denali Therapeutics Inc. · 6 participants
📍 Germany · Netherlands
2025-524082-25-00 on CTIS ↗
Phase III Congenital, Hereditary, and Neonatal Diseases and Abnormalities Authorised 29/05/2026
MOOD - MethOxyflurane analgesia in vasoOcclusive crises of sickle cell Disease
Sickle cell disease
Assistance Publique Hopitaux De Paris · 198 participants
📍 France
2024-518043-38-00 on CTIS ↗
Phase II Immune System Diseases Authorised 29/05/2026
Sublingual Birch Immunotherapy for Pollen-associated Food Allergy
Pollen-associated Food Allergy, Birch pollen Allergy
Klinikum der Technischen Universitaet Muenchen (TUM Klinikum) · 96 participants
📍 Germany
2025-523653-34-00 on CTIS ↗
Phase I/II Congenital, Hereditary, and Neonatal Diseases and Abnormalities Authorised 29/05/2026
An open-label, single-arm, phase 1/2 first-in-human study to assess the safety and efficacy of autologous CD34+ cells transduced with a lentiviral vector encoding the human NCF1 gene (SGX-001) in paediatric and adult patients with chronic granulomatous disease caused by p47phox deficiency
Chronic granulomatous disease (CGD) caused by p47phox deficiency (p47-CGD)
Somagenetix AG · 4 participants
📍 Germany · Spain
2025-524423-50-00 on CTIS ↗
Phase II Hemic and Lymphatic Diseases Authorised 29/05/2026
A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APPROACH. ALL-TARGET TRIAL
Relapsed/refractory T-cell Acute Lymphoblastic Leukemia
Centre Hospitalier De Versailles · 86 participants
📍 Germany · France · Czechia · Netherlands · Spain
2024-516570-30-00 on CTIS ↗
Phase II Mental Disorders Authorised 29/05/2026
Leveraging the neural mechanisms of social reward for drug relapse prevention
substance use disorder
Fondazione Santa Lucia IRCCS · 70 participants
📍 Italy
2023-504518-31-01 on CTIS ↗
Phase II Nervous System Diseases Authorised 29/05/2026
Intravenous iron in the management of drug-resistant restless legs syndrome: a randomized controlled delayed-start trial. IRON-RLS
Restless legs syndrome
Centre Hospitalier Universitaire De Montpellier · 60 participants
📍 France
2026-525613-31-00 on CTIS ↗
Phase IV Cardiovascular Diseases Authorised 29/05/2026
Discontinuation or Continuation of SGLT-2 Inhibitors Before Cardiac Surgery: Impact on Postoperative Cardiovascular Outcomes – DISCO Study
heart failure
Centre Hospitalier Universitaire De Toulouse · 458 participants
📍 France
2025-524395-30-00 on CTIS ↗
Phase I/II Neoplasms Authorised 29/05/2026
C6461006 - An Interventional Phase 1b/2, Open-Label Study to Investigate the Safety, Antitumor Activity, and Pharmacokinetics of PF-08634404 Monotherapy or in Combination With Enfortumab Vedotin in Adult Participants With Locally Advanced or Metastatic Urothelial Cancer.
Locally Advanced or Metastatic Urothelial Cancer
Pfizer Inc. · 36 participants
📍 Netherlands · Spain
2025-523523-21-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 29/05/2026
A Phase 3 Multicenter, Open-label Study to Assess the Long-term Safety and Tolerability of KarXT in Adolescents (13 to 17 years of age) with Schizophrenia and KarXT+KarX-EC in Children and Adolescents (5 to 17 years of age) with Irritability Associated with Autism Spectrum Disorder
Schizophrenia and Autism Spectrum Disorder (ASD)
Bristol-Myers Squibb Services Unlimited Company · 40 participants
📍 Romania
2025-524062-16-00 on CTIS ↗
Phase III Neoplasms Authorised 29/05/2026
A Phase 3, Randomized, Double-Blind, Active-Control Study of Pelabresib (DAK539) and Ruxolitinib vs. Placebo and Ruxolitinib in Adult Patients with Myelofibrosis who are JAK inhibitor naive
Myelofibrosis
Novartis Pharma AG · 173 participants
📍 Belgium · Germany · Austria · Poland · Spain · Italy · Netherlands · Czechia · France
2025-523555-66-00 on CTIS ↗
Phase II Immune System Diseases Authorised 29/05/2026
J5D-MC-FPAD: A Phase 2a, Randomized, 24-Week, Multicenter, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Investigate Efficacy and Safety of LY4005130 in Adult Participants with Non-Segmental Vitiligo
Non-Segmental Vitiligo (NSV), Vitiligo
Eli Lilly & Co. · 14 participants
📍 Poland · Belgium
2025-524726-18-00 on CTIS ↗
Phase II Musculoskeletal Diseases Authorised 29/05/2026
Pilot study comparing the efficacy of intra-articular glenohumeral injection combined with suprascapular nerve block versus intra-articular glenohumeral corticosteroid injection in adhesive capsulitis.
Retractile Capsulitis
Centre Hospitalier Universitaire De Nantes · 38 participants
📍 France
2026-525317-31-00 on CTIS ↗
Phase III Therapeutics Authorised 29/05/2026
Tranexamic Acid in Hind and Midfoot Arthrodesis Surgery: A Multicentre, Randomized, Placebo-Controlled Trial (TRASH Trial)
Deformity, Osteoarthritis
HUS-yhtymae · 450 participants
📍 Finland
2026-526142-27-01 on CTIS ↗
Phase III Immune System Diseases Authorised 29/05/2026
A prospective, randomized, double-blind, placebo-controlled, multicentre, dose-finding clinical trial with polymerised mannan-conjugated allergoid Dactylis glomerata/Phleum pratense administered subcutaneously to patients with grass pollen-induced allergic rhinitis or rhinoconjunctivitis.
Grass pollen induced allergic rhinitis or rhinoconjunctivitis
Inmunotek S.L. · 450 participants
📍 Germany
2025-524580-21-00 on CTIS ↗
Phase I Nutritional and Metabolic Diseases Authorised 29/05/2026
A Study of Eloralintide (LY3841136) in Participants With Overweight or Obesity
Overweight Obesity
Eli Lilly & Co. · 115 participants
📍 Germany
2025-523873-41-00 on CTIS ↗
Phase III Digestive System Diseases Authorised 29/05/2026
COPE-CP: The effect of Celecoxib on pain, quality of life, use of opioids, and inflammation in patients suffering from chronic pancreatitis: a multicenter randomized placebo-controlled, double-blinded clinical trial
Chronic pancreatitis
Odense University Hospital · 80 participants
📍 Denmark
2025-522956-25-00 on CTIS ↗
Phase II Congenital, Hereditary, and Neonatal Diseases and Abnormalities Authorised 29/05/2026
A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX‑828/Deutivacaftor With and Without Tezacaftor in Subjects Aged 18 Years and Older With Cystic Fibrosis
Cystic fibrosis
Vertex Pharmaceuticals Inc. · 80 participants
📍 Spain · Sweden · Germany · Italy · Belgium · Czechia · Ireland · Portugal · Netherlands · France · Denmark
2025-523400-72-00 on CTIS ↗
Phase III Neoplasms Authorised 29/05/2026
Efficacy and Tolerability of N-AVD compared to BrECADD in patients with advanced Hodgkin Lymphoma (N-BRAVE)
Hodgkin lymphoma
Polska Grupa Badawcza Chloniakow · 370 participants
📍 Poland
2026-525263-41-00 on CTIS ↗
Phase II Nervous System Diseases Authorised 29/05/2026
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a Long-term Extension of Povetacicept in Adults with Generalized Myasthenia Gravis
Generalized Myasthenia Gravis
Vertex Pharmaceuticals Inc. · 5 participants
📍 Poland
2025-523950-15-01 on CTIS ↗
Phase I Immune System Diseases Authorised 29/05/2026
A First-in-Human, Open-label, Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of NBIM-1008 in Patients with Rheumatoid Arthritis
Rheumatoid Arthritis
Neurocrine Biosciences Inc. · 15 participants
📍 Poland · Romania
2025-525113-22-00 on CTIS ↗
Phase I/II Hemic and Lymphatic Diseases Authorised 29/05/2026
Prospective, multicentre, two-arms, I/II phase study to Optimise and Personalise Immunological Therapy of relapsed chronic lymphocytic leukaemia patients (OPTIC)
Adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (PBL) with an indication to start treatment of relapsed disease according to IWCLL recommendations.
Uniwersytet Medyczny W Lublinie · 36 participants
📍 Poland
2024-513917-11-01 on CTIS ↗
Phase II Neoplasms Authorised 28/05/2026
Phase II Clinical Trial of KORTUC (KRC-01) Combined with Radiotherapy for Locally Advanced Rectal Cancer: Towards a New Organ Preservation Approach (K-BOOST)
Locally advanced high‑risk stage III rectal adenocarcinoma (non‑metastatic)
Institut Gustave Roussy · 24 participants
📍 France
2025-524378-40-00 on CTIS ↗
Phase II Neoplasms Authorised 28/05/2026
A Phase 2A/B, Multi-center, Open-Label Study Evaluating the Efficacy and Safety of Dabogratinib (TYRA-300) in Participants with Low Grade Upper Tract Urothelial Carcinoma (SURF303)
Low Grade Upper Tract Urothelial Carcinoma
Tyra Biosciences Inc. · 34 participants
📍 Bulgaria · France · Spain
2025-523539-20-00 on CTIS ↗
Phase III Bacterial Infections and Mycoses Authorised 28/05/2026
A Randomized, Multicenter, Single-Blind, Parallel-Group Phase III Non-Inferiority Trial Comparing the Efficacy and Tolerability of a Fixed-Dose Combination of Metronidazole, Bismuth Oxide and Tetracycline HCl to Standard Concomitant Non-Bismuth Quadruple Therapy for First-Line Eradication of Helicobacter pylori in Adults.
Helicobacter Pylori Infection
Verisfield Single Member S.A. · 420 participants
📍 Greece
2026-525291-26-00 on CTIS ↗
Phase IV Respiratory Tract Diseases Authorised 28/05/2026
A Phase 4, Multicenter, Double-blind, Study to Investigate the Efficacy, Safety, and Tolerability of 3 Active Doses of Respreeza® / Zemaira® Weekly Intravenous Infusions Administered over 3 Years as Longterm Maintenance Therapy in Adult Subjects with Emphysema Related to Alpha1 Antitrypsin Deficiency
Alpha1-proteinase inhibitor deficiency, Alpha1 antitrypsin deficiency, Emphysema
CSL Behring LLC · 33 participants
📍 Denmark
2025-522964-33-00 on CTIS ↗
Phase IV Bacterial Infections and Mycoses Authorised 28/05/2026
A multicenter, randomized, double-blind, placebo-controlled, adaptive, non-inferiority trial to investigate shortening treatment duration in uncomplicated candidemia: the CanTEN trial
Candidemia
University Of Cologne · 420 participants
📍 Germany
2026-525640-14-00 on CTIS ↗
Phase IV Anesthesia and Analgesia Authorised 28/05/2026
A randomized, Phase 4, double-blind, placebo-controlled, 6-arm crossover study to investigate the systemic effect of lidocaine and ropivacaine when used for Transversus Abdominis Plane (TAP) blocks on hyperalgesia and pain perception in healthy volunteers aged 18 to 64 years.
Acute pain
Oslo University Hospital HF · 20 participants
📍 Norway
2025-520910-67-01 on CTIS ↗
Phase IV Female Urogenital Diseases and Pregnancy Complications Authorised 28/05/2026
Optimising the protocol of labour induction using misoprostol – randomised open-label clinical trial (OPTIMISO)
Labour induction
Fakultni Nemocnice Brno · 200 participants
📍 Czechia
2026-525770-19-00 on CTIS ↗
Phase I/II Neoplasms Authorised 28/05/2026
A Phase 1b/2 Study to Evaluate the Safety and Efficacy of MK‑1045 Monotherapy or in Combination with Other Anticancer Agents in Participants with Non-Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Merck Sharp & Dohme LLC · 73 participants
📍 Poland · Italy · France · Germany · Spain
2025-523005-15-00 on CTIS ↗
Phase II Virus Diseases Authorised 28/05/2026
Dosing EvaLuation of Tenofovir Alafenamide on Epstein-Barr Virus (The DELTA-EBV study)
Epstein-Barr virus infection
Helse Bergen HF · 45 participants
📍 Norway
2025-522781-77-01 on CTIS ↗
Phase I Nutritional and Metabolic Diseases Authorised 28/05/2026
Bioavailability, Biopotency and Food effect study of SCD0503 compared to subcutaneous regular human insulin
Type 1 diabetes
Samchundang Pharm. Co. Ltd. · 16 participants
📍 Germany
2024-519502-12-00 on CTIS ↗
Phase II Respiratory Tract Diseases Authorised 27/05/2026
Efficacy of an anti-TSLP monoclonal antibody in the management of chronic bronchial disease induced by bronchiolitis obliterans syndrome in allogeneic hematopoietic stem cells transplantation recipients.
The medical condition studied in IMMUNO-BOS is Bronchiolitis obliterans syndrome (BOS) after allogeneic stem cell transplantation
Hospital Foch · 36 participants
📍 France
2024-516796-33-00 on CTIS ↗
Phase I/II Neoplasms Authorised 27/05/2026
A Phase I/II open label study of DJI136, a DLL3-targeted CAR-T therapy, in adult patients with ES-SCLC
Extensive stage small cell lung cancer
Novartis Pharma AG · 25 participants
📍 Spain · France
2025-523276-23-00 on CTIS ↗
Phase II Immune System Diseases Authorised 27/05/2026
An Extension Study to Evaluate the Long-Term Safety and Efficacy of Afimkibart (RO7790121) in Patients with Rheumatoid Arthritis who Participated in Previous Afimkibart Clinical Trials
moderate to severe rheumatoid arthritis (RA)
F. Hoffmann-La Roche AG · 46 participants
📍 Italy · Spain · Germany · France · Denmark · Poland · Belgium
2025-523579-47-00 on CTIS ↗
Phase I/II Neoplasms Authorised 27/05/2026
Phase 1b/2 Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Previously Treated Unresectable Advanced or Metastatic Sarcomas
Sarcoma
Glaxosmithkline Research & Development Limited · 14 participants
📍 France
2025-523997-18-00 on CTIS ↗
Phase III Immune System Diseases Authorised 27/05/2026
A Phase 3b, Multicenter, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Guselkumab versus Risankizumab in the Treatment of Participants with Moderately to Severely Active Crohn’s Disease
Moderately to Severely Active Crohn’s Disease
Janssen Cilag International · 302 participants
📍 Slovakia · Germany · Denmark · France · Spain · Italy · Netherlands · Belgium · Poland · Sweden · Austria · Czechia · Hungary
2025-521590-13-00 on CTIS ↗
Phase II Mental Disorders Authorised 27/05/2026
An Open-Label Study to Assess the Long-Term Safety and Tolerability of ML-007C-MA in Adult Participants with Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis
Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis
Maplight Therapeutics Inc. · 85 participants
📍 Italy · Poland · Czechia · Portugal · Bulgaria · France · Slovakia · Romania · Hungary
2025-521757-16-00 on CTIS ↗
Phase III Musculoskeletal Diseases Authorised 26/05/2026
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy of a Single Intravenous Dose of SGT-003 in Ambulant Males With Duchenne Muscular Dystrophy
Duchenne muscular dystrophy
Solid Biosciences Inc. · 62 participants
📍 Spain · Netherlands · France · Italy · Belgium · Germany
2025-522949-22-00 on CTIS ↗
Phase I/II Neoplasms Authorised 26/05/2026
LIGHTBEAM-U01 Substudy 01D: A Phase 1b/2 Substudy to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors
Neoplasm malignant
Merck Sharp & Dohme LLC · 21 participants
📍 France · Spain · Sweden · Germany · Italy · Belgium · Denmark
2025-522339-32-00 on CTIS ↗
Phase II Musculoskeletal Diseases Authorised 26/05/2026
POMREP - Efficacy and safety of zoledronate versus placebo on pain at week 12 in pediatric patients with chronic recurrent multifocal osteomyelitis resistant to non-steroidal anti-inflammatory drug
Chronic recurrent multifocal osteomyelitis (CRMO)
Assistance Publique Hopitaux De Paris · 30 participants
📍 France
2023-506420-93-00 on CTIS ↗
Phase II Musculoskeletal Diseases Authorised 26/05/2026
Repurposed Drug Evaluation for Biological Aging, Pain, and Inflammation Reduction in Osteoarthritis
Osteoarthritis
Radboud universitair medisch centrum Stichting · 175 participants
📍 Netherlands
2025-524885-12-00 on CTIS ↗
Phase I Anesthesia and Analgesia Authorised 26/05/2026
A study comparing different dosage forms of midazolam and how they are taken up in the body.
Bioavailability Study under Fasting Conditions
MIDAS Pharma GmbH · 16 participants
📍 Czechia
2025-524999-37-00 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 26/05/2026
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of GB-0895 Adjunctive Therapy in Adults and Adolescents with Severe Uncontrolled Asthma
Severe uncontrolled asthma
Generate Biomedicines Inc. · 73 participants
📍 Italy · Slovakia · Spain · Ireland · Belgium · France
2025-524040-35-00 on CTIS ↗
Phase I Musculoskeletal Diseases Authorised 26/05/2026
First-in-human study to assess the safety and feasibility of intra-articular administration of allogeneic engineered gingival fibroblasts (aeGF) in participants with knee osteoarthritis.
Knee osteoarthritis
Scarcell Therapeutics · 10 participants
📍 Denmark
2026-525604-99-00 on CTIS ↗
Phase IV Cardiovascular Diseases Authorised 25/05/2026
Platelet function testing in outpatients after heart transplantation on aspirin therapy
Patients who have undergone heart transplantation.
Medical University Of Vienna · 100 participants
📍 Austria
2025-521699-71-01 on CTIS ↗
Phase III Immune System Diseases Authorised 25/05/2026
D. pteronyssinus and D. farinae allergen extracts. Study of the sensitivity and specificity of the prick test diagnostic preparation
Allergy to Dermatophagoides pteronyssinus, Allergy to Dermatophagoides farinae
Inmunotek S.L. · 70 participants
📍 Spain
2025-522469-31-00 on CTIS ↗
Phase II Hemic and Lymphatic Diseases Authorised 25/05/2026
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma (r/r MM)
relapsed/refractory multiple myeloma
C4 Therapeutics Inc. · 43 participants
📍 Italy · France · Spain · Poland
2025-524181-26-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 22/05/2026
Comparison of iodinated contrast media injection protocols with reduced flow rates and volumes on image quality in diagnostic cerebral angiography for the evaluation of unruptured intracranial aneurysms: towards a standardization of practices (OPIAC)
Intracranial aneurysms
Les Hopitaux Universitaires De Strasbourg · 244 participants
📍 France
2025-524884-18-01 on CTIS ↗
Phase II Neoplasms Authorised 22/05/2026
UNLOCK - EPIBREAST, a phase II study of prifetrastat (PF-07248144), a KAT6 inhibitor, plus fulvestrant for advanced HR+/HER2- breast cancer with biomarkers analysis
Adult patients with advanced hormone receptor positive (HR+), HER2- breast cancer after at least a first line of endocrine therapy combined with CDK4/6 inhibitor in the metastatic setting
Unicancer · 51 participants
📍 France
2025-521982-29-00 on CTIS ↗
Phase I Not possible to specify Authorised 22/05/2026
A study in healthy people to compare two tablet formulations of pramipexole
Healthy volunteer trial
Boehringer Ingelheim International GmbH · 24 participants
📍 Germany
2026-525704-98-00 on CTIS ↗
Phase IV Cardiovascular Diseases Authorised 22/05/2026
Reassessment of statin-associated musscle symptoms in adults with familial hypercholesterolemia: A phase IV randomized double-blinded n-of-1 crossover trial including periods with atorvastatin, placebo and no study treatment
Familial hypercholesterolaemia
Oslo University Hospital HF · 70 participants
📍 Norway
2025-521589-83-00 on CTIS ↗
Phase I Immune System Diseases Authorised 22/05/2026
A study to test single and multiple doses of MER511 given to adults with Graves’ disease
Graves’ disease
Merida Biosciences Inc. · 28 participants
📍 Spain
2025-523823-23-00 on CTIS ↗
Phase I Not possible to specify Authorised 22/05/2026
Thorough QT/QTc study with GLPG3667, placebo, and active comparator in healthy subjects
Healthy volunteers
Galapagos · 25 participants
📍 Netherlands
2026-525788-42-00 on CTIS ↗
Phase I Behavior and Behavior Mechanisms Authorised 22/05/2026
A PET Study to Assess the Occupancy of M4 Muscarinic Acetylcholine Receptors by BMS-986521 in Healthy Adult Participants
Neuropsychiatric indications and potentially other conditions
Bristol-Myers Squibb Services Unlimited Company · 12 participants
📍 Belgium
2025-524564-38-00 on CTIS ↗
Phase IV Neoplasms Authorised 22/05/2026
Comparing intraoperative indocyanine green fluorescence imaging with standard clinical assessment for flap perfusion in head and neck reconstruction: A randomised controlled Trial (VISION Trial)
Head and neck cancer
Region Skane · 244 participants
📍 Sweden
2025-524710-29-00 on CTIS ↗
Phase IV Bacterial Infections and Mycoses Authorised 22/05/2026
A randomized, placebo-controlled, blinded, parallel-group clinical trial to assess the efficacy of N-acetylcysteine in adults with acute infections or sepsis and evidence of liver dysfunction: the IMPACT-NAC trial
Acute infection, Sepsis
Region Hovedstaden · 360 participants
📍 Denmark
2026-525895-25-00 on CTIS ↗
Phase I Bacterial Infections and Mycoses Authorised 22/05/2026
A randomized, balanced, two-treatment, two-sequence, single oral dose, two stage crossover adaptative bioequivalence study of Rifaximin 200 mg film-coated tablets (Antibiotice SA) vs. Normix® 200 mg, film- coated tablets (Alfasigma S.P.A) in healthy subjects under fed conditions
healthy subjects
Antibiotice S.A. · 64 participants
📍 Romania
2025-525078-12-00 on CTIS ↗
Phase I Nervous System Diseases Authorised 22/05/2026
Bioequivalence study 1 to compare pharmacokinetics of Parkinson´s disease drugs in healthy volunteers
Parkinson disease
Orion Corporation · 40 participants
📍 Czechia
2026-525448-14-00 on CTIS ↗
Phase II Eye Diseases Authorised 22/05/2026
Safety and efficacy of T10430 eye drops in controlling paediatric myopia progression
Paediatric myopia
Laboratoires Thea · 20 participants
📍 Ireland
2025-521563-13-01 on CTIS ↗
Phase IV Female Urogenital Diseases and Pregnancy Complications Authorised 22/05/2026
Exogenous progesterone as ovulation trigger – a pilot study
Infertility
Instituto Valenciano De Infertilidade Clinica De Reproducao Assistida Lda. · 10 participants
📍 Portugal
2025-523850-15-00 on CTIS ↗
Phase I Immune System Diseases Authorised 22/05/2026
150 mg CIT-013 phase 1 trial
Immune mediated inflammatory diseases
Citryll B.V. · 10 participants
📍 Netherlands
2026-526153-34-00 on CTIS ↗
Phase III Neoplasms Authorised 22/05/2026
ROSETTA Lung-201: A Randomized, Multicenter, Open-label Phase 3 study of Pumitamig Monotherapy Compared to Durvalumab in Participants with Unresectable Stage III NSCLC Without Progression After Platinum-based Concurrent Chemoradiation Therapy
Unresectable Stage III non-small cell lung cancer without progression
Bristol-Myers Squibb Services Unlimited Company · 279 participants
📍 France · Ireland · Germany · Greece · Bulgaria · Spain · Netherlands · Italy · Sweden · Romania · Hungary · Belgium · Austria · Poland
2025-523576-23-00 on CTIS ↗
Phase II Male Urogenital Diseases Authorised 22/05/2026
A phase 2 trial of BMS-986365 in mCSPC patients with suboptimal PSA-response after 7 months of Androgen Deprivation Therapy (ADT) plus Androgen Receptor Pathway Inhibition (ARPI).
Metastatic Castrate Sensitive Prostate Cancer - mCSPC
UroTrials GmbH, AIO-Studien gGmbH · 42 participants
📍 Germany
2025-523672-23-00 on CTIS ↗
Phase I/II Neoplasms Authorised 22/05/2026
A 2-part phase 1/2 open-label trial evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ODM-212 in combination with anti-cancer therapy in participants with advanced solid tumours
Neoplasms benign malignant and unspecified (incl. cysts and polyps)
Orion Corporation · 85 participants
📍 Finland · Denmark · Spain · France
2025-524620-22-00 on CTIS ↗
Phase II Neoplasms Authorised 21/05/2026
A Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Participants with Stage 4 Non-Small Cell Lung Cancer (TeLuRide-008).
Stage 4 (IV) Non-Small Cell Lung Cancer (NSCLC)
Eikon Therapeutics Inc. · 115 participants
📍 Germany · Spain · Netherlands · Romania · Greece · Italy
2025-525013-23-00 on CTIS ↗
Phase I Respiratory Tract Diseases Authorised 21/05/2026
Clinical trial to evaluate the safety, tolerability and effectiveness of a medicinal nasal insert in the treatment of chronic hay fever.- Inspicare
Chronic allergic rhinitis
Dianosic · 25 participants
📍 Netherlands
2026-525200-99-00 on CTIS ↗
Phase II Metabolism Authorised 21/05/2026
An open-label, single-arm extension study to evaluate the long-term safety, tolerability, and efficacy of KL1333 (napazimone) in patients with primary mitochondrial disease
Adult patients with primary mitochondrial disease
Pharming Technologies B.V. · 117 participants
📍 Belgium · Germany · Czechia · Spain · Denmark · Italy · France
2025-524367-20-00 on CTIS ↗
Phase I Neoplasms Authorised 21/05/2026
First time in human (FTIH) study to investigate the safety and preliminary activity of GSK5533524 alone or in combination in adult participants with advanced solid tumors
Neoplasms
Glaxosmithkline Research & Development Limited · 52 participants
📍 Spain · Denmark · Finland · France
2025-524165-25-00 on CTIS ↗
Phase IV Nutritional and Metabolic Diseases Authorised 21/05/2026
Effect of an adjunctive intervention on the tolerability of semaglutide in overweight adults without diabetes: a prospective, randomised, double-blind, single-centre, placebo-controlled clinical trial (SEMTOL)
Overweight and obesity
University Of Tartu · 100 participants
📍 Estonia
2025-524612-11-00 on CTIS ↗
Phase IV Neoplasms Authorised 21/05/2026
Intensified Monitoring of PhArmacology of Cabozantinib as a tool for Toxicity management in patients with renal cell carcinoma
Renal cell carcinoma
Centro Di Riferimento Oncologico Di Aviano · 216 participants
📍 Italy
2026-525267-40-00 on CTIS ↗
Phase II Eye Diseases Authorised 20/05/2026
An Open-Label, Rollover Study for Participants With Thyroid Eye Disease Previously Enrolled in Amgen-Sponsored AMG 732 Studies and are Primary Proptosis Non-responders or who Relapsed During the Safety Follow-up
Thyroid Eye Disease
Amgen Inc. · 5 participants
📍 Spain · Poland
2025-523280-38-00 on CTIS ↗
Phase III Skin and Connective Tissue Diseases Authorised 20/05/2026
An open-label, multi-center protocol for patients who have completed a previous Novartis sponsored remibrutinib study and are judged by the investigator to benefit from continued treatment with remibrutinib
Chronic Spontaneous Urticaria
Novartis Pharma AG · 154 participants
📍 Germany · Spain · France · Poland · Bulgaria · Czechia
2025-524078-40-00 on CTIS ↗
Phase I/II Genetic Phenomena Authorised 20/05/2026
An Open Label, Single Arm, Phase I/II Clinical Study of Autologous CD4+ T-Cells Edited Ex-Vivo at the CD40LG Locus by CRISPR/Cas9 and IDLV-based vector in Patients with X-linked Hyper IgM Syndrome Type 1 (HIGM1)
X-linked immunodeficiency with hyper-IgM type 1 (HIGM1)
Fondazione Telethon Ets, San Raffaele Hospital · 4 participants
📍 Italy
2025-524635-39-00 on CTIS ↗
Phase I Immune System Diseases Authorised 20/05/2026
SAR447971 first-in-human study
Hidradenitis
Sanofi-Aventis Recherche & Developpement · 134 participants
📍 Netherlands
2026-525333-22-00 on CTIS ↗
Phase III Immune System Diseases Authorised 20/05/2026
A double-blind, double-dummy, parallel group, multicenter Phase 3 extension study evaluating the long-term safety and efficacy of 2 doses of remibrutinib in adult participants with moderate to severe hidradenitis suppurativa
Hidradenitis Suppurativa (HS)
Novartis Pharma AG · 307 participants
📍 Portugal · Greece · Germany · Hungary · France · Spain · Bulgaria · Slovakia · Poland · Czechia · Belgium · Italy
2025-523259-72-00 on CTIS ↗
Phase III Musculoskeletal Diseases Authorised 20/05/2026
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study with an Open-Label Extension to Evaluate the Efficacy and Safety of Intravenous AOC 1044 (delpacibart zotadirsen) for the Treatment of DMD with Gene Mutations Amenable to Exon 44 Skipping
Duchenne muscular dystrophy
Avidity Biosciences Inc. · 42 participants
📍 Italy · Germany · France · Spain · Belgium · Poland · Netherlands
2025-523087-20-00 on CTIS ↗
Phase IV Respiratory Tract Diseases Authorised 20/05/2026
Erdosteine effect on oxidative stress, inflammatory response and immune modulation in patients with COPD. A single center, open label, double arm, controlled, 4-week, explorative, ex vivo study.
COPD
ASST Fatebenefratelli Sacco · 30 participants
📍 Italy
2025-524821-42-00 on CTIS ↗
Phase II Immune System Diseases Authorised 19/05/2026
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety and Efficacy of ELV001 as Add-on Therapy in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY)
Rheumatoid arthritis
Elevara Medicines Limited · 95 participants
📍 Czechia · Bulgaria · Hungary · Netherlands · Poland · Spain
2025-524005-32-00 on CTIS ↗
Phase I Digestive System Diseases Authorised 19/05/2026
An Early-Stage Study in Multiple Clinics of how Afimkibart May Affect the Body’s Processing of Medicines that Rely on Cytochrome P450 Enzymes in Patients with Ulcerative Colitis
Active Ulcerative Colitis (UC)
F. Hoffmann-La Roche AG · 19 participants
📍 Germany · Poland · Belgium
2025-524060-38-00 on CTIS ↗
Phase II Immune System Diseases Authorised 19/05/2026
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of JNJ-95597528 for the Treatment of Adult Participants with Moderate to Severe Atopic Dermatitis
Moderate to Severe Atopic Dermatitis
Janssen Cilag International · 14 participants
📍 Germany · Poland
2025-523464-20-00 on CTIS ↗
Phase III Neoplasms Authorised 19/05/2026
Phase III Randomized, International, Open-Label Clinical Trial of Treatment Intensification with Docetaxel plus Apalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment with Apalutamide: REINFORCE Trial
Metastatic hormone-sensitive prostate cancer
Alianza Multidisciplinar Para La Investigacion De Los Tumores Genitourinarios Guard · 292 participants
📍 Spain · Germany · France · Portugal · Italy
2025-524408-30-01 on CTIS ↗
Phase III Hemic and Lymphatic Diseases Authorised 19/05/2026
A Phase 3 prospective randomised clinical trial of VMX-C001 vs usual pharmacological care in patients receiving a FXa direct oral anticoagulant (FXa DOAC) who require urgent surgery or other invasive procedure that is associated with a high risk of bleeding, with or without planned administration of heparin (EQUILIBRIX-S)
Patients on Factor Xa inhibitor treatment needing an urgent intervention associated with a high risk of bleeding
VarmX B.V. · 443 participants
📍 Belgium · Germany · Italy · France · Czechia · Bulgaria · Hungary · Spain · Netherlands · Poland · Austria · Estonia · Romania · Portugal · Lithuania
2025-521632-12-00 on CTIS ↗
Phase II Nutritional and Metabolic Diseases Authorised 19/05/2026
PODOMOUNT-Basket, a Phase II, multicentre, randomised, 2-arm parallel-group, double-blind, placebo-controlled basket trial to assess safety, tolerability, PK, and efficacy of BI 764198 in four proteinuric kidney diseases
Proteinuric kidney diseases
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A. · 66 participants
📍 Portugal · Greece · Italy · Poland · Estonia · Slovakia · Sweden · Denmark · Belgium · Norway · Romania · France · Spain · Germany · Netherlands · Croatia
2025-523425-17-00 on CTIS ↗
Phase II Neoplasms Authorised 19/05/2026
Beamion 44: A randomized, open-label, multi-center Phase IIa platform trial to evaluate the safety and tolerability of zongertinib plus Pt-doublet with or without pembrolizumab (and potential other combinations) in treatment-naïve patients with locally advanced/metastatic non-squamous NSCLC with activating HER2 mutations
locally advanced or metastatic NSCLC
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A. · 19 participants
📍 Germany · France · Spain
2025-523567-38-00 on CTIS ↗
Phase II Neoplasms Authorised 19/05/2026
A Phase II Study of Naxitamab Added to Induction Therapy for Subjects with Newly Diagnosed High-Risk Neuroblastoma
Neuroblastoma or ganglioneuroblastoma (nodular or intermixed)
Fundacio Sant Joan De Deu · 22 participants
📍 Spain
2025-524140-35-00 on CTIS ↗
Phase II Neoplasms Authorised 19/05/2026
An Open-label, Single-arm, Global Study of Perioperative Durvalumab With Cisplatin-based Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)
Patients With Muscle-Invasive Bladder Cancer
AstraZeneca AB · 60 participants
📍 Italy · Spain · France · Netherlands
2024-519246-75-01 on CTIS ↗
Phase III Virus Diseases Authorised 19/05/2026
A multicentre, open-label trial in healthy volunteers to assess the boostability of three different rabies pre-exposure prophylaxis regimens when administering a single-dose, intramuscular vaccination as simulated post-exposure prophylaxis at least five years following priming. "BAZOOKA_221"
Rabies infection/prophylaxis
Institute Of Tropical Medicine · 561 participants
📍 Belgium
2025-524765-24-00 on CTIS ↗
Phase II Neoplasms Authorised 19/05/2026
A Phase II, Open-Label Randomized Study of Intravenous Tambiciclib in Combination with the Standard of care Venetoclax and Azacitidine in Patients with Newly Diagnosed AML Who Failed to Achieve at Least MLFS After the First Two Cycles of Treatment with Venetoclax and Azacitidine Alone
Acute myeloid leukemia
Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l., IIS La Fe · 40 participants
📍 Italy · Spain
2025-524308-31-00 on CTIS ↗
Phase III Neoplasms Authorised 19/05/2026
A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
Metastatic Microsatellite Stable Colorectal Cancer
Incyte Corp. · 292 participants
📍 Poland · France · Denmark · Norway · Spain · Germany · Belgium · Netherlands · Austria · Italy
2025-523735-19-00 on CTIS ↗
Phase III Bacterial Infections and Mycoses Authorised 19/05/2026
Multicentre, randomised, double-blind, placebo-controlled clinical trial to confirm the efficacy, safety, and clinical impact of the mucosal bacterial therapeutic vaccine MV140 in women with non-complicated recurrent urinary tract infections (rUTIs).
Recurrent Non-Complicated Urinary Tract Infections (rUTIs).
Inmunotek S.L. · 252 participants
📍 Portugal
2025-524377-16-00 on CTIS ↗
Phase III Bacterial Infections and Mycoses Authorised 18/05/2026
Efficacy of Temocillin compared to standard of care in the Treatment of Neisseria gonorrhoeae Infections: A Multicenter Randomized Controlled Non-Inferiority Trial (TEMtoGo).
Neisseria gonorrhoeae Infections
Assistance Publique Hopitaux De Paris · 360 participants
📍 France
2025-524475-23-00 on CTIS ↗
Phase I Nervous System Diseases Authorised 18/05/2026
A multi-part study to investigate MTX325 in healthy volunteers and patients with Parkinson's Disease
Parkinson's Disease
Mission Therapeutics Limited · 18 participants
📍 Germany · Netherlands · France
2024-517310-15-00 on CTIS ↗
Phase IV Reproductive and Urinary Physiological Phenomena Authorised 18/05/2026
A Multicenter Randomized Controlled Trial Assessing the Efficacy and Safety of Recombinant Human Follicle Stimulating Hormone (r-hFSH-alfa originator) and Human Chorionic Gonadotropin (hCG) in Enhancing Sperm Concentration in Men with Oligozoospermia, Low Testosterone, and Normal FSH Serum Levels (APHRODITE Group 3): A Collaborative Research Initiative
Male Infertility
Martin-Luther-Universitaet Halle-Wittenberg · 138 participants
📍 Italy · Spain · Germany
2025-525005-20-00 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 18/05/2026
EPISSOC : Randomized controlled trial comparing an Early Pleural Irrigation strategy with Saline to the Standard of Care for the management of complicated pleural infections
Pleural infections
Centre Hospitalier Universitaire Amiens Picardie · 244 participants
📍 France
2025-524697-42-00 on CTIS ↗
Phase II Nutritional and Metabolic Diseases Authorised 18/05/2026
INCREDIBLE: INCREmental DIalysis and diet for a Better Life Experience; Clinical relevance of an “add-on” Ketosteril supplementation on incremental haemodialysis period in incident haemodialysis patients. An exploratory randomized controlled trial
Incremental Haemodialysis
Centre Hospitalier Le Mans · 70 participants
📍 France
2025-524093-41-00 on CTIS ↗
Phase I Immune System Diseases Authorised 18/05/2026
Mass Balance and Absolute Oral Bioavailability of [14C]VH4524184
human immunodeficiency virus (HIV)
Viiv Healthcare UK Limited · 9 participants
📍 Netherlands
2026-525590-40-00 on CTIS ↗
Phase II Nutritional and Metabolic Diseases Authorised 18/05/2026
A Phase 2a, Randomized, Open-Label, Active-Controlled, Crossover Study to Evaluate Safety and Explore Efficacy of Different Doses of New Lipase NHS7108 Administered Orally in Participants with Exocrine Pancreatic Insufficiency.
​​Exocrine Pancreatic Insufficiency​
Aimmune Nestle Health Science US R&D LLC · 29 participants
📍 Poland · Hungary · Spain · Bulgaria · Italy
2025-521816-20-00 on CTIS ↗
Phase III Immune System Diseases Authorised 18/05/2026
Prospective, randomised, double-blind, placebo-controlled multicenter clinical trial to evaluate efficacy and safety of immunotherapy in patients with rhinitis/rhinoconjunctivitis with or without mild to moderate asthma, allergic to Dermatophagoides pteronyssinus and/or Dermatophagoides farinae and Blomia tropicalis
Aetiological treatment of moderate-to-severe allergic rhinitis/rhinoconjunctivitis with or without mild-to-moderate controlled allergic asthma
Inmunotek S.L. · 120 participants
📍 Spain
2025-522773-12-00 on CTIS ↗
Phase II Bacterial Infections and Mycoses Authorised 18/05/2026
Multicentre study evaluating the efficacy of a 7-day course of doxycycline for the treatment of asymptomatic anal lymphogranuloma venereum SHORT-LGV
Asymptomatic anal LGV infection
Centre Hospitalier Universitaire De Bordeaux · 120 participants
📍 France
2025-524978-42-00 on CTIS ↗
Phase I/II Hemic and Lymphatic Diseases Authorised 18/05/2026
mRNA Therapy to restore lymphatic flow in secondary lymphedema
Lymphedema
Centre Hospitalier Universitaire De Toulouse · 9 participants
📍 France
2024-520149-22-00 on CTIS ↗
Phase IV Neoplasms Authorised 18/05/2026
Prognostic value of early assessment by ⁶⁸Ga-DOTATATE PET/CT for the treatment of well-differentiated grade 2 gastroenteropancreatic neuroendocrine tumors with ¹⁷⁷Lutetium-oxodotreotide.”
Gastroenteropancreatic neuroendocrine tumors
Centre De Lutte Contre Le Cancer Eugene Marquis · 40 participants
📍 France
2025-524942-87-00 on CTIS ↗
Phase I/II Neoplasms Authorised 18/05/2026
A Phase 1/2 Study of BMS-986525 as Monotherapy and in Combination with Nivolumab in Participants with Relapsed/Refractory Small Cell Lung Cancer
Relapsed/Refractory Small Cell Lung Cancer
Bristol-Myers Squibb Services Unlimited Company · 21 participants
📍 Italy · Spain · Romania
2025-524090-16-00 on CTIS ↗
Phase II Neoplasms Authorised 18/05/2026
TAILOR-PANC: Molecularly Tailored Therapy versus Standard Care in Advanced Pancreatic Cancer (DPCG-02)
Advanced pancreatic cancer
Region Hovedstaden · 1200 participants
📍 Denmark
2025-522431-34-00 on CTIS ↗
Phase II Neoplasms Authorised 18/05/2026
A Phase 2 Study to Evaluate the Safety and Efficacy of Telisotuzumab Adizutecan for the Treatment of Subjects with Locally Advanced or Metastatic Solid Tumors that Harbor MET Amplification
Locally Advanced or Metastatic Solid Tumours that harbour MET Amplification gene
AbbVie Deutschland GmbH & Co. KG · 29 participants
📍 Spain · France · Denmark
2024-518871-74-00 on CTIS ↗
Phase II Immune System Diseases Authorised 18/05/2026
THRILL: Treat Hyperinflammation in child oncology study - A single arm, historically controlled, open label phase II study on the efficacy and safety of the recombinant interleukin (IL)-1R antagonist anakinra in pediatric cancer patients admitted to the intensive care with sepsis and signs of hyperinflammation
Sepsis, Hyperinflammation
Prinses Maxima Centrum voor Kinderoncologie B.V. · 76 participants
📍 Netherlands
2025-524541-27-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 18/05/2026
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Primary Progressive Multiple Sclerosis
Primary Progressive Multiple Sclerosis (PPMS)
Zenas Biopharma (USA) LLC · 398 participants
📍 Italy · Finland · Bulgaria · Greece · Belgium · Estonia · Portugal · Spain · Germany · France · Czechia · Slovakia · Romania · Croatia · Poland · Austria · Netherlands · Denmark · Sweden · Hungary
2025-524316-11-00 on CTIS ↗
Phase II Neoplasms Authorised 18/05/2026
A phase II, multicenter, open-label, single arm study to evaluate the safety and efficacy of asciminib in pediatric participants newly diagnosed or previously treated with Philadelphia positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) with or without known T315I mutation
Philadelphia positive Chronic Myeloid leukemia in Chronic Phase with newly diagnosed and resistant/intolerant to previous TKIs, with or without the T315I mutation
Novartis Pharma AG · 14 participants
📍 Spain · France · Germany · Poland · Italy · Netherlands
2025-522138-29-00 on CTIS ↗
Phase IV Cardiovascular Diseases Authorised 18/05/2026
The effect of beta-blockers on how you feel and recover after a heart attack when your heart is still pumping well
Myocardial infarction with preserved ejection fraction
UZ Leuven · 160 participants
📍 Belgium
2026-525475-96-00 on CTIS ↗
Phase IV Respiratory Tract Diseases Authorised 18/05/2026
A pragmatic, phase IV, randomized, open-label, multinational, multicentre, 2-arm parallel group, prospective study comparing efficacy and safety of Single Inhaler ICS/LABA/LAMA (beclometasone/formoterol fumarate/glycopyrronium bromide [87/5/9 pMDI {BD/FF/GB - 100/6/12.5 µg}]) vs Single Inhaler ICS/LABA (beclometasone dipropionate plus formoterol fumarate [200/6 pMDI {BD/FF - 200/6 µg}]) in asthma subjects.
Asthma
Chiesi Farmaceutici S.p.A. · 606 participants
📍 Germany · Romania · Italy · Bulgaria · Poland · Slovakia · Spain · France
2025-524289-56-00 on CTIS ↗
Phase III Neoplasms Authorised 18/05/2026
A Phase 3 Randomized Study Comparing JNJ-79635322 and an Anti-BCMAxCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti-CD38 Antibody
Relapsed or Refractory Multiple Myeloma
Janssen Cilag International · 157 participants
📍 Spain · Norway · Germany · Greece · France · Italy · Netherlands
2025-522007-18-00 on CTIS ↗
Phase I Neoplasms Authorised 18/05/2026
A Phase I, Open-label, Multi-center, First-in-human Trial to Investigate E303, in Participants with Advanced Refractory Solid Tumors
advanced refractory solid tumors
Samsung Bioepis Co. Ltd. · 40 participants
📍 Spain
2025-524192-24-00 on CTIS ↗
Phase II Surgical Procedures, Operative Authorised 17/05/2026
SISTAR: Stratifying Immunosuppression to Allogenic Risk. A randomized, open label, assessor blinded, controlled, non-inferiority, safety study of half- vs standard dose immunosuppression in kidney transplant recipients with a well-matched donor.
Kidney Transplant Recipient
Medical University Of Vienna · 120 participants
📍 Austria
2025-525091-29-00 on CTIS ↗
Phase III Neoplasms Authorised 15/05/2026
ROSETTA Lung-202: A Randomized, Double-Blind, Phase 3 Study of Pumitamig Monotherapy Compared to Pembrolizumab as First-line Treatment in Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with PD-L1 ≥ 50%
Non-Small Cell Lung Cancer
Bristol-Myers Squibb Services Unlimited Company · 265 participants
📍 Portugal · Norway · Sweden · Bulgaria · France · Belgium · Austria · Germany · Finland · Poland · Romania · Netherlands · Spain · Italy · Hungary · Czechia
2025-523586-18-00 on CTIS ↗
Phase I/II Immune System Diseases Authorised 15/05/2026
A Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety and Efficacy of Aritinercept, a Dual BAFF/APRIL Inhibitor, in Patients with Generalized Myasthenia Gravis
Generalized Myasthenia Gravis
Aurinia Pharmaceuticals Inc. · 19 participants
📍 Poland
2025-525127-27-00 on CTIS ↗
Phase I Nervous System Diseases Authorised 15/05/2026
A study to investigate how a single dose of the drug melflufen reaches brain tumor tissue, and how it affects the tumour, in patients who are already scheduled for surgery for a returning glioblastoma
Recurrent glioblastoma
Oncopeptides AB · 10 participants
📍 Norway
2026-525543-32-00 on CTIS ↗
Phase I/II Neoplasms Authorised 15/05/2026
A Multicenter, Multi-Part, Phase 1/2 Study of EIK1005 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors, including Checkpoint Inhibitor Naïve Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors
Advanced Solid Tumors
Eikon Therapeutics Inc. · 49 participants
📍 France · Spain · Norway · Italy · Germany · Austria · Poland · Finland
2026-525248-13-00 on CTIS ↗
Phase I Nutritional and Metabolic Diseases Authorised 15/05/2026
Multiple Dose Study of RO7795068 and its effect on Gastric Emptying, and on PK of Oral Contraceptives
Healthy Overweight or Obese
F. Hoffmann-La Roche AG · 60 participants
📍 Netherlands
2025-524052-58-00 on CTIS ↗
Phase III Neoplasms Authorised 15/05/2026
NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing sacituzumab govitecan+pembrolizumab vs. SoC chemotherapy in clinical stage II-III, triple-negative early breast cancer (ADAPT-TN-IV)
triple-negative early breast cancer
WSG Westdeutsche Studiengruppe GmbH · 690 participants
📍 Germany
2024-516734-35-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 15/05/2026
Efficacy and safety of NNC0487-0111 s.c. once-weekly compared to semaglutide s.c. once-weekly in participants with overweight or obesity, and type 2 diabetes (AMAZE 8)
Participants with overweight or obesity, and type 2 diabetes
Novo Nordisk A/S · 440 participants
📍 Germany · Croatia · Portugal · Hungary · Bulgaria · Romania · Poland
2024-520446-31-00 on CTIS ↗
Phase II Neoplasms Authorised 14/05/2026
A Phase 2, Open-label Study of JNJ-79635322 in Participants with Relapsed or Refractory Multiple Myeloma (RRMM) who Have Received at least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti-CD38 Antibody
Relapsed or Refractory Multiple Myeloma (RRMM)
Janssen Cilag International · 54 participants
📍 Poland · Italy
2025-521976-80-00 on CTIS ↗
Phase III Immune System Diseases Authorised 14/05/2026
Prospective, randomised, double-blind, placebo-controlled multicenter clinical trial to evaluate efficacy and safety of immunotherapy in patients with rhinitis/rhinoconjunctivitis with or without mild to moderate asthma, allergic to Dermatophagoides pteronyssinus and/or Dermatophagoides farinae and Lepidoglyphus destructor.
Aetiological treatment of moderate-to-severe allergic rhinitis/rhinoconjunctivitis with or without mild-to-moderate controlled allergic asthma
Inmunotek S.L. · 120 participants
📍 Spain
2025-522771-28-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 14/05/2026
A Phase 3, Multi-regional, Open-label, Randomized Study of Tirabrutinib vs Rituximab and Temozolomide in Participants with Relapsed/Refractory Primary Central Nervous System Lymphoma
Relapsed/refractory primary central nervous system lymphoma
Deciphera Pharmaceuticals Inc. · 74 participants
📍 Czechia · Germany · Italy · Belgium · Spain · Poland · Austria · France
2025-523389-26-00 on CTIS ↗
Phase III Neoplasms Authorised 13/05/2026
A Pivotal Open-label Phase 3 Clinical Study Evaluating the Efficacy and Safety of QTX-2101 in Combination With All-trans Retinoic Acid in Newly Diagnosed, Low-risk Acute Promyelocytic Leukemia
Acute Promyelocytic Leukemia
Quetzal Therapeutics LLC · 89 participants
📍 Germany · Poland · Spain · Romania · Italy · France
2025-524810-28-00 on CTIS ↗
Phase II Nervous System Diseases Authorised 13/05/2026
Open-Label Extension Study to Provide Access to ATH434 in Patients with Multiple System Atrophy
Multiple System Atrophy
Alterity Therapeutics Limited · 7 participants
📍 France
2025-524317-88-00 on CTIS ↗
Phase I Cardiovascular Diseases Authorised 13/05/2026
A Randomized Study in Healthy Participants to Identify the Optimal Subcutaneous Injection Strategy for COR-1167
Chronic Heart Failure
Corteria Pharmaceuticals · 20 participants
📍 Netherlands
2026-526096-31-00 on CTIS ↗
Phase I/II Neoplasms Authorised 13/05/2026
Phase 1/2 evaluating the addition of venetoclax to standard 3+7 and midostaurin induction treatment in patients with FLT3-mutated Acute Myeloid Leukemia eligible to intensive chemotherapy - MIDOVEN
FLT3-mutated Acute Myeloid Leukemia
Centre Hospitalier Universitaire De Bordeaux · 41 participants
📍 France
2024-517130-17-00 on CTIS ↗
Phase IV Reproductive and Urinary Physiological Phenomena Authorised 13/05/2026
Reproductive outcomes with letrozole co-treatment during ovarian stimulation in women with endometriosis undergoing IVF/ICSI: a randomised, multicentre, parallel group pragmatic trial
Women with endometriosis undergoing IVF/ICSI
UZ Brussel · 854 participants
📍 Belgium
2025-524995-53-00 on CTIS ↗
Phase III Neoplasms Authorised 13/05/2026
A Phase III, multi-center, open-label, randomised, controlled trial of intravenous obrixtamig in combination with carboplatin and etoposide vs. carboplatin and etoposide as first-line therapy in DLL3-positive patients with unresectable locally advanced or metastatic extrapulmonary neuroendocrine carcinomas.
advanced or metastatic extrapulmonary neuroendocrine carcinoma
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A. · 144 participants
📍 Portugal · Spain · Poland · Sweden · Italy · Czechia · France · Netherlands · Finland · Denmark · Austria · Germany · Belgium · Norway
2025-523869-22-00 on CTIS ↗
Phase II Skin and Connective Tissue Diseases Authorised 13/05/2026
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of ICP-332 in Participants with Prurigo Nodularis
Prurigo Nodularis
Innocare Pharma Inc. · 56 participants
📍 Belgium · Poland · Germany · France · Austria
2025-523404-74-00 on CTIS ↗
Phase IV Virus Diseases Authorised 13/05/2026
A phase IV proof-of-concept study to assess the safety and efficacy of Maribavir to inhibit high Virus Epstein-Barr (VEB) replication among young adult kidney transplant recipie
Transplant patients with high recurrent Epstein-Barr infection
Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca · 10 participants
📍 Spain
2025-524786-25-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 13/05/2026
Randomized, Placebo-Controlled, Double-Blind, Phase 3b Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children and Adolescents, 6 to 17 Years of Age, with Heterozygous Familial Hypercholesterolemia on Stable Diet and Oral Lipid-Lowering Therapy (LIBerate-Kids)
Heterozygous Familial Hypercholesterolemia
LIB Therapeutics Inc. · 5 participants
📍 Norway
2025-524214-28-00 on CTIS ↗
Phase II Therapeutics Authorised 13/05/2026
SCARFREE-001: A Phase 2 Dose-Finding and Proof-of-Concept Study of Intradermal Verteporfin for Scar Prevention in Open and Closed Surgical Wounds
Scar formation following surgical wounds
Odense University Hospital · 12 participants
📍 Denmark
2025-525083-14-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 13/05/2026
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 Administered to Participants With Obesity or Overweight and Type 2 Diabetes
Obesity or Overweight and Type 2 Diabetes
F. Hoffmann-La Roche AG · 551 participants
📍 Germany · Romania · Czechia · Poland · Hungary · France · Spain · Italy
2025-523106-32-00 on CTIS ↗
Phase III Neoplasms Authorised 12/05/2026
IMMUNOTIME « EVALUATION OF THE EFFECT OF TIME OF ADMINISTRATION ON THE ACTIVITY ON FIRST LINE OF PEMBROLIZUMAB IN ASSOCIATION WITH CARBOPLATIN PEMETREXED IN METASTATIC NON-SQUAMOUS LUNG CANCER. A RANDOMISED MULTICENTER PHASE III TRIAL»
Adult patients with stage IV non squamous non-small cell lung cancer (NSCLC)
Assistance Publique Hopitaux De Paris · 254 participants
📍 France
2025-521891-78-00 on CTIS ↗
Phase I Cardiovascular Diseases Authorised 12/05/2026
A clinical trial of MK-1824 in healthy participants (MK-1824-001)
Heart failure with preserved ejection fraction
Merck Sharp & Dohme LLC · 16 participants
📍 Belgium
2026-525748-14-00 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 12/05/2026
Effect of vasopressin versus norepinephrine on post-operative mean pulmonary arterial pressure following pulmonary endarterectomy surgery, a randomized open label trial
Chronic thromboembolic pulmonary hypertension
Fondation Hopital Saint Joseph · 90 participants
📍 France
2025-525153-39-00 on CTIS ↗
Phase II Neoplasms Authorised 12/05/2026
A Phase 2 Open-Label, Umbrella Platform Design Study of Investigational Agent(s) in Participants With 2L/3L Unresectable Locally Advanced or Metastatic Esophageal Cancer: KEYMAKER-U06 Substudy 06F
Esophageal squamous cell carcinoma
Merck Sharp & Dohme LLC · 12 participants
📍 Czechia · Germany · France · Norway
2026-525213-31-00 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 12/05/2026
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of GB-0895 Adjunctive Therapy in Adults and Adolescents with Severe Uncontrolled Asthma
severe uncontrolled asthma
Generate Biomedicines Inc. · 271 participants
📍 Latvia · Hungary · Bulgaria · Romania · Portugal · Netherlands · Croatia · Germany · Greece · Czechia
2025-521950-41-00 on CTIS ↗
Phase III Neoplasms Authorised 12/05/2026
DAREON®-Lung-1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig in combination with atezolizumab, carboplatin, and etoposide vs. atezolizumab, carboplatin, and etoposide as first-line treatment in patients with extensive-stage small cell lung cancer.
small cell lung cancer
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A. · 295 participants
📍 Czechia · Sweden · Poland · Netherlands · Greece · Latvia · Finland · Norway · Belgium · Austria · Portugal · Romania · Italy · Estonia · France · Ireland · Germany · Spain · Bulgaria · Hungary
2025-520565-51-00 on CTIS ↗
Phase III Musculoskeletal Diseases Authorised 12/05/2026
A Phase 3, Multicenter, Long-Term Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who are Either Biologic DMARD-Naïve or Biologic DMARD-Experienced, Including Those With Inadequate Response to Biologic DMARDs
Psoriatic Arthritis
Takeda Development Center Americas Inc. · 638 participants
📍 Germany · Belgium · Spain · Czechia · Croatia · Portugal · Poland · Latvia · Bulgaria · France · Estonia · Hungary · Italy
2025-522586-30-00 on CTIS ↗
Phase II Neoplasms Authorised 12/05/2026
Maintenance AVElumab after SECond line platinum-based chemotherapy for metastatic urothelial carcinoma: AVESEC trial - GOIRC-02-2025
metastatic urothelial carcinoma
G.O.I.R.C. Gruppo Oncologico Italiano Di Ricerca Clinica · 144 participants
📍 Italy
2025-524077-16-00 on CTIS ↗
Phase II Neoplasms Authorised 12/05/2026
A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors
Non-small cell lung cancer (NSCLC), Cervical cancer (CC), Melanoma, Hepatocellular carcinoma (HCC), Ovarian cancer (OC), Squamous cell carcinoma of head and neck
Dualitybio Inc. · 102 participants
📍 Italy · Poland · France · Spain · Germany
2025-523895-22-00 on CTIS ↗
Phase II Mental Disorders Authorised 11/05/2026
Microdosing with a serotonergic agent for ADHD and emotion regulation: biological factors explaining and predicting treatment response
Attention Deficit Hyperactivity Disorder (ADHD)
Universiteit Maastricht · 120 participants
📍 Netherlands
2025-520906-36-00 on CTIS ↗
Phase III Musculoskeletal Diseases Authorised 11/05/2026
MAINRITSys : Rituximab vs placebo for maintenance in systemic sclerosis – interstitial lung disease
Patient with stabilized SSc-ILD (as defined by a decline of FVC ≤ 5%) following RTX induction treatment
Assistance Publique Hopitaux De Paris · 120 participants
📍 France
2025-521331-36-00 on CTIS ↗
Phase III Bacterial Infections and Mycoses Authorised 11/05/2026
A randomized controlled non-inferiority trial comparing 7 versus 14 days of ciprofloxacin for male urinary tract infections with systemic involvement.
Urinary tract infection with systemic involvement (UTI: definite, probable, or possible UTI according to the diagnostic criteria of the research reference standard for UTI proposed by Bilsen et al (see reference 19 in protocol)). Systemic involvement: one or more of the following, attributable to the UTI: • Temperature ≥38°C • Flank pain or costovertebral angle tenderness • Systolic blood pressure <90 mmHg without alternative cause • Significant elevation of inflammatory markers related to the UTI: o C-reactive protein concentration ≥50 mg/L, Procalcitonin concentration ≥0·5 ng/mL or white blood cell count ≥12×10^9 per L (all without other plausible source, based on at least history and examination). • Bacteraemia with the same pathogen as isolated from urine culture
UZ Brussel · 264 participants
📍 Belgium
2025-524703-76-00 on CTIS ↗
Phase II Therapeutics Authorised 11/05/2026
Evaluation of hANP for prevention of acute kidney injury after cardiac surgery: A two-part randomized controlled trial with open-label extension in children aged 0–12 months.
Acute kidney injury (AKI) occurring in newborns and infants after cardiac surgery with cardiopulmonary bypass. The study targets early postoperative renal dysfunction and fluid imbalance in this high-risk population.
Vaestra Goetalandsregionen · 100 participants
📍 Sweden
2025-524069-26-00 on CTIS ↗
Phase I Nutritional and Metabolic Diseases Authorised 11/05/2026
A research study to see how NNC0487-0111 affects the body’s energy use after a weight loss in adults living with obesity, compared to a low-calorie diet or placebo
Obesity
Novo Nordisk A/S · 120 participants
📍 Netherlands · Denmark
2025-522744-40-00 on CTIS ↗
Phase IV Neoplasms Authorised 11/05/2026
PROTECx - Pembrolizumab Registry for Outcomes and Treatment Evaluation in Cervical Cancer
Metastatic cervical cancer
Universitair Medisch Centrum Groningen · 261 participants
📍 Netherlands
2025-522883-34-00 on CTIS ↗
Phase III Musculoskeletal Diseases Authorised 11/05/2026
The GranStone Trial - Prevention of Kidney Stones due to Paraffin Oil Induced Granuloma
Paraffin Oil Induced Granulomatous Disease
Region Hovedstaden · 100 participants
📍 Denmark
2026-525608-85-00 on CTIS ↗
Phase I Nutritional and Metabolic Diseases Authorised 11/05/2026
A three-part first-in-human trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of GUB-UCN2 in healthy lean and obese participants and participants with T2D
Type 2 Diabetes, Obesity
Gubra A/S · 220 participants
📍 Germany
2025-524921-42-00 on CTIS ↗
Phase I Not possible to specify Authorised 11/05/2026
A First in Human Study to Assess Safety, Tolerability and Pharmacokinetics of a single dose of REGN22044 in Healthy Adults
Heathy volunteer trial
Regeneron Pharmaceuticals Inc. · 64 participants
📍 Belgium
2025-523562-24-00 on CTIS ↗
Phase I Nervous System Diseases Authorised 11/05/2026
A Study to Assess the Safety of RG6496 in Huntington’s Disease Gene Expansion Carriers with the Selected Genetic Variant (POINT-HD)
Huntington’s Disease Gene Expansion Carriers
F. Hoffmann-La Roche AG · 43 participants
📍 Italy · Poland · Denmark · Germany · Portugal · Spain
2025-520631-17-00 on CTIS ↗
Phase III Hemic and Lymphatic Diseases Authorised 11/05/2026
A Double-Blind, Randomized, Comparative Study of Obicetrapib and Bempedoic Acid on top of Maximally Tolerated Lipid-Lowering Therapy in Patients With Dyslipidemia at High to Very High Cardiovascular Risk (MEDICI Study)
Dyslipidemia at High to Very High Cardiovascular Risk
A. Menarini International Licensing S.A. · 338 participants
📍 Spain · Poland · Netherlands · Italy · Slovakia · Czechia · Germany
2025-524265-24-00 on CTIS ↗
Phase I Immune System Diseases Authorised 11/05/2026
A study to investigate a potential effect of rilzabrutinib (SAR444671) on ethinylestradiol and levonorgestrel from combined oral contraceptives in healthy female participants
Immune Thrombocytopenia Purpura
Sanofi-Aventis Recherche & Developpement · 24 participants
📍 Germany
2026-525350-11-00 on CTIS ↗
Phase III Immune System Diseases Authorised 11/05/2026
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Panzyga for Prevention of Major Infections in Patients with Hypogammaglobulinemia and Autoimmune or Rheumatic Conditions Receiving Treatment with B-cell Depletion Therapy ("PROTECT")
Prevention of a Major infection in patients with Hypogammaglobulinemia and Autoimmune or Rheumatic Conditions receiving treatment with B-cell depletion therapy.
Octapharma Pharmazeutika Produktionsgesellschaft mbH · 215 participants
📍 Czechia · Lithuania · Greece · Poland · Germany · Latvia · Bulgaria · Italy
2025-522854-37-00 on CTIS ↗
Phase III Neoplasms Authorised 11/05/2026
J5E-MC-JZXB - FRAmework-01: A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan plus Bevacizumab versus Platinum-Based Chemotherapy plus Bevacizumab in Platinum-Sensitive Ovarian Cancer
Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms
Eli Lilly & Co. · 486 participants
📍 Netherlands · Hungary · France · Austria · Poland · Italy · Denmark · Romania · Greece · Norway · Czechia · Belgium · Spain · Ireland · Germany
2025-522255-25-00 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 11/05/2026
A double-blinded extension study to evaluate the long-term safety and tolerability of itepekimab in adult participants with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) who participated in either EFC18418 or EFC18419 clinical studies
Chronic rhinosinusitis with nasal polyps
Sanofi-Aventis Recherche & Developpement · 146 participants
📍 Germany · Netherlands · Portugal · Denmark · Sweden · Finland · France · Spain · Austria · Italy · Hungary · Romania · Belgium · Czechia · Poland
2025-522983-33-00 on CTIS ↗
Phase III Neoplasms Authorised 11/05/2026
A national randomised multi-centre phase II/III trial using MesoPher in ABC borderline resectable pancreatic cancer (PREOPANC-6 trial)
ABC borderline resectable pancreatic cancer
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) · 143 participants
📍 Netherlands
2025-523134-28-00 on CTIS ↗
Phase I Neoplasms Authorised 08/05/2026
First-in-Human Trial of DS3610a in Participants with Advanced Solid Tumors
Advanced Solid Tumors
Daiichi Sankyo Inc. · 24 participants
📍 France · Spain
2025-521173-13-00 on CTIS ↗
Phase II Neoplasms Authorised 08/05/2026
FINACCESS - Finnish National Study for Early Access to Cancer Therapies
Cancer
HUS-yhtymae · 1500 participants
📍 Finland
2025-524769-26-00 on CTIS ↗
Phase II Skin and Connective Tissue Diseases Authorised 08/05/2026
A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 250 mg lebrikizumab in patients with localized scleroderma (LEMO)
Localized Scleroderma
Charite Universitaetsmedizin Berlin KöR · 78 participants
📍 Germany
2025-524435-39-00 on CTIS ↗
Phase I/II Neoplasms Authorised 08/05/2026
A Phase 1/2a, Open-Label, Dose-Escalation and Dose-Expansion First-In-Human Study of the Safety, Tolerability, Activity, and Pharmacokinetics of REGN10597 (Anti PD-1-IL2RA-IL2 Fusion Protein) Alone or in Combination with Cemiplimab in Patients with Advanced Solid Organ Malignancies
Advanced Solid Tumours, Melanoma, Clear-Cell Renal-Cell Carcinoma (ccRCC)
Regeneron Pharmaceuticals Inc. · 99 participants
📍 Italy · Spain · Germany · France
2025-523399-22-00 on CTIS ↗
Phase II Skin and Connective Tissue Diseases Authorised 08/05/2026
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Dose-Range Finding Study of ORKA-001 in Participants with Moderate-to-Severe Plaque Psoriasis
Moderate-to-Severe Plaque Psoriasis
Oruka Therapeutics Inc. · 32 participants
📍 Germany · Spain
2025-523797-17-00 on CTIS ↗
Phase III Physical Phenomena Authorised 07/05/2026
A phase III, multicentre, double-blind, randomised, placebo-controlled and open-label study to evaluate the efficacy and safety of a single dose of IPN10200 in the improvement of moderate to severe glabellar lines in adult participants, and to evaluate the long-term efficacy and safety of repeat doses of IPN10200 in the same indication.
Treatment of moderate to severe glabellar lines
Ipsen Innovation · 230 participants
📍 France · Germany
2025-522618-22-00 on CTIS ↗
Phase I/II Virus Diseases Authorised 07/05/2026
LAMP-COVID: Locating Amyloid-containing Microclots with total-body PET in post-COVID syndrome
post-COVID syndrome (long COVID)
Amsterdam UMC Stichting · 65 participants
📍 Netherlands
2025-522348-42-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 07/05/2026
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 Administered to Participants With Obesity or Overweight Without Type 2 Diabetes
Obesity or Overweight Without Type 2 Diabetes
F. Hoffmann-La Roche AG · 754 participants
📍 Poland · Hungary · France · Belgium · Italy · Netherlands · Czechia · Germany · Spain
2025-523104-71-00 on CTIS ↗
Phase III Not possible to specify Authorised 07/05/2026
Optimizing Aspirin Use for Preeclampsia Prevention
Obstetrics – Preeclampsia
Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca · 11836 participants
📍 Spain
2025-524646-94-00 on CTIS ↗
Phase II Neoplasms Authorised 07/05/2026
Neoadjuvant Immunotherapy and Organ-sparing Treatment in Patients with Stage I-III dMMR Colon Cancer: A National, Multicentre, Personalised, Phase II Study (RESET C2)
Localised dMMR Colon Cancer
Region Sjaelland · 152 participants
📍 Denmark
2026-525214-62-00 on CTIS ↗
Phase II Respiratory Tract Diseases Authorised 06/05/2026
A prospective, multinational, multicenter, randomized, sequential, double-blind, placebo-controlled, phase 2a clinical study to assess the safety and pharmacokinetics (PK) of OMN6 in hospital-acquired bacterial pneumonia (HABP) or ventilated-associated bacterial pneumonia (VABP) caused by Acinetobacter baumannii complex (ABC).
Hospital-acquired bacterial pneumonia or ventilated-associated bacterial pneumonia caused by Acinetobacter baumannii complex.
Omnix Medical Ltd. · 32 participants
📍 Italy · Hungary · Greece
2025-524200-29-00 on CTIS ↗
Phase I Congenital, Hereditary, and Neonatal Diseases and Abnormalities Authorised 06/05/2026
A study to investigate the safety, tolerability, pharmacokinetics, immunogenicity and pharmacodynamics of a single subcutaneous dose of GSK4771261 in healthy participants aged 25 to 55 years of age inclusive
Autosomal Dominant Polycystic Kidney Disease
Glaxosmithkline Research & Development Limited · 30 participants
📍 Netherlands
2025-525073-37-00 on CTIS ↗
Phase I Not possible to specify Authorised 06/05/2026
PHARMACOKINETICS OF PETRELINTIDE FOLLOWING ADMINISTRATION TO PARTICIPANTS WITH IMPAIRED HEPATIC FUNCTION
Healthy / hepatic impaired volunteers only study to assess PK parameters
Zealand Pharma A/S · 36 participants
📍 Slovakia · Poland
2025-523641-10-00 on CTIS ↗
Phase II Female Urogenital Diseases and Pregnancy Complications Authorised 06/05/2026
A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multicenter Trial Evaluating the Effects of Two Dosing Regimens of Nolasiban on Uterine Contractility and Endocrine Parameters
Women with an indication for IVF/ICSI
ReproNovo ApS · 120 participants
📍 Spain
2025-524896-22-00 on CTIS ↗
Phase I Nervous System Diseases Authorised 06/05/2026
A clinical trial of MK-4605 in healthy participants (MK-4605-001)
Dementia
Merck Sharp & Dohme LLC · 16 participants
📍 Belgium
2026-525627-24-00 on CTIS ↗
Phase II Neoplasms Authorised 06/05/2026
A Master Protocol of an Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumour Activity of Novel Combinations in Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (LIBRA)
Non-Small Cell Lung Cancer
AstraZeneca AB · 70 participants
📍 France · Italy · Spain
2025-524843-11-00 on CTIS ↗
Phase IV Cardiovascular Diseases Authorised 06/05/2026
Colchicine Assessment of Low-grade Inflammation and Biomarker Response in Atherosclerosis with Targeted Evaluation
Ischemic Heart Disease, Coronary Artery Disease, Chronic Coronary Artery Syndrome
Region Hovedstaden · 70 participants
📍 Denmark
2026-525547-32-01 on CTIS ↗
Phase I/II Skin and Connective Tissue Diseases Authorised 05/05/2026
Single-centre, randomised, double-blind, split-face comparative design clinical trial to evaluate the efficacy and safety of the topical formulation with 4% hydroquinone and 0,025% tretinoin versus the formulation with 4% hydroquinone in patients with facial melasma
facial melasma
Mesoestetic Pharma Group S.L. · 21 participants
📍 Spain
2025-521806-16-00 on CTIS ↗
Phase I Neoplasms Authorised 05/05/2026
Phase 1b Study of Tarlatamab + ZL-1310 +/- Anti-PD-L1 in Small Cell Lung Cancer
Small Cell Lung Cancer
Amgen Inc. · 53 participants
📍 Spain · Germany · Poland · Belgium · France
2025-522888-15-00 on CTIS ↗
Phase II Neoplasms Authorised 05/05/2026
A Phase II, Multi-Center, Master Protocol to Evaluate the Efficacy and Safety of Volrustomig as Monotherapy or in Combination with Anti-cancer Agents in Participants with Advanced/Metastatic Solid Tumors (eVOLVE-02)
Sub-study 5: Unresectable Pleural Mesothelioma (Volrustomig Monotherapy), Sub-study 4: Esophageal Squamous Cell Carcinoma (Volrustomig in Combination with Chemotherapy).
AstraZeneca AB · 42 participants
📍 Italy · Germany
2025-523947-36-00 on CTIS ↗
Phase IV Not possible to specify Authorised 05/05/2026
Phase IV, randomized, open label, parallel groups clinical trial for evaluating the early Stop of antibiotic Treatment in high-risk febrile neutropenic Oncohaematological Paediatric patients (e-STOP 2)
Infectious diseases
Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca · 136 participants
📍 Spain
2025-524264-38-00 on CTIS ↗
Phase I Mental Disorders Authorised 05/05/2026
An open label, balanced, randomized, three treatment, three period, three sequence, single dose, crossover study to assess the effect of food and effect of apple sauce on bioavailability of the Test product (Bupropion Hydrochloride Extended Release Capsules 150 mg, manufactured by Sun Pharmaceutical Industries Limited, India) in healthy, adult, human subjects.
Seasonal affective disorder, Major depressive disorder
Sun Pharmaceutical Industries Limited · 72 participants
📍 Romania
2025-523411-11-00 on CTIS ↗
Phase I Mental Disorders Authorised 05/05/2026
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose crossover, bioavailability study comparing Bupropion Hydrochloride Extended Release Capsules 150 mg, Manufactured by Sun Pharmaceutical Industries Limited, India with WELLBUTRIN XL (Bupropion hydrochloride) extended release tablets 300 mg, Distributed by: Bausch Health US, LLC Bridgewater, NJ 08807 USA. Manufactured by: Bausch Health Companies, Inc. Steinbach, MB R5G 1Z7, Canada, in healthy, adult, human subjects under fasting condition.
Seasonal affective disorder, Major depressive disorder
Sun Pharmaceutical Industries Limited · 72 participants
📍 Romania
2025-523410-84-00 on CTIS ↗
Phase I/II Neoplasms Authorised 05/05/2026
PHASE IB/II STUDY TO EVALUATE SAFETY AND PRELIMINARY EFFICACY OF ZANIDATAMAB IN COMBINATION WITH TUCATINIB AND CHEMOTHERAPY (CAPECITABINE OR ERIBULIN MESYLATE) IN HER2-POSITIVE ADVANCED BREAST CANCER (The JAZMINE Study)
HER2 positive advanced breast cancer
Medica Scientia Innovation Research S.L. · 129 participants
📍 Spain
2025-524613-89-00 on CTIS ↗
Phase I Nervous System Diseases Authorised 05/05/2026
Bioequivalence study comparing two temazepam 20 mg tablet formulations after fasted administration; an open, randomized, single centre, single dose study with crossover design in healthy subjects
short-term treatment of insomnia
Orion Corporation · 24 participants
📍 Czechia
2025-524376-36-00 on CTIS ↗
Phase III Eye Diseases Authorised 05/05/2026
Phase 3, Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Recombinant Human Nerve Growth Factor Eye Drop Solution in Participants With Persistent Corneal Epithelial Defect (PCED)
Persistent Corneal Epithelial Defect (PCED)
Dompe' Farmaceutici S.p.A. · 91 participants
📍 Czechia · Italy · Netherlands · Poland · Germany · Spain · Hungary · France
2025-523443-35-00 on CTIS ↗
Phase II Immune System Diseases Authorised 05/05/2026
A Long-Term Extension Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Patients With Graves' Disease
Graves’ Disease
Immunovant Sciences GmbH · 128 participants
📍 Italy · Greece · Germany · Hungary · Poland · Czechia · Netherlands · Spain · Belgium · Bulgaria · Latvia
2025-524001-33-00 on CTIS ↗
Phase I Neoplasms Authorised 05/05/2026
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Imatinib Mesylate Tablets 400 mg, manufactured by Sun Pharmaceutical Industries Limited, India with Glivec® (Imatinib mesylate) Coated tablets 400 mg, Produced by Novartis Pharma Produktions GmbH, Wehr, Germany or Novartis Pharmaceutical Manufacturing LLC, Ljubljana; Imported and Registered by Novartis Biosciences SA, Prof. Vicente Rao Avenue, 90, Sao Paulo – SP, CNPJ: 56.994.502/0001-30, Brazilian Industry, in healthy adult, human subjects under fed condition.
Acute Lymphoblastic Leukemia (Ph+ ALL), (Ph+) Chronic Myeloid Leukemia
Sun Pharmaceutical Industries Limited · 28 participants
📍 Romania
2025-524935-38-00 on CTIS ↗
Phase I Anesthesia and Analgesia Authorised 05/05/2026
A Phase I, open-label study in healthy adults comparing the availability in the body of the active substance lidocaine following administration of 2% and 4% lidocaine gel into the urethra
bioavailability trial with healthy participants, therapeutic indication not studied
Farco-Pharma GmbH · 28 participants
📍 Germany
2026-525752-29-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 05/05/2026
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living with Obesity or Overweight with Weight-Related Comorbidities Who Do Not Have Diabetes
Obesity
Kailera Therapeutics Inc. · 612 participants
📍 Bulgaria · Hungary · Spain · Germany · Czechia · Poland
2025-523486-17-00 on CTIS ↗
Phase III Congenital, Hereditary, and Neonatal Diseases and Abnormalities Authorised 05/05/2026
A Multicenter, Randomized, Operationally Seamless Phase 2/3 Study to Evaluate the Efficacy and Safety of BMN 333 versus Vosoritide in Children with Achondroplasia
Achondroplasia
Biomarin Pharmaceutical Inc. · 25 participants
📍 Poland · Italy · Romania
2025-523811-12-00 on CTIS ↗
Phase III Immune System Diseases Authorised 05/05/2026
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Nipocalimab in Adults with Moderate to Severe Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
Janssen Cilag International · 271 participants
📍 Denmark · Hungary · Portugal · Italy · Norway · Greece · Slovakia · Czechia · France · Poland · Bulgaria · Germany · Spain · Romania · Finland
2025-523552-31-00 on CTIS ↗
Phase II Pathological Conditions, Signs and Symptoms Authorised 04/05/2026
An Open-Label Phase IIa Trial Exploring the Safety, Tolerability, and Efficacy of the T Cell Engager OM336 for Desensitization of Kidney Transplant Candidates
End stage renal failure
Medical University Of Vienna · 6 participants
📍 Austria
2025-523222-40-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 04/05/2026
Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with obesity (AMAZE 1)
Obesity
Novo Nordisk A/S · 270 participants
📍 Denmark · France · Germany · Belgium
2024-520440-42-00 on CTIS ↗
Phase II Eye Diseases Authorised 04/05/2026
A randomized, double masked, placebo-controlled, multicenter, dose-range finding study to assess the efficacy and safety of FWY003 in patients with geographic atrophy secondary to age-related macular degeneration
Geographic atrophy secondary to age-related macular degeneration
Novartis Pharma AG · 142 participants
📍 Bulgaria · Romania · Germany · Czechia · Spain · Poland · Italy · Hungary · France
2025-523704-77-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 04/05/2026
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living with Obesity or Overweight and Diabetes
Obesity
Kailera Therapeutics Inc. · 626 participants
📍 Hungary · Poland · Bulgaria · Germany · Czechia · Spain
2025-523510-87-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 04/05/2026
Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with overweight or obesity, and type 2 diabetes (AMAZE 2)
Overweight or obesity, and type 2 diabetes
Novo Nordisk A/S · 265 participants
📍 Italy · Croatia · Hungary · Slovakia · Romania
2024-520441-23-00 on CTIS ↗
Phase II Immune System Diseases Authorised 04/05/2026
Randomised, placebo-controlled, double-blind, parallel-group Phase II study to evaluate the efficacy and safety of oral BI 3000202 in patients with moderate to severe systemic lupus erythematosus (SLE)
Systemic lupus erythematosus
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A. · 106 participants
📍 Bulgaria · Romania · Germany · Spain · Hungary · Poland · Croatia
2025-523488-39-00 on CTIS ↗
Phase III Digestive System Diseases Authorised 04/05/2026
Modafinil for debilitating fatigue in quiescent inflammatory bowel disease: a multicentre, randomised, double-blind, placebo-controlled, clinical trial (MODIFI-IBD trial)
Inflammatory bowel disease, Fatigue
Radboud universitair medisch centrum Stichting · 60 participants
📍 Netherlands
2026-525163-41-00 on CTIS ↗
Phase IV Mental Disorders Authorised 04/05/2026
Efficacy and Safety of Daridorexant in Patients with Major Depressive Disorder (MDD) and Insomnia: Double-blind, randomized, controlled trial
Patients with major depressive episode and moderate to severe insomnia disorder
Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL · 134 participants
📍 Spain
2025-524794-16-00 on CTIS ↗
Phase II Mental Disorders Authorised 04/05/2026
Antidepressant effects of psilocybin in the absence of serotoninergic psychedelic experience: a dimensional functional neuroimaging approach
Major depressive disorder
Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau · 60 participants
📍 Spain
2025-521690-14-00 on CTIS ↗
Phase III Immune System Diseases Authorised 04/05/2026
A multicenter open-label extension study to evaluate the long-term safety and tolerability of zigakibart in adults with primary IgA nephropathy
IgA nephropathy
Novartis Pharma AG · 69 participants
📍 Belgium · France · Czechia · Croatia · Greece · Germany · Italy · Spain
2024-519638-22-00 on CTIS ↗
Phase III Neoplasms Authorised 04/05/2026
A Phase 3, Randomized, Double-blind, Study of Belzutifan + Zanzalintinib Versus Belzutifan + Placebo in Participants with Advanced RCC who have progressed on or after both PD-1/L1 and VEGF-TKI therapies in sequence or in combination (LITESPARK-034)
Renal Cell Carcinoma
Merck Sharp & Dohme LLC · 311 participants
📍 Denmark · Spain · Netherlands · Germany · France · Czechia · Poland · Italy · Greece
2024-516993-31-00 on CTIS ↗
Phase I Bacterial Infections and Mycoses Authorised 04/05/2026
CD5CAR-NK cells for refractory invasive mold disease
refractory invasive mold disease
Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer · 10 participants
📍 Spain
2025-524638-24-00 on CTIS ↗
Phase II Bacterial Infections and Mycoses Authorised 04/05/2026
Staphylococcus aureus Network Adaptive Platform trial (SNAP)
Staphylococcus aureus bacteraemia
Fundacion Para La Gestion De La Investigacion En Salud De Sevilla · 230 participants
📍 Spain
2025-521388-11-00 on CTIS ↗
Phase I Not possible to specify Authorised 04/05/2026
An open-label, single-center study to evaluate the safety and test-retest characteristics of [11C]MODAG-005 as PET radioligand for imaging pathological alpha-synuclein deposition in the brains of patients with Parkinson’s disease (PD) or Multiple System Atrophy (MSA) compared to age-matched healthy controls (AMHC)
Parkinson Disease, Multiple System Atrophy, Healthy Volunteer
Modag GmbH · 28 participants
📍 Germany
2023-506965-72-00 on CTIS ↗
Phase I Not possible to specify Authorised 01/05/2026
A PHASE 1, OPEN-LABEL, SINGLE-DOSE MASS BALANCE AND METABOLITE PROFILING STUDY OF 14C-LABELED IZICOPAN (INF904) IN HEALTHY MALE PARTICIPANTS
Not applicable, healthy volunteers
InflaRx GmbH · 8 participants
📍 Netherlands
2026-525517-31-00 on CTIS ↗
Phase IV Respiratory Tract Diseases Authorised 30/04/2026
PHASE IV, PROSPECTIVE, OPEN-LABEL, SINGLE ARM STUDY ON THE PAIN-RELIEF EFFECT OF BENZYDAMINE HYDROCHLORIDE LOZENGES 3 MG MINT TASTE (TANTUM VERDE) IN NON STREPTOCOCCAL PHARYNGOTONSILLITIS IN PEDIATRIC AGE (6-11 YEARS OLD).
NON STREPTOCOCCAL PHARYNGOTONSILLITIS
Angelini Pharma Italia Aziende Chimiche Riunite Angelini Francesc O A.C.R.A.F. S.p.A. Enunciabile Anche Angelini Pharma Italia S.p.A. Angelini Pharma S.p.A. A.C.R.A.F. S.p.A. Acraf S.p.A. Angelini S.p.A. Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. · 120 participants
📍 Italy
2025-521526-15-00 on CTIS ↗
Phase IV Digestive System Diseases Authorised 30/04/2026
Multicenter clinical trial on the effectiveness and safety of outpatient treatment of acute uncomplicated diverticulitis without antibiotics versus antibiotic treatment. ADIANA Trial.
Diverticular disease of the intestine,
Fundacion Para La Formacion E Investigacion Sanitaria De La Region De Murcia · 282 participants
📍 Spain
2025-523121-17-00 on CTIS ↗
Phase II Neoplasms Authorised 30/04/2026
"Contribution of 68Ga-FAPI-46 PET-CT in the initial staging of gastric cancers eligible for curative treatment" "FAPGASTRO"
gastric cancer
Centre Hospitalier Universitaire De Bordeaux · 40 participants
📍 France
2025-524434-25-00 on CTIS ↗
Phase II Nervous System Diseases Authorised 30/04/2026
Impact of epilepsy on the brainstem adenosine pathway and its relation with arousal and respiratory reactivity BRAVE
Neurology
Hospices Civils De Lyon · 50 participants
📍 France
2025-524511-36-00 on CTIS ↗
Phase IV Digestive System Diseases Authorised 30/04/2026
Switching to Mesalazine Monotherapy vs Continuing Thiopurines in Older Patients with Ulcerative Colitis in Sustained Remission: A Multicenter Randomized Controlled Trial (IDEA).
Ulcerative Colitis
Grupo Espanol De Trabajo En Enfermedad De Crohn y Colitis Ulcerosa · 304 participants
📍 Spain
2025-524675-23-00 on CTIS ↗
Phase I Skin and Connective Tissue Diseases Authorised 30/04/2026
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants with Atopic Dermatitis
Atopic Dermatits
Regeneron Pharmaceuticals Inc. · 64 participants
📍 Belgium
2025-524205-32-00 on CTIS ↗
Phase I Virus Diseases Authorised 30/04/2026
Study to Learn How Safe EV25 is and the Amount of EV25 in the Body Over a Period of Time, When Given as a Single Dose to Adult Healthy People [CCI]
Influenza
Eradivir Inc. · 16 participants
📍 Belgium
2026-525176-26-00 on CTIS ↗
Phase I Immune System Diseases Authorised 30/04/2026
A first in human study of the safety, pharmacokinetics and pharmacodynamics of KLR-003 in healthy participants and patients with immune mediated diseases.
Psoriasis
Klear Bio Inc. · 182 participants
📍 Netherlands
2026-525575-22-00 on CTIS ↗
Phase I Neoplasms Authorised 30/04/2026
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover bioequivalence study comparing Trametinib tablets 2 mg, Manufactured by Sun Pharmaceutical Industries Limited, India with MEKINIST® (Trametinib) tablets 2 mg, Distributed by: Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936, USA in healthy, adult, human subjects under fasting condition.
Adjuvant treatment of BRAF V600E or V600K mutation-positive melanoma (in combination with dabrafenib);, BRAF V600E mutation-positive unresectable or metastatic solid tumors;, BRAF V600E mutation-positive metastatic non-small cell lung cancer (NSCLC), in combination with dabrafenib;, BRAF V600E mutation-positive low-grade glioma (LGG)., BRAF V600E mutation-positive locally advanced or metastatic anaplastic thyroid cancer (ATC);, BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma, as a single agent in BRAF-inhibitor treatment-naïve patients or in combination with dabrafenib;
Sun Pharmaceutical Industries Limited · 72 participants
📍 Romania
2025-524267-20-00 on CTIS ↗
Phase I Bacterial Infections and Mycoses Authorised 30/04/2026
A study to assess the safety, and blood levels of CTX-187 after single and repeated intravenous doses in healthy volunteers and patients with bacterial infection
Bacterial Infection
Centauri Therapeutics Limited · 68 participants
📍 Netherlands
2026-525619-15-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 30/04/2026
A phase III randomised, double-blind, placebo-controlled, multicentre efficacy and safety clinical trial of angiotensin II in paediatric patients of 0 to 17 years of age with refractory hypotension in distributive shock receiving fluid resuscitation and standard-of-care vasopressors
refractory hypotension in distributive shock
Paion Pharma GmbH · 143 participants
📍 Italy · Germany · France · Spain
2025-523750-14-00 on CTIS ↗
Phase I Not possible to specify Authorised 30/04/2026
A PHASE 1, OPEN-LABEL STUDY TO ASSESS THE ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION, INCLUDING THE MASS BALANCE, OF A SINGLE ORAL DOSE OF [14C]-VAFIDEMSTAT IN HEALTHY MALE PARTICIPANTS
Healthy volunteers
Oryzon Genomics S.A. · 8 participants
📍 Netherlands
2025-524832-20-00 on CTIS ↗
Phase II Neoplasms Authorised 30/04/2026
GLO-Surgery: Indocyanine Green and near infrared fLuorescence in paediatric Oncology surgery
Patients with pulmonary metastasis from any primary tumour, or who have an abdominal or thoracic Rhabdomyosarcoma (RMS), Non-rhabdomyosarcomatous soft tissue sarcoma (NRSTS), Neuroblastoma (NBL) or a Malignant Germ cell tumour (mGCT) where complete resection by keyhole or open surgery is planned, and/or patients with a renal tumour or para-testicular RMS (ptRMS) requiring lymph node dissection
The University Of Birmingham · 30 participants
📍 Netherlands
2024-514089-37-00 on CTIS ↗
Phase II Musculoskeletal Diseases Authorised 30/04/2026
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Psoriatic Arthritis.
Psoriatic arthritis​​
Merck Sharp & Dohme LLC · 49 participants
📍 Poland · Germany · Spain
2025-520997-21-00 on CTIS ↗
Phase III Neoplasms Authorised 30/04/2026
A Phase III Open-label, Randomised, Multicentre Study Comparing AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA and CD19, versus Standard Regimens in Participants with Relapsed Refractory Multiple Myeloma (DURGA-4)
Relapsed or Refractory Multiple Myeloma
AstraZeneca AB · 153 participants
📍 Norway · Poland · Spain · Germany · France · Italy
2025-523285-25-00 on CTIS ↗
Phase I Neoplasms Authorised 30/04/2026
A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BG-C0979 in Patients with Selected Advanced Solid Tumors
Advanced Solid Tumors
BeOne Medicines I GmbH · 24 participants
📍 Spain
2025-524857-15-00 on CTIS ↗
Phase II Mental Disorders Authorised 29/04/2026
Oral rifaximin in patients with opioid use disorder (OUD): multicenter clinical trial on the microbiota–gut–brain axis
substance use disorder
Fondazione Santa Lucia · 50 participants
📍 Italy
2025-524778-41-00 on CTIS ↗
Phase IV Bacterial Infections and Mycoses Authorised 29/04/2026
EaRly impAct theraPy with ceftazidime-avibactam via rapID diagnostics versus standard of care antibiotics and diagnostics in patients with bloodstream infection, hospital-acquired pneumonia or ventilator-associated pneumonia due to Pseudomonas aeruginosa or carbapenemase producing Enterobacterales ("RAPID")
Bloodstream Infection, Ventilator Associated Pneumonia and Hospital-Acquired Pneumonia
National University Of Singapore · 80 participants
📍 Italy
2024-520067-13-00 on CTIS ↗
Phase I Nervous System Diseases Authorised 29/04/2026
Effect of NBI-921355 on corticospinal excitability in healthy participants
Epilepsy
Neurocrine Biosciences Inc. · 24 participants
📍 Netherlands
2025-524134-26-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 29/04/2026
An International, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Trial on the Effects of EA-230 on the Length of Hospital Stay Following On-Pump Coronary Artery Bypass Grafting Surgery
Coronary artery disease
EBI Anti Sepsis B.V. · 150 participants
📍 Belgium · Netherlands
2025-525053-39-00 on CTIS ↗
Phase I/II Digestive System Diseases Authorised 29/04/2026
A Phase 1b/2a, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of MB-001 in Participants With Moderately to Severely Active Ulcerative Colitis
Ulcerative Colitis
Mage Biologics Inc. · 30 participants
📍 Poland
2025-524719-35-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 29/04/2026
A Phase 3, Randomized, Active- and Placebo-Controlled, Partially-Blinded Study to Compare the Efficacy and Safety of KAI-9531 Administered Once Weekly Versus Semaglutide and Placebo in Participants Living with Obesity Who Do Not Have Diabetes
Obesity
Kailera Therapeutics Inc. · 268 participants
📍 Poland · Bulgaria
2025-523511-11-00 on CTIS ↗
Phase I Skin and Connective Tissue Diseases Authorised 29/04/2026
Phase I clinical trial evaluating the safety, tolerability, and absorption of a topical product containing latanoprost acid in healthy participants.
Androgenetic alopecia
Bioresearch Pharma S.A. · 24 participants
📍 Poland
2025-522468-34-00 on CTIS ↗
Phase III Therapeutics Authorised 29/04/2026
THE ROLE OF PANCREATIC STONE PROTEIN (PSP) AND PSP-GUIDED EARLY MEROPENEM TREATMENT TO MITIGATE SEPSIS RISK AT THE EMERGENCY DEPARTMENT: THE PROMISE DOUBLE BLIND, PHASE III, RANDOMIZED CONTROLLED CLINICAL TRIAL
Infection and sepsis
Elliniko Institouto Meletis Tis Sipsis · 398 participants
📍 Greece
2025-525006-37-00 on CTIS ↗
Phase III Neoplasms Authorised 29/04/2026
HO183 CAR T: A phase III randomized trial comparing academically produced BCMA-directed CAR T-cells (ARI0002h) with standard of care regimen in patients with relapsed/refractory multiple myeloma
relapsed/refractory multiple myeloma
Universitair Medisch Centrum Groningen · 126 participants
📍 Netherlands
2025-524876-43-00 on CTIS ↗
Phase I Not possible to specify Authorised 29/04/2026
Bioequivalence clinical trial of two formulations of canagliflozin
Healthy volunteers
Laboratorios Normon S.A. · 36 participants
📍 Spain
2026-525944-14-00 on CTIS ↗
Phase I Not possible to specify Authorised 29/04/2026
Bioequivalence clinical trial of two formulations of loperamide.
Healthy volunteers
Laboratorios Normon S.A. · 40 participants
📍 Spain
2026-525278-20-00 on CTIS ↗
Phase I Not possible to specify Authorised 29/04/2026
Pilot, randomized, crossover, comparative bioavailability study of two tadalafil formulations (oral suspension and film-coated tablets) after a single oral dose of 20 mg under fasting conditions in healthy male volunteers.
Healthy volunteers
Farmalider S.A. · 8 participants
📍 Spain
2026-525930-47-00 on CTIS ↗
Phase II Mental Disorders Authorised 29/04/2026
A Phase 2a, Randomized, Participant- and Investigator blinded, Parallel-group, Placebo-controlled, Multicenter Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults with DSM-5 Schizophrenia (STAR-1)
Schizophrenia
Novartis Pharma AG · 42 participants
📍 Bulgaria
2025-524058-32-00 on CTIS ↗
Phase I/II Immune System Diseases Authorised 28/04/2026
A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Subjects with Active Idiopathic Inflammatory Myopathy or Active Juvenile Idiopathic Inflammatory Myopathy
Active Idiopathic Inflammatory Myopathy including dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy or Juvenile Idiopathic Inflammatory Myopathy
Cabaletta Bio Inc. · 13 participants
📍 Italy · Spain · Germany
2025-521145-24-01 on CTIS ↗
Phase III Mental Disorders Authorised 28/04/2026
A Multicenter, Long-term, Open-Label, Safety, Tolerability, and Efficacy Study of Azetukalner in Bipolar I or II Depression
Depressive episodes associated with Bipolar disorder I or II (Bipolar Depression)
Xenon Pharmaceuticals Inc. · 70 participants
📍 Bulgaria · Germany · France · Spain
2025-522872-10-00 on CTIS ↗
Phase II Hemic and Lymphatic Diseases Authorised 28/04/2026
Efficacy of cell therapy with allo-MSCs in patients with gvhd resistant to ruxolitinib second line therapy: a Phase IIB Clinical Trial - MSC-GRR2 Study
Gvhd Resistant to ruxolitinib and steroids
Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia · 26 participants
📍 Italy
2025-523448-10-00 on CTIS ↗
Phase I Respiratory Tract Diseases Authorised 28/04/2026
A randomised, open-label, single-centre, drug-drug-interaction trial to evaluate the impact of carboxylesterase 2 (CES2)- and CYP3A4-inhibition on the pharmacokinetics of buloxibutid in healthy volunteers
Idiopathic pulmonary fibrosis
Vicore Pharma AB · 24 participants
📍 Sweden
2026-526135-18-00 on CTIS ↗
Phase I Neoplasms Authorised 28/04/2026
​​AMG 436 as monotherapy and combination therapy in participants with Microsatellite Instability-High/Mismatch Repair Deficient Solid Tumors ​
microsatellite instability high/mismatch repair deficient (MSI-H/dMMR) solid tumors
Amgen Inc. · 77 participants
📍 Spain · France · Belgium
2025-524056-63-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 28/04/2026
An Adaptive, 2-Part, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of IKT-001 in Pulmonary Arterial Hypertension.
Pulmonary Arterial Hypertension
Inhibikase Therapeutics Inc. · 94 participants
📍 Spain · Poland · Italy · Belgium · Latvia · Denmark · Czechia · Germany · France · Netherlands · Portugal · Ireland · Greece
2024-520218-23-00 on CTIS ↗
Phase II Neoplasms Authorised 28/04/2026
A Phase 2 Study of [68Ga]BED003 for PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
Colorectal cancer (CRC), gastric cancer (GC), pancreatic ductal adenocarcinoma (PDAC), invasive lobular breast cancer (ILC), and epithelial ovarian cancer (EOC).
Blue Earth Diagnostics Ireland Limited · 65 participants
📍 Netherlands · Italy
2025-521983-36-00 on CTIS ↗
Phase III Neoplasms Authorised 28/04/2026
CIRCULATE III - Tailoring the decision for adjuvant chemotherapy using circulating tumour DNA, in patients with stage III colorectal cancer
Stage III colorectal cancer
Unicancer · 300 participants
📍 France · Sweden
2025-521045-24-00 on CTIS ↗
Phase III Neoplasms Authorised 28/04/2026
A Multicenter, Open-label, Phase 3 Extension Study to Evaluate the Long‑term Efficacy and Safety in Participants Who Are Currently on Treatment in a Belzutifan Study (LITESPARK-043)
Renal Cell Carcinoma, hepatocellular carcinoma, nonMSI-H/dMMR colorectal cancer, pancreatic ductal adenocarcinoma, biliary tract cancer, non-MSIH/dMMR endometrial cancer, esophageal squamous cell carcinoma, Advanced Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, von Hippel-Lindau (VHL)Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor, Advanced Solid Tumors With HIF-2α related Genetic Alterations
Merck Sharp & Dohme LLC · 37 participants
📍 Czechia · Spain · Poland · Belgium · Finland · Germany · France · Netherlands · Hungary · Denmark
2025-524160-38-00 on CTIS ↗
Phase III Female Urogenital Diseases and Pregnancy Complications Authorised 28/04/2026
ANTIPROM - Comparison of two prophylactic antibiotic regimens in case of preterm prelabor rupture of membranes before 34 weeks of gestation: a randomized controlled trial
Population of study participants Pregnant women with PPROM at 22 to 33 weeks’ gestation
Assistance Publique Hopitaux De Paris · 1008 participants
📍 France
2025-520842-31-00 on CTIS ↗
Phase II Hemic and Lymphatic Diseases Authorised 28/04/2026
Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety of Anumigilimab (CSL324) in Adults with Sickle Cell Disease
Sickle Cell Disease
CSL Behring LLC · 12 participants
📍 Belgium · Netherlands · France · Italy
2025-521154-42-00 on CTIS ↗
Phase III Neoplasms Authorised 28/04/2026
A two-part, seamless, multicenter, RANDOMIZED, open-label, ADAPTIVE Phase ii/III STUDY OF THE BLOOD-BRAIN barrier PENETRANT RO7771950 versus Tucatinib, both in combination with trastuzumab and capecitabine, in patients with Pretreated unresectable locally advanced or metastatic HER2-positive breast cancer, with or without central nervous system metastases
Pretreated Unresectable Locally Advanced or Metastatic human epidermal growth factor receptor 2 (HER2)-Positive Breast Cancer, with or without Central Nervous System (CNS) Metastases
F. Hoffmann-La Roche AG · 237 participants
📍 Belgium · France · Italy · Austria · Romania · Poland · Portugal · Czechia · Germany · Spain · Hungary
2025-524498-17-00 on CTIS ↗
Phase I Nervous System Diseases Authorised 28/04/2026
A Study to Compare the Blood Levels of Two Dosage Formulations of the Study Medicine in Healthy Adults
Migraine with or without aura
Pfizer Inc. · 36 participants
📍 Belgium
2025-525125-12-00 on CTIS ↗
Phase IV Skin and Connective Tissue Diseases Authorised 28/04/2026
MERCURE study: MEthotrexate in ReCurrent dVIN
dVIN caused by Lichen Sclerosus
Amsterdam UMC Stichting · 30 participants
📍 Netherlands
2025-524373-17-00 on CTIS ↗
Phase II Mental Disorders Authorised 28/04/2026
Electrophysiological analysis of Gamma-Hydroxybutyrate-induced sleep in intensive care patients: A Pilot Double-Blind Randomized Controlled Trial.(GAMMA-SLEEP)
The study population includes adult ICU patients with a hospitalization of more than 48 hours. We have chosen to include patients with or without mechanical ventilation, as sleep disorders affect all ICU patients after 48 hours.
Assistance Publique Hopitaux De Paris · 24 participants
📍 France
2025-521967-11-00 on CTIS ↗
Phase III Digestive System Diseases Authorised 28/04/2026
A randomized, phase 3, double-blind, double-dummy, active comparator-controlled multicenter clinical trial to evaluate the efficacy and safety of linaprazan glurate compared to lansoprazole in maintenance of healing in participants with healed erosive esophagitis (EE) due to gastroesophageal reflux disease (GERD) of Los Angeles (LA) grades A to D
Erosive esophagitis (EE) due to gastroesophageal reflux disease (GERD)
Cinclus Pharma Holding AB (publ) · 96 participants
📍 Hungary · Germany · Romania · Bulgaria · Czechia · Poland
2025-522750-39-00 on CTIS ↗
Phase II Mental Disorders Authorised 28/04/2026
A phase II, double-blinded, placebo-controlled, clinical trial to determine the efficacy and safety of AP707 in the treatment of Borderline Personality Disorder.
Borderline personality disorder
Apurano Pharmaceuticals GmbH · 154 participants
📍 Germany
2024-510873-11-00 on CTIS ↗
Phase I Eye Diseases Authorised 28/04/2026
Safety of stem cells in treatmemt of retinal diseases.
Retinal degenerative diseases
Bioinova a.s. · 10 participants
📍 Czechia
2023-503573-38-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 28/04/2026
A Phase 3, Randomized, Double-Blind, 48-Week Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of DYNE-101 Administered to Participants with Myotonic Dystrophy Type 1
Myotonic Dystrophy Type 1
Dyne Therapeutics Inc. · 72 participants
📍 Netherlands · Spain · Italy · Denmark · Germany · Belgium · France
2025-522957-20-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 28/04/2026
Efficacy, safety and pharmacokinetics of cagrilintide s.c. 2.4 mg as monotherapy and in combination with semaglutide s.c. 2.4 mg (CagriSema) once weekly for weight management in children and adolescents with overweight or obesity
Obesity and T2D
Novo Nordisk A/S · 157 participants
📍 Slovakia · Austria · Spain · Romania · Portugal · Italy · Denmark · Belgium · Sweden · Poland · Netherlands · Croatia · Hungary · Bulgaria
2023-509176-42-00 on CTIS ↗
Phase III Anesthesia and Analgesia Authorised 28/04/2026
A randomized, open-label, Phase III trial to assess the efficacy and safety of BupiZenge compared to lidocaine for pain associated with oral mucositis in head and neck cancer
Head and neck cancer, Oral mucositis
OncoZenge AB · 150 participants
📍 Germany · Denmark · Norway · Sweden
2025-524386-24-00 on CTIS ↗
Phase III Neoplasms Authorised 28/04/2026
A Phase 3, Randomized, Open-label, Multicenter Study of Sacituzumab Tirumotecan (sac-TMT, MK-2870) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care in Participants With Newly Diagnosed Advanced HRD-Negative Ovarian Cancer Following First-line Platinum-based Chemotherapy (TroFuse-021/ENGOTov85/ GOG-3102)
Ovarian cancer
Merck Sharp & Dohme LLC · 349 participants
📍 Norway · Ireland · Spain · Greece · France · Poland · Denmark · Austria · Hungary · Belgium · Czechia · Finland · Germany · Italy · Sweden
2023-508047-40-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 28/04/2026
Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Clemizole HCl as Adjunctive Therapy in Patients with Lennox-Gastaut Syndrome
Lennox-Gastaut Syndrome
Epygenix Therapeutics Inc. · 98 participants
📍 Italy · Spain · Hungary · Romania · Czechia · Poland
2025-522552-20-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 28/04/2026
Phase 2/3, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Participants with Alzheimer’s Disease Dementia
Agitation in Alzheimer's Disease Dementia
Exciva GmbH · 222 participants
📍 Italy · Slovakia · Spain · Poland · Czechia · Germany
2024-517388-22-00 on CTIS ↗
Phase I Not possible to specify Authorised 28/04/2026
A study in healthy people or otherwise healthy but overweight or obese to compare 2 formulations of survodutide given in different ways, either as a pre-filled syringe or a pen-like injector
Healthy volunteer trial
Boehringer Ingelheim International GmbH · 56 participants
📍 Germany
2025-524135-39-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 27/04/2026
A Phase 3, Parallel-group Treatment, Blinded, Randomized, Placebo-controlled Study to Assess the Efficacy and Safety of Pegtibatinase Administered Subcutaneously in Addition to Standard of Care in Participants with Classical Homocystinuria due to Cystathionine Beta Synthase Deficiency (HARMONY)
Classical Homocystinuria
Travere Therapeutics Inc. · 22 participants
📍 Belgium · Ireland · Spain · Italy · Germany · France · Portugal · Poland
2023-504135-40-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 27/04/2026
Efficacy and safety of NNC0487-0111s.c once weekly in participants with obesity who have reached target dose during run-in period (AMAZE12).
Obesity
Novo Nordisk A/S · 325 participants
📍 Belgium · Germany · Bulgaria · France · Spain · Denmark · Italy · Netherlands
2025-523804-62-00 on CTIS ↗
Phase III Digestive System Diseases Authorised 27/04/2026
RASolute 304: A Phase 3 Multicenter, Open-label, Randomized, 2‑Arm Study of Adjuvant Daraxonrasib Versus Standard of Care Observation Following Completion of Neoadjuvant and/or Adjuvant Chemotherapy in Patients with Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Revolution Medicines Inc. · 98 participants
📍 France · Spain · Italy · Germany
2025-523495-23-00 on CTIS ↗
Phase III Hemic and Lymphatic Diseases Authorised 27/04/2026
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of REGN7508, a Monoclonal Antibody Against FXI, for Primary Prophylaxis of Cancer-Associated Thrombosis for Participants with Solid Tumors Undergoing Cancer Treatment (ROXI-CAT-I)
Cancer-Associated Thrombosis (CAT).
Regeneron Pharmaceuticals Inc. · 324 participants
📍 Belgium · Czechia · France · Romania · Germany · Poland · Bulgaria · Spain
2024-519298-21-00 on CTIS ↗
Phase II Respiratory Tract Diseases Authorised 27/04/2026
A Phase IIb, multicentre, randomised, doubleblind, placebocontrolled, three-arm parallel-group study to evaluate the efficacy, safety, and tolerability at Week 24 of 2 doses of CHF10067 (zampilimab), with an optional 24-week doubleblind, placebocontrolled extension phase in participants with idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF)
Chiesi Farmaceutici S.p.A. · 103 participants
📍 Belgium · Germany · Italy · Czechia · Bulgaria · Netherlands · France · Portugal · Poland · Spain · Romania
2024-514246-37-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 27/04/2026
SEMAFORCRANIO : Multicenter, double-blind, parallel, randomized controlled trial of the efficacy of semaglutide in hypothalamic obesity secondary to craniopharyngioma in children aged 12 to 17 years
Craniopharyngioma
Centre Hospitalier Universitaire D'Angers · 50 participants
📍 France
2024-511114-20-00 on CTIS ↗
Phase I Not possible to specify Authorised 27/04/2026
A research study looking into blood levels of the medicine NNC0487 0111 in the body and how well it is tolerated in people with reduced liver function and normal liver function
hepatic impairment
Novo Nordisk A/S · 35 participants
📍 Slovakia
2025-521647-20-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 27/04/2026
Phase II/III randomized controlled open-label trial to evaluate the efficacy and safety of personalized tissue engineered veins in patients with chronic venous insufficiency
Chronic Venous Insufficiency
VeriGraft AB · 60 participants
📍 Spain
2025-524103-69-00 on CTIS ↗
Phase IV Immune System Diseases Authorised 27/04/2026
A Study to Evaluate Mirikizumab Concentrations in Breast Milk Following Administration of Mirikizumab by Subcutaneous Injection in Lactating Participants Receiving Mirikizumab Therapeutically for an Approved Indication
severely active ulcerative colitis (US) and CD (Crohn’s disease)
Eli Lilly & Co. · 16 participants
📍 Spain · Denmark · Germany · Italy · Poland
2025-522362-78-00 on CTIS ↗
Phase II Pathological Conditions, Signs and Symptoms Authorised 27/04/2026
A randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and quality of life outcomes of Vi-Siblin in patients with low anterior resection syndrome following rectal cancer surgery.
Low anterior resection syndrome after low anterior resection for rectal cancer
Sykehuset Telemark HF · 120 participants
📍 Norway
2024-514541-11-00 on CTIS ↗
Phase II Nervous System Diseases Authorised 27/04/2026
Methylphenidate for Early Awakening in Coma (MEAWAKE)
Coma due to acute brain injury
Rigshospitalet · 324 participants
📍 Austria · Denmark · Germany · France
2025-524937-19-00 on CTIS ↗
Phase II Neoplasms Authorised 27/04/2026
The MAVRiC Study: A Phase II Study of Disease Risk Mutation-guided Finite Duration Acalabrutinib plus Venetoclax for Relapse in CLL/SLL after First-line Finite covalent BTKi plus BCL2i combination, with or without Obinutuzumab
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
AstraZeneca AB · 63 participants
📍 Italy · Austria · Spain · Ireland · Czechia · Poland
2024-518858-17-00 on CTIS ↗
Phase I/II Respiratory Tract Diseases Authorised 27/04/2026
Study of IBI3009 alone or in combination with other therapies for extensive-stage small cell lung cancer
Extensive-Stage Small Cell Lung Cancer
Fortvita Biologics (USA) Inc. · 30 participants
📍 Poland · Denmark · Spain
2025-523972-21-00 on CTIS ↗
Phase II Congenital, Hereditary, and Neonatal Diseases and Abnormalities Authorised 27/04/2026
Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of MRM-3379 in Male Participants with Fragile X Syndrome
​​Fragile X Syndrome​
Mirum Pharmaceuticals Inc. · 15 participants
📍 Spain
2025-523738-21-00 on CTIS ↗
Phase I/II Neoplasms Authorised 27/04/2026
A multi-center, open-label, phase I/II study to evaluate the safety and efficacy of asciminib with chemotherapy followed by blinatumomab in pediatric, adolescent, and young adult patients with relapsed or refractory BCR::ABL1-positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)
relapsed or refractory BCR::ABL1-positive (Philadelphia positive, Ph+) or BCR::ABL1-like (Ph-like) acute lymphoblastic leukemia (ALL)
Novartis Pharma AG · 21 participants
📍 Italy · Spain · Germany · Netherlands · France · Denmark · Czechia
2025-522019-40-00 on CTIS ↗
Phase I Immune System Diseases Authorised 27/04/2026
Relative bioavailability and effect of food study with GLPG3667 in healthy subjects
inflammatory and autoimmune diseases
Galapagos · 16 participants
📍 Belgium
2026-525706-35-00 on CTIS ↗
Phase I Not possible to specify Authorised 27/04/2026
A Study of GEN1106 in Participants with Solid Tumors
Metastatic or advanced malignant solid tumors
Genmab A/S · 50 participants
📍 Spain
2025-523760-21-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 24/04/2026
A Phase 3, Randomized, Double-Blind, Active-Controlled, Parallel-Group, Multicenter, 12-Week Trial to Evaluate the Efficacy and Safety of Treatment with K-924 HD in Participants with Hypercholesterolemia with Inadequate Response to EU-Marketed Pitavastatin 4 mg
Hypercholesterolemia
Kowa Co. Ltd. · 40 participants
📍 Spain
2025-523739-20-00 on CTIS ↗
Phase II Nervous System Diseases Authorised 24/04/2026
Diving into the noradrenergic system : Role of the alpha2C-adrenergic receptors NA2C-TEP-IRM
Neurology
Hospices Civils De Lyon · 165 participants
📍 France
2025-524602-15-00 on CTIS ↗
Phase III Not possible to specify Authorised 24/04/2026
ADRESS : Efficacy of the Alpha 2 agonist dexmedetomidine for sympathetic Deactivation in REfractory Septic Shock: a randomized, controlled trial
Septic shock
Hospices Civils De Lyon · 360 participants
📍 France
2025-524122-18-00 on CTIS ↗
Phase I/II Neoplasms Authorised 24/04/2026
A Multicenter, Open-label, Phase 1/2 Safety Run-in and Expansion Study of PM54 in Combination With Immunotherapy Evaluating Safety and Efficacy in Adult Participants who were Previously Treated for Advanced Malignancies
Advanced malignancies
Pharma Mar S.A. · 36 participants
📍 Spain
2025-523774-16-00 on CTIS ↗
Phase II Mental Disorders Authorised 24/04/2026
Prevention of Sexual Offending with Cognitive Behavioral Therapy Alone Versus Therapy Combined with Testosterone Suppression – the PREVENT-MED randomized clinical trial
Paraphilic disorder, Compulsive sexual behavior disorder
Vaestra Goetalandsregionen · 180 participants
📍 Sweden
2024-518120-68-01 on CTIS ↗
Phase II Neoplasms Authorised 24/04/2026
A randomized phase 2 trial of neoadjuvant pembrolizumab plus belzutifan with or without lenvatinib in patients with localized renal cell carcinoma. The moonlanding trial
Patients with localized renal cell carcinoma
Vall D Hebron Institute Of Oncology · 90 participants
📍 Spain
2024-519673-18-00 on CTIS ↗
Phase I Immune System Diseases Authorised 24/04/2026
Phase 1b study to assess the safety and tolerability of SR-878 in patients with rheumatoid arthritis
rheumatoid arthritis
SciRhom GmbH · 12 participants
📍 Romania
2025-523678-17-00 on CTIS ↗
Phase I Not possible to specify Authorised 24/04/2026
Multiple-dose, open-label, laboratory blinded, randomized, 2-period, 2-sequence, crossover, steady-state bioequivalence study comparing the Test Product Naproxen sodium 660 mg modified release tablets with the Reference Product Actromadol 660 mg Modified-Release tablets in healthy adult male and female subjects under fed conditions.
No medical condition
Laboratorios Cinfa S.A. · 32 participants
📍 Czechia
2026-526102-33-00 on CTIS ↗
Phase IV Cardiovascular Diseases Authorised 24/04/2026
Infusion of Furosemide to Improve Diuretic Efficiency in Acute Heart Failure (INFUSE-AHF)
Acute heart failure with volume overload
Region Midtjylland · 436 participants
📍 Denmark
2025-523589-26-00 on CTIS ↗
Phase II Virus Diseases Authorised 24/04/2026
Curing HIV: proof of concept randomized clinical trial with Pyrimethamine, Lenalidomide, TOpiramate (PLUTO)
HIV-1
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) · 30 participants
📍 Netherlands
2026-525211-14-00 on CTIS ↗
Phase II Neoplasms Authorised 24/04/2026
Mechanisms of Resistance to anti-PD-1 Therapy in cutaneous Squamous Cell Carcinomas: Impact of Tumor Cell Plasticity on Promoting Myeloid Suppressor Cell Infiltration. A phase II single arm, unicenter study of cemiplimab in patients with locally advanced cSCCs.
Cutaneous squamous cell carcinoma (ccSCC)
Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL · 15 participants
📍 Spain
2025-524255-32-00 on CTIS ↗
Phase II Hemic and Lymphatic Diseases Authorised 23/04/2026
Colchicine to Quench the Inflammatory Response after Deep Vein Thrombosis: The CONQUER-DVT Randomized Controlled Trial
deep vein thrombosis
Universita' Degli Studi G. D'Annunzio Di Chieti · 122 participants
📍 Italy
2025-521836-12-00 on CTIS ↗
Phase II Immune System Diseases Authorised 23/04/2026
A randomized controlled, two-arm (1:1 ratio) Phase IIa trial to assess the efficacy and safety of obinutuzumab in treating adults with de novo minimal change disease
Kidney disease
Medizinische Universitaet Innsbruck · 48 participants
📍 Germany · Austria · France
2025-520641-69-00 on CTIS ↗
Phase I/II Nutritional and Metabolic Diseases Authorised 23/04/2026
A Phase 1/2 Open-Label, Single Ascending Dose, First-In-Human Study to Assess Safety and Tolerability of Endoscopic Ultrasound-Guided Pancreatic Infusion of RJVA-001 in Adults With Inadequately Controlled Type 2 Diabetes on Multiple Glucose-Lowering Agents.
Type 2 Diabetes
Fractyl Health Inc. · 15 participants
📍 Netherlands
2025-524438-24-00 on CTIS ↗
Phase IV Respiratory Tract Diseases Authorised 23/04/2026
A randomized double-blind placebo-controlled study to demonstrate the efficacy of PMBL® sublingual tablets in reducing the incidence of respiratory tract infections in children aged 3-12 years (PIRTIK).
Respiratory Tract Infections
Lallemand Pharma Europe filial af Lallemand Pharma AG Schweiz · 224 participants
📍 Poland
2025-524212-11-00 on CTIS ↗
Phase I Neoplasms Authorised 23/04/2026
Phase I study of CDK8 inhibitor RVU120 in combination with everolimus in children with recurrent or progressive Group 3 or 4 medulloblastoma; MEDWAY
Medulloblastoma (recurrent or progressive)
Instytut Pomnik Centrum Zdrowia Dziecka · 48 participants
📍 Poland
2025-524031-39-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 23/04/2026
Impact of Oral Semaglutide on Platelet Reactivity in Patients with Diabetes Mellitus or Overweight with High Risk or established Cardiovascular Disease: the SEMA-PLAT Study
Diabetes Mellitus, Cardiovascular disease, Overweight (BMI ≥27 kg/m²), Obesity (BMI≥30kg/m2)
Casa Di Cura Accreditata Istituto Chirurgico Ortopedico Traumatologico Marco Pasquali · 212 participants
📍 Italy
2025-522486-29-01 on CTIS ↗
Phase I Nutritional and Metabolic Diseases Authorised 23/04/2026
A research study investigating the effect of NNC0497-0040 in healthy participants, participants with overweight or obesity, and participants with type 1 diabetes with overweight or obesity.
Type I diabetes
Novo Nordisk A/S · 146 participants
📍 Germany
2025-523978-16-00 on CTIS ↗
Phase I Neoplasms Authorised 22/04/2026
Phase I, first-in-human clinical trial to evaluate safety of infusion of STAb-T19 cells: genetically modified T lymphocytes secreting αCD19xαCD3 bispecific antibodies for malignant B-cell neoplasms
Malignant B-cell neoplasms
Fundacion Para La Investigacion Biomédica Del Hospital Universitario 12 De Octubre · 24 participants
📍 Spain
2025-524814-27-00 on CTIS ↗
Phase I/II Musculoskeletal and Neural Physiological Phenomena Authorised 22/04/2026
Exploratory study on the effect of Rimonabant on hand function in patients with spinal cord injury (RIMOHANDOPEN)
Spinal cord injury
Sinfatin S.L. · 8 participants
📍 Spain
2025-524279-22-00 on CTIS ↗
Phase I/II Neoplasms Authorised 22/04/2026
COLOMBE - A multicentre, single arm, phase 1/2 study, aiming to assess the safety and efficacy of nivolumab and imiquimod combination in vulvar squamous cell carcinoma patients
Vulvar Squamous Cell Carcinoma (VSCC) patients
Centre Leon Berard · 50 participants
📍 France
2025-524759-29-00 on CTIS ↗
Phase I Not possible to specify Authorised 22/04/2026
Single-Dose Study in Healthy Participants to Compare the Bioavailability of One Film-Coated Mini-Tablet of Indapamide SR 1.5 mg versus One Film-Coated Tablet of Indapamide IR 2.5 mg Under Fasting Conditions, and to Compare the Bioavailability of One Film-Coated Mini-Tablet of Indapamide SR 1.5 mg Under Fasting versus Fed Conditions.
No medical condition.
Institut De Recherches Internationales Servier IRIS · 24 participants
📍 Portugal
2026-526040-13-00 on CTIS ↗
Phase I Neoplasms Authorised 22/04/2026
A FIRST-IN-HUMAN (FIH) PHASE 1/2 STUDY TO ASSESS SAFETY, TOLERABILITY, AND PRELIMINARY ANTI-TUMOR ACTIVITY OF REGN17372, AN ANTI-GPRC5D X ANTI-CD28 COSTIMULATORY BISPECIFIC MONOCLONAL ANTIBODY, IN COMBINATION WITH LINVOSELTAMAB, AN ANTI-BCMA X ANTI-CD3 BISPECIFIC MONOCLONAL ANTIBODY, IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
Relapsed/Refractory Multiple Myeloma
Regeneron Pharmaceuticals Inc. · 26 participants
📍 Greece
2025-522776-93-00 on CTIS ↗
Phase II Immune System Diseases Authorised 22/04/2026
A Multicentre, Parallel-group, Phase II, Randomised, Double-blind, 4 Arm Study to Evaluate Efficacy and Safety of AZD1163 in Participants with Moderately-to-Severely Active Rheumatoid Arthritis (LaunchPAD-RA)
Rheumatoid arthritis
AstraZeneca AB · 97 participants
📍 Hungary · Spain · Bulgaria · Germany · Poland
2025-522076-85-00 on CTIS ↗
Phase II Nutritional and Metabolic Diseases Authorised 22/04/2026
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Finding Study of CX11 Tablets in Patients with Type 2 Diabetes Mellitus.
Type 2 Diabetes Mellitus
Corxel Pharmaceuticals Inc. · 121 participants
📍 Poland
2025-524514-28-00 on CTIS ↗
Phase I/II Neoplasms Authorised 22/04/2026
ROSETTA HCC-206: An Open-Label, Multi-Center, Randomized Phase 1/2 Study of Pumitamig Alone or In Combination with Ipilimumab in Participants with First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC)
Advanced or unresectable Hepatocellular Carcinoma (HCC)
Bristol-Myers Squibb Services Unlimited Company · 47 participants
📍 Poland · Spain · Germany · France · Italy
2025-523602-33-00 on CTIS ↗
Phase I Immune System Diseases Authorised 22/04/2026
Clinical Study to Evaluate the Effects of Cevostamab in Patients with Lupus with or without Active Lupus Nephritis
Systemic Lupus Erythematosus (SLE) With or Without Active Lupus Nephritis (LN)
Genentech Inc. · 17 participants
📍 Italy · Spain · France · Germany
2025-522904-26-00 on CTIS ↗
Phase I Neoplasms Authorised 22/04/2026
A Phase I study to evaluate the safety and dosimetry of imaging with 68Ga-OncoACP3 in prostate cancer.
Patients with prostate cancer with: - suspected metastasis who are candidates for initial definitive therapy - suspected recurrence based on elevated serum prostate-specific antigen (PSA) level (i.e., a progressive and confirmed serum PSA level > 0.2 ng/mL) - metastatic disease who might be candidates for treatment with 177Lu-labelled PSMA ligands
Philogen S.p.A. · 20 participants
📍 Italy
2025-524594-16-00 on CTIS ↗
Phase II Neoplasms Authorised 22/04/2026
A phase II trial evaluating treatment intensification with Ezabenlimab in patients with PD-L1–expressing, locally advanced head and neck squamous cell carcinoma (LA-HNSCC) with minimal residual disease (MRD) as detected by circulating tumor DNA (ctDNA) after curative-intent chemoradiation
Locally advanced head and neck squamous cell carcinoma (LA-HNSCC)
Cliniques Universitaires Saint-Luc · 160 participants
📍 Belgium
2025-523575-36-00 on CTIS ↗
Phase III Musculoskeletal Diseases Authorised 21/04/2026
Topical Clobetasol Propionate for Inflammatory Hand osteoarthritis: A randomized trial versus placebo.(PROCLAME)
Adult patients with symptomatic and inflammatory Hand osteoarthritis HOA.
Assistance Publique Hopitaux De Paris · 187 participants
📍 France
2025-520678-20-00 on CTIS ↗
Phase II Neoplasms Authorised 21/04/2026
NoELA_No Endocrine therapy in small HR+ HER2- low relapse risk Luminal A early breast cancer, a single-arm de-escalation trial
Postmenopausal patients with small (pT1a-b pN0) hormone receptor positive (HR⁺) and HER2 negative (HER2⁻) early breast cancer with a Luminal A phenotype and at low risk of recurrence.
Unicancer · 630 participants
📍 France
2025-523683-20-00 on CTIS ↗
Phase III Not possible to specify Authorised 21/04/2026
A Randomized, Multi-Center, Double-Blind, Phase III Study Evaluating the Efficacy and Safety of Hetrombopag Olamine Tablets vs Placebo in Patients with Chemotherapy-Induced Thrombocytopenia
Chemotherapy induced thrombocytopenia
Jiangsu Hengrui Pharmaceuticals Co. Ltd. · 58 participants
📍 France · Romania · Poland · Spain · Bulgaria
2025-524209-34-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 21/04/2026
A Phase III, randomized, placebo-controlled, parallel group, double-blind study to evaluate the efficacy and safety of NIO752 in participants with Progressive Supranuclear Palsy followed by an Open Label Extension
Participants with Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
Novartis Pharma AG · 138 participants
📍 Netherlands · Germany · Spain · Italy · France · Belgium
2025-523481-24-00 on CTIS ↗
Phase I/II Musculoskeletal Diseases Authorised 21/04/2026
A single-arm, open-label, multi-centre, phase I/II first-in-human study evaluating the safety and clinical activity of QEL-005, an autologous CAR T-regulatory cell therapy treatment targeting CD19, in patients with diffuse cutaneous systemic sclerosis (dcSSc) and in patients with difficult to treat rheumatoid arthritis (D2TRA).
Diffuse cutaneous systemic sclerosis (dcSSc) Difficult to treat rheumatoid arthritis (D2TRA)
Quell Therapeutics Limited · 8 participants
📍 Spain · Germany
2025-523971-46-00 on CTIS ↗
Phase I Nutritional and Metabolic Diseases Authorised 21/04/2026
A research study to compare blood levels of cagrilintide after multiple doses of different versions of cagrilintide in adults with overweight or obesity
obesity
Novo Nordisk A/S · 234 participants
📍 Germany
2025-521384-12-00 on CTIS ↗
Phase II Nutritional and Metabolic Diseases Authorised 21/04/2026
Albuminuria Reduction Trial and Investigation with Survodutide Treatment in CKD (ARTIST-CKD)
Chronic Kidney Disease
Universitair Medisch Centrum Groningen · 95 participants
📍 Germany · Spain · Netherlands
2025-525068-13-00 on CTIS ↗
Phase I/II Neoplasms Authorised 21/04/2026
C6461008 - AN INTERVENTIONAL PHASE 1B/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-08634404 MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA
ADVANCED OR METASTATIC RENAL CELL CARCINOMA
Pfizer Inc. · 50 participants
📍 Germany · Spain
2025-523524-53-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 21/04/2026
J3R-MC-YDAL - A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Persistent Obesity or Overweight Treated With a Weekly Incretin, With and Without Type 2 Diabetes
Obesity, Overweight
Eli Lilly & Co. · 286 participants
📍 Spain · Romania · Belgium · Czechia
2025-523659-73-00 on CTIS ↗
Phase I Immune System Diseases Authorised 21/04/2026
An Open-Label, Phase 1b, Multiple Ascending Dose Study of OM336 in Participants with Active Sjogren’s Disease or Idiopathic Inflammatory Myopathy
Seropositive autoimmune disease: Sjogren’s disease or idiopathic inflammatory myopathy
Ouro Medicines Limited · 8 participants
📍 Czechia
2025-524100-29-00 on CTIS ↗
Phase II Hormonal diseases Authorised 21/04/2026
Protocol Title: Efficacy and safety of once-weekly subcutaneous NNC0662-0419 in participants with type 2 diabetes – a dose-finding study
type 2 diabetes
Novo Nordisk A/S · 145 participants
📍 Spain · Hungary · Portugal · Poland · Slovakia · Croatia
2025-523260-20-00 on CTIS ↗
Phase II Not possible to specify Authorised 21/04/2026
A single center study to evaluate the safety and tolerability of oral Azathioprine in patients with ADPKD
Autosomal dominant polycystic kidney and liver disease
UZ Leuven · 40 participants
📍 Belgium
2025-524313-86-00 on CTIS ↗
Phase I/II Neoplasms Authorised 21/04/2026
A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination with Other Anti-Cancer Therapies in Patients with KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies
Malignancies with Documented KRAS, BRAF and Other Selected RAS/MAPK Mutations
Institut De Recherches Internationales Servier IRIS · 105 participants
📍 France · Spain · Denmark · Italy
2025-523474-16-00 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 20/04/2026
KARMA - INtenSive care TreAtmeNT with adjuvant KetAmine and Recovery after Mechanical ventilAtion: a multicenter doubleblind randomized controlled trial
Adult patients admitted to the ICU and receiving unplanned invasive mechanical ventilation
Assistance Publique Hopitaux De Paris · 640 participants
📍 France
2025-523149-80-00 on CTIS ↗
Phase III Neoplasms Authorised 20/04/2026
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) plus Zanubrutinib (BGB-3111) Compared with Venetoclax plus Acalabrutinib in Patients with Previously Untreated Chronic Lymphocytic Leukemia
treatment-naive Chronic Lymphocytic Leukemia
BeOne Medicines I GmbH · 186 participants
📍 Netherlands · Poland · Italy · Germany · Spain · Romania · Czechia · France · Sweden
2025-524366-21-00 on CTIS ↗
Phase II Congenital, Hereditary, and Neonatal Diseases and Abnormalities Authorised 20/04/2026
A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study of the Efficacy and Safety of Vamifeport in Adult Subjects with HFE-related Hereditary Hemochromatosis (FERROCLEAR Study)
Homeostatic iron regulator gene-related hereditary hemochromatosis
CSL Behring LLC · 50 participants
📍 Austria · Poland · Spain · Germany · France · Ireland · Romania · Belgium · Italy · Czechia · Netherlands
2025-523793-16-00 on CTIS ↗
Phase II Neoplasms Authorised 20/04/2026
A randomized phase II study comparing the safety and efficacy of mifamurtide and standard therapy containing sorafenib in pediatric and young adult patients with high-risk osteosarcoma
Relapsed/refractory osteosarcoma, High-grade osteosarcoma
Instytut Matki I Dziecka · 40 participants
📍 Poland
2026-525223-24-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 20/04/2026
A Multicenter, Open-Label, Dose Escalation Study of the Safety, Tolerability, and Efficacy of Budiodarone for the Treatment of Subjects with Non-permanent Atrial Fibrillation
Non-permanent Atrial Fibrillation
Xyra LLC · 100 participants
📍 Poland
2025-523860-19-00 on CTIS ↗
Phase I/II Neoplasms Authorised 20/04/2026
Double-blind, randomized, placebo-controlled, study to evaluate the safety and efficacy of HRX215 in participants after major hepatectomy, preceded by two open pilot parts in participants after minor and after major hepatectomy due to colon carcinoma metastases
colon carcinoma metastases
HepaRegeniX GmbH · 40 participants
📍 France · Spain · Germany
2025-523630-59-00 on CTIS ↗
Phase III Mental Disorders Authorised 20/04/2026
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (13 to 17 years of age)
Schizophrenia
Bristol-Myers Squibb Services Unlimited Company · 28 participants
📍 Romania
2025-523711-11-00 on CTIS ↗
Phase I Neoplasms Authorised 20/04/2026
A study to test how well different doses of BI 3820768 are tolerated by people with advanced cancer (solid tumours)
Advanced relapsed or refractory ovarian cancer, Advanced relapsed or refractory endometrial cancer, Advanced relapsed or refractory germ cell tumours
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A. · 102 participants
📍 Spain · France · Belgium · Germany
2025-522913-45-00 on CTIS ↗
Phase I Neoplasms Authorised 20/04/2026
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Ponatinib Tablets 15 mg, manufactured by Sun Pharmaceutical Industries Limited, India with Iclusig (Ponatinib hydrochloride) tablets 15 mg, Produced by: Patheon Inc. Mississauga, Canada or Takeda Ireland Limited Bray, Ireland, Imported and registered by: Pint Pharma Medical-Hospital and Pharmaceutical Products Ltd. Nelson Pontes Street, 125, Block 03, Jardim Margarida Zip Code 06739-024, Vargem Grande Paulista – SP CNPJ No. 21,896,000/0001-91, in healthy adult, human subjects under fasting condition.
chronic myeloid leukemia, Philadelphia chromosome-positive acute lymphoblastic leukemia
Sun Pharmaceutical Industries Limited · 56 participants
📍 Romania
2025-524311-37-00 on CTIS ↗
Phase I Neoplasms Authorised 20/04/2026
A Phase 1b Study of the Safety and Pharmacokinetics of Pivekimab Sunirine in Pediatric Subjects with Relapsed or Refractory Acute Myeloid Leukemia (AML).
Relapsed or Refractory Acute Myeloid Leukemia; Acute Myeloid Leukemia, Acute Myeloid Leukemia
AbbVie Deutschland GmbH & Co. KG · 18 participants
📍 Spain · Hungary · Czechia · France · Italy · Belgium
2024-520125-36-00 on CTIS ↗
Phase III Neoplasms Authorised 20/04/2026
A Phase 3, Randomized, Open-label Study of Sacituzumab Tirumotecan (MK-2870) Versus Investigator’s Choice of Non-platinum Chemotherapy in Participants with Pretreated Locally Advanced/Metastatic Urothelial Carcinoma
Locally advanced/metastatic urothelial carcinoma
Merck Sharp & Dohme LLC · 265 participants
📍 Netherlands · Greece · Italy · Germany · Spain · Belgium · Sweden · France
2024-520014-22-00 on CTIS ↗
Phase I Not possible to specify Authorised 20/04/2026
Multiple-Dose Study in Healthy Participants Under Fasting Conditions to Evaluate the Bioequivalence of One Film-Coated Mini-Tablet of Indapamide SR 1.5 mg versus One Film-Coated Tablet of Indapamide SR 1.5 mg and to Compare the Bioavailability of One Film-Coated Mini-Tablet of Indapamide SR 1.5 mg versus One Film-Coated Tablet of Indapamide IR 2.5 mg.
No medical condition.
Institut De Recherches Internationales Servier IRIS · 48 participants
📍 Portugal
2026-525823-26-00 on CTIS ↗
Phase II Immune System Diseases Authorised 20/04/2026
An autologous and antigen-specific cell-based therapy of vitamin D3-treated and myelin-derived peptide loaded tolerogenic dendritic cells in subjects with progressive forms of multiple sclerosis: a phase IIa, open-label, self-controlled, multi-center clinical trial.
Multiple Sclerosis
Universitair Ziekenhuis Antwerpen, Hospital Germans Trias I Pujol · 14 participants
📍 Belgium · Spain
2025-522040-40-01 on CTIS ↗
Phase III Hemic and Lymphatic Diseases Authorised 20/04/2026
C0371017 - A PHASE 3, NON-INVESTIGATIONAL PRODUCT, MULTI COUNTRY COHORT STUDY TO DESCRIBE THE LONG-TERM SAFETY AND EFFECTIVENESS OF A PRIOR SINGLE-DOSE TREATMENT WITH INVESTIGATIVE GIROCTOCOGENE FITELPARVOVEC OR FIDANACOGENE ELAPARVOVEC IN PARTICIPANTS WITH HEMOPHILIA A OR HEMOPHILIA B, RESPECTIVELY
hemophilia A, severe to moderately severe hemophilia B (FIX:C ≤ 2%)
Pfizer Inc. · 31 participants
📍 Italy · Germany · France · Spain · Sweden · Greece
2025-523660-21-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 20/04/2026
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pridopidine in Participants with Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis
Ferrer Internacional S.A., Prilenia Therapeutics B.V. · 420 participants
📍 Belgium · Netherlands · Poland · France · Germany · Ireland · Italy · Sweden · Spain
2025-524002-16-00 on CTIS ↗
Phase III Neoplasms Authorised 20/04/2026
J4G-MC-JZVD - FORAGER-2: A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Vepugratinib Combined with Enfortumab Vedotin and Pembrolizumab in Adults with Untreated Locally Advanced or Metastatic Urothelial Carcinoma with an FGFR3 Genetic Alteration.
Urinary Bladder Neoplasms, Neoplasm Metastasis, Carcinoma, Transitional Cell
Eli Lilly & Co. · 197 participants
📍 Italy · Poland · Denmark · Czechia · France · Hungary · Germany · Netherlands · Spain
2025-522855-25-00 on CTIS ↗
Phase IV Reproductive and Urinary Physiological Phenomena Authorised 20/04/2026
CoCo-PCOS - Comprehensive Health Effects of Combined Contraceptives: a 6-month randomized, controlled, open-label trial of E4+DRSP, EE20µg+DRSP, and DRSP-only in women with PCOS
Contraception
Pohjois-Pohjanmaan hyvinvointialue, University Of Oulu · 156 participants
📍 Finland
2025-523358-15-00 on CTIS ↗
Phase IV Hormonal diseases Authorised 20/04/2026
Impact of treatment with TransCon PTH on Quality of Life, cognitive function, brain structure, and cerebral capillary bloodflow in patients with hypoparathyroidism
Hypoparathyroidism
Region Midtjylland · 40 participants
📍 Denmark
2025-523930-14-00 on CTIS ↗
Phase I Nutritional and Metabolic Diseases Authorised 19/04/2026
A research study to evaluate the safety of NNC1679-0001 when given to healthy participants and participants with T2DM
Healthy participants and participants with type 2 diabetes
Novo Nordisk A/S · 58 participants
📍 Austria
2025-523304-68-00 on CTIS ↗
Phase II Neoplasms Authorised 17/04/2026
IFCT-2502 LIMPID Phase II trial assessing 1st line and 2nd line treatment in patients with advanced Non-Small Cell Lung Cancer and Interstitial Lung Disease
Non Small Cell Lung Cancer, Interstitial Lung Disease
Intergroupe Francophone De Cancerologie Thoracique · 108 participants
📍 France
2025-522790-10-00 on CTIS ↗
Phase II Digestive System Diseases Authorised 17/04/2026
A Multicentre, Open-Label Study Evaluating the Safety, Tolerability and Efficacy of MaaT013 in Ruxolitinib-Refractory or Intolerant Paediatric and Adolescent participants with Gastrointestinal Acute Graft-versus-Host Disease
Gastrointestinal Acute Graft-versus-Host Disease (GI-aGvHD)
MaaT PHARMA · 18 participants
📍 Netherlands · Italy · France · Spain
2025-524302-15-00 on CTIS ↗
Phase III Neoplasms Authorised 17/04/2026
A Phase 3, Randomized, Open-Label Study of INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum Resistant Ovarian Cancer With Cyclin E1 Overexpression (MAESTRA 2)
Ovarian cancer
Incyte Corp. · 308 participants
📍 Ireland · Poland · France · Netherlands · Spain · Italy · Germany · Belgium
2025-522748-42-00 on CTIS ↗
Phase IV Nervous System Diseases Authorised 17/04/2026
Effects of CLADribine tablets on the Immune Synapse, in Relapsing Multiple Sclerosis (RMS) patients_CLADIS.
Multiple Sclerosis
Aristotle University Of Thessaloniki · 30 participants
📍 Greece
2025-521910-24-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 17/04/2026
Efficacy and safety of NNC0487-0111 compared to placebo on morbidity and mortality in people with heart failure with preserved or mildly reduced ejection fraction and obesity (HF-POLARIS).
HFpEF or HFmrEF and obesity
Novo Nordisk A/S · 1992 participants
📍 Denmark · Greece · Bulgaria · Italy · Netherlands · Spain · Poland · Czechia · Germany · France
2025-523717-29-00 on CTIS ↗
Phase I Respiratory Tract Diseases Authorised 17/04/2026
A Phase 1 Study of AIR-001 in Adults with AATD.
Alpha-1 Antitrypsin Deficiency
Airna Corp. · 19 participants
📍 Sweden · Ireland · Spain · Netherlands · Portugal · Germany
2025-523558-14-00 on CTIS ↗
Phase IV Reproductive and Urinary Physiological Phenomena Authorised 17/04/2026
CoCo3 - Comprehensive Health Effects of Combined Contraceptives: a 12-month randomized, controlled, open-label trial of E4+DRSP, EE20μg+DRSP and DRSP-only
Contraception
Pohjois-Pohjanmaan hyvinvointialue, University Of Oulu · 156 participants
📍 Finland
2025-523359-71-00 on CTIS ↗
Phase III Hemic and Lymphatic Diseases Authorised 17/04/2026
A Phase 3, Multicenter, Open-Label, Randomized Trial to Compare the Efficacy and Safety of Elritercept versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in ESA-naïve Adult Participants Who Require Red Blood Cell Transfusions
Myelodysplastic neoplasms/syndromes (MDS)
Takeda Development Center Americas Inc. · 114 participants
📍 France · Belgium · Germany · Italy · Bulgaria · Ireland · Lithuania · Norway · Romania · Hungary · Spain · Greece · Poland · Netherlands
2025-523544-12-00 on CTIS ↗
Phase II Not possible to specify Authorised 17/04/2026
Omalizumab for monotherapy treatment of patients with food allergies to plant-based foods due to sensitization to LTP and profilin
Categoria 2, Patients with vegetable allergies due to sensitization to profilin and LTPs, and those patients in whom sublingual immunotherapy with Pru p 3 (peach LTP) has not been effective, were evaluated in a before-after study to assess changes in clinical reactivity to LTP (peach) and profilin (melon) and immunological changes after intervention with omalizumab.
Fundacion Publica Andaluza Para La Investigacion De Malaga En Biomedicina Y Salud · 37 participants
📍 Spain
2025-524629-42-00 on CTIS ↗
Phase II Neoplasms Authorised 16/04/2026
METAREM / META-1 - METAREM : Adaptive Master Trial for Advanced Cancers with Rapid Evaluation of Molecular & Immune Status for Stratified Immunotherapies in Oncology / META-1 : Anti-PD1 monotherapy in 1L advanced NSCLC patients with PDL1 TPS > 50% and PTI=0
METAREM:Patients with advanced cancer, as defined as unresectable locally advanced malignancies or metastatic cancers (including leukemias and lymphomas). META-1: Patients in first-line therapy for advanced metastatic NSCLC with PD-L1 Tumor Proportion Score (TPS) >50%, without EGFR/ ALK/ ROS1 mutations and irrespective of their histological subtype (squamous or non-squamous)
Unicancer · 55 participants
📍 France
2025-522655-26-00 on CTIS ↗
Phase IV Digestive System Diseases Authorised 16/04/2026
OPTIMAL CARE WITH GUSELKUMAB IN CROHN’S DISEASE
Crohn's disease
i-GETAID · 210 participants
📍 France
2025-524573-16-00 on CTIS ↗
Phase I/II Neoplasms Authorised 16/04/2026
An open-label, multi-center, phase I/II study of GVV858 as a single agent and in combination with endocrine therapy in patients with advanced hormone receptor positive, HER2-negative breast cancer and other advanced solid tumors
Advanced HR+/HER- breast cancer
Novartis Pharma AG · 55 participants
📍 Italy · Germany · France · Czechia · Denmark · Spain
2025-521911-38-00 on CTIS ↗
Phase I Respiratory Tract Diseases Authorised 16/04/2026
A Phase 1b, Double-Blind Study to Investigate Safety, Tolerability, Pharmacokinetics, Efficacy, and Pharmacodynamics of Single Dose of ATI-052 in Participants with Mild to Moderate Asthma
Mild to Moderate Asthma
Aclaris Therapeutics Inc. · 10 participants
📍 Germany
2025-524987-39-00 on CTIS ↗
Phase I Anesthesia and Analgesia Authorised 16/04/2026
A study to evaluate how well single and multiple doses of S072 are tolerated in healthy adult participants
Pain
Sea4us Biotecnologia E Recursos Marinhos S.A. · 64 participants
📍 Spain
2025-525039-15-01 on CTIS ↗
Phase III Hemic and Lymphatic Diseases Authorised 16/04/2026
The INFLUENCE Trial: Improving EveNt Free Survival by Optimizing FLUdarabine Exposure during LymphodepletioN for CAR T CEll Therapy: a randomized, multi-center study of children and young adults with B-cell acute lymphoblastic leukemia
B-cell Acute Lymphoblastic Leukemia
Prinses Maxima Centrum voor Kinderoncologie B.V. · 35 participants
📍 Spain · Germany · Netherlands
2025-523096-34-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 16/04/2026
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects with Friedreich’s Ataxia
Friedreich’s ataxia is the most common inherited ataxia in humans and results from a deficiency of the mitochondrial protein, FXN. Friedreich’s ataxia is a rare, progressive, multisystem disease with an incidence that is estimated to be 1:29,000, and a carrier frequency of ~1:85.
Larimar Therapeutics Inc. · 18 participants
📍 France
2025-521628-31-00 on CTIS ↗
Phase III Musculoskeletal Diseases Authorised 16/04/2026
A Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo and Active-Controlled Phase III Therapeutic Superiority Trial Comparing the Efficacy and Tolerability of a Fixed-Dose Combination of Diclofenac potassium + Thiocolchicoside to Diclofenac potassium (Cataflam®) in Patients with Acute Severe Low Back Pain.
LOW BACK PAIN
Verisfield Single Member S.A. · 110 participants
📍 Cyprus · Greece
2025-523153-33-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 16/04/2026
EVALUATING THE EFFICACY AND SAFETY OF MET097, A FULLY- BIASED ULTRA LONG-ACTING GLP-1 RA IN PEOPLE WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES: A PHASE 3, MULTI-CENTER RANDOMIZED PLACEBO-CONTROLLED TRIAL (VESPER-5)
Obesity
Metsera Inc. · 919 participants
📍 Czechia · Bulgaria · Slovakia · Spain · Hungary · Germany · Romania · Poland
2025-523975-48-00 on CTIS ↗
Phase I/II Neoplasms Authorised 15/04/2026
Multicentre, open-label, phase 1/2 study of LB-208, selective antagonist of the serotonin 5-hydroxytryptamine receptor 1B (HTR1B), in adults with relapse or refractory (r/r) acute myeloid leukaemia (AML) and r/r higher-risk (HR) myelodysplastic syndrome (MDS)
Relapse or refractory (r/r) acute myeloid leukaemia (AML) and r/r higher-risk (HR) myelodysplastic syndrome (MDS)
Aop Orphan Pharmaceuticals GmbH · 60 participants
📍 Spain
2025-523396-38-00 on CTIS ↗
Phase II Respiratory Tract Diseases Authorised 15/04/2026
A single arm phase II study evaluating intracranial efficacy of tarlatamab in patients with asymptomatic active brain metastases from small cell lung cancer
patients with asymptomatic active brain metastases from small cell lung cancer
Academisch Ziekenhuis Maastricht · 35 participants
📍 Netherlands
2025-522162-75-00 on CTIS ↗
Phase II Congenital, Hereditary, and Neonatal Diseases and Abnormalities Authorised 15/04/2026
Phase 2, Open-Label, Long-Term, Extension (OLE) Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children with Hypochondroplasia: ACCEL OLE
Hypochondroplasia
Qed Therapeutics Inc. · 22 participants
📍 Spain · Norway
2025-523509-13-00 on CTIS ↗
No trials match your search.

Browse by country

Spain · 232 France · 219 Germany · 188 Italy · 162 Netherlands · 135 Poland · 127 Belgium · 105 Czechia · 81 Denmark · 77 Romania · 53 Hungary · 52 Greece · 50 Austria · 48 Bulgaria · 48 Sweden · 39 Portugal · 36 Norway · 34 Finland · 23 Slovakia · 22 Ireland · 20 Croatia · 17 Estonia · 9 Latvia · 8 Lithuania · 6
Cite this page

Priya Life Science (2026). EU Clinical Trials Tracker. Available at: https://priyalifescience.com/clinical-trials-europe (Accessed: 6 July 2026).

Source: Clinical Trials Information System (CTIS), European Medicines Agency - trials authorised under the EU Clinical Trials Regulation (Regulation 536/2014), showing the most recent EU authorisation decisions, refreshed daily. Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See our Ireland Clinical Trials Tracker. For approved medicines, see the EMA Approvals Tracker.